### List of Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>4-ABP</td>
<td>4-aminobiphenyl</td>
</tr>
<tr>
<td>AAP</td>
<td>American Academy of Pediatrics</td>
</tr>
<tr>
<td>AAT</td>
<td>α-1 antitrypsin</td>
</tr>
<tr>
<td>ACE</td>
<td>acute coronary events</td>
</tr>
<tr>
<td>ACOG</td>
<td>American Congress of Obstetricians and Gynecologists</td>
</tr>
<tr>
<td>ACS</td>
<td>American Cancer Society</td>
</tr>
<tr>
<td>ADHD</td>
<td>attention deficit hyperactivity disorder</td>
</tr>
<tr>
<td>AMA</td>
<td>American Medical Association</td>
</tr>
<tr>
<td>AMD</td>
<td>age-related macular degeneration</td>
</tr>
<tr>
<td>AMI</td>
<td>acute myocardial infarction</td>
</tr>
<tr>
<td>anti-CCP</td>
<td>anti-cyclic citrullinated peptide</td>
</tr>
<tr>
<td>anti-HCV</td>
<td>antibodies to hepatitis C virus</td>
</tr>
<tr>
<td>ANR</td>
<td>Americans for Nonsmokers’ Rights</td>
</tr>
<tr>
<td>ANRF</td>
<td>American Nonsmokers’ Rights Foundation</td>
</tr>
<tr>
<td>AOR</td>
<td>adjusted odds ratio</td>
</tr>
<tr>
<td>ARIC</td>
<td>Atherosclerosis Risk in Communities</td>
</tr>
<tr>
<td>ASSIST</td>
<td>American Stop Smoking Intervention Study</td>
</tr>
<tr>
<td>ATS</td>
<td>American Thoracic Society</td>
</tr>
<tr>
<td>B[a]P</td>
<td>benzo[a]pyrene</td>
</tr>
<tr>
<td>BACH</td>
<td>Boston Area Community Health survey</td>
</tr>
<tr>
<td>BALT</td>
<td>bronchus-associated lymphoid tissue</td>
</tr>
<tr>
<td>BAT</td>
<td>British American Tobacco</td>
</tr>
<tr>
<td>BCFR</td>
<td>Breast Cancer Family Registry</td>
</tr>
<tr>
<td>BMI</td>
<td>body mass index</td>
</tr>
<tr>
<td>Breg</td>
<td>B regulatory cells</td>
</tr>
<tr>
<td>BRFSS</td>
<td>Behavioral Risk Factor Surveillance System</td>
</tr>
<tr>
<td>B&amp;W</td>
<td>Brown &amp; Williamson Tobacco Co.</td>
</tr>
<tr>
<td>Cal/EPA</td>
<td>California Environmental Protection Agency</td>
</tr>
<tr>
<td>CBCL</td>
<td>child behavior checklist</td>
</tr>
<tr>
<td>CBO</td>
<td>Congressional Budget Office</td>
</tr>
<tr>
<td>CC16</td>
<td>Clara cell secretory protein 16</td>
</tr>
<tr>
<td>CDC</td>
<td>Centers for Disease Control and Prevention</td>
</tr>
<tr>
<td>CF</td>
<td>cystic fibrosis</td>
</tr>
<tr>
<td>CFTR</td>
<td>cystic fibrosis transmembrane conductance regulator</td>
</tr>
<tr>
<td>CHARGE</td>
<td>Cohorts for Heart and Aging Research in Genomic Epidemiology</td>
</tr>
<tr>
<td>CHD</td>
<td>coronary heart disease</td>
</tr>
<tr>
<td>CHF</td>
<td>congestive heart failure</td>
</tr>
<tr>
<td>CI</td>
<td>confidence interval</td>
</tr>
<tr>
<td>CISNET</td>
<td>Cancer Intervention and Surveillance Modeling Network</td>
</tr>
<tr>
<td>CL/P</td>
<td>cleft lip with or without cleft palate</td>
</tr>
<tr>
<td>CLUE II</td>
<td>Campaign Against Cancer and Heart Disease</td>
</tr>
<tr>
<td>cm</td>
<td>centimeter</td>
</tr>
<tr>
<td>CMS</td>
<td>Centers for Medicare &amp; Medicaid Services</td>
</tr>
<tr>
<td>CNS</td>
<td>central nervous system</td>
</tr>
<tr>
<td>CNV</td>
<td>choroidal neovascularization</td>
</tr>
<tr>
<td>CO</td>
<td>carbon monoxide</td>
</tr>
<tr>
<td>COLD</td>
<td>chronic obstructive lung disease</td>
</tr>
<tr>
<td>COMMIT</td>
<td>Community Intervention Trial for Smoking Cessation</td>
</tr>
<tr>
<td>COPD</td>
<td>chronic obstructive pulmonary disease</td>
</tr>
<tr>
<td>COSMIC</td>
<td>Catalogue of Somatic Mutations in Cancer</td>
</tr>
<tr>
<td>CP</td>
<td>cleft palate</td>
</tr>
<tr>
<td>CPP</td>
<td>Collaborative Perinatal Project</td>
</tr>
<tr>
<td>CPS</td>
<td>Cancer Prevention Study</td>
</tr>
<tr>
<td>CRP</td>
<td>C-reactive protein</td>
</tr>
<tr>
<td>CSE</td>
<td>cigarette smoke extract</td>
</tr>
<tr>
<td>CT</td>
<td>computed tomography</td>
</tr>
<tr>
<td>CVD</td>
<td>cardiovascular disease</td>
</tr>
<tr>
<td>CYP</td>
<td>cytochrome P-450</td>
</tr>
<tr>
<td>DALYs</td>
<td>disability-adjusted life years</td>
</tr>
<tr>
<td>DAMPs</td>
<td>damage-associated molecular patterns</td>
</tr>
<tr>
<td>DFS</td>
<td>decayed/filled tooth surface</td>
</tr>
<tr>
<td>DFT</td>
<td>decayed/filled permanent teeth</td>
</tr>
<tr>
<td>dL</td>
<td>deciliter</td>
</tr>
<tr>
<td>DMF</td>
<td>decayed/missing due to caries/filled</td>
</tr>
<tr>
<td>DMFS</td>
<td>decayed/missing due to caries/filled tooth surface</td>
</tr>
<tr>
<td>DMFT</td>
<td>decayed/missing due to caries/filled permanent teeth</td>
</tr>
<tr>
<td>DOD</td>
<td>U.S. Department of Defense</td>
</tr>
<tr>
<td>DOJ</td>
<td>U.S. Department of Justice</td>
</tr>
<tr>
<td>DTPs</td>
<td>dissolvable tobacco products</td>
</tr>
<tr>
<td>E1</td>
<td>estrone</td>
</tr>
<tr>
<td>E2</td>
<td>estradiol</td>
</tr>
<tr>
<td>E3</td>
<td>estriol</td>
</tr>
<tr>
<td>ECLIPSE</td>
<td>Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>nAChR</td>
<td>nicotinic acetylcholine receptor</td>
</tr>
<tr>
<td>NAQC</td>
<td>North American Quitline Consortium</td>
</tr>
<tr>
<td>NAT</td>
<td>N-acetyltransferase</td>
</tr>
<tr>
<td>NBDPS</td>
<td>National Birth Defects Prevention Study</td>
</tr>
<tr>
<td>NCHS</td>
<td>National Center for Health Statistics</td>
</tr>
<tr>
<td>NCI</td>
<td>National Cancer Institute</td>
</tr>
<tr>
<td>NE</td>
<td>neutrophil elastase</td>
</tr>
<tr>
<td>NETT</td>
<td>National Emphysema Treatment Trial</td>
</tr>
<tr>
<td>NF-kB</td>
<td>nuclear factor-kappa B</td>
</tr>
<tr>
<td>NFPA</td>
<td>National Fire Protection Association</td>
</tr>
<tr>
<td>ng</td>
<td>nanogram</td>
</tr>
<tr>
<td>NHANES</td>
<td>National Health and Nutrition Examination Survey</td>
</tr>
<tr>
<td>NHDS</td>
<td>National Hospital Discharge Survey</td>
</tr>
<tr>
<td>NHIS</td>
<td>National Health Interview Survey</td>
</tr>
<tr>
<td>NHLBI</td>
<td>National Heart, Lung, and Blood Institute</td>
</tr>
<tr>
<td>NHS</td>
<td>Nurses’ Health Study</td>
</tr>
<tr>
<td>NIDA</td>
<td>National Institute on Drug Abuse</td>
</tr>
<tr>
<td>NIH</td>
<td>National Institutes of Health</td>
</tr>
<tr>
<td>NK</td>
<td>natural killer</td>
</tr>
<tr>
<td>NKG2D</td>
<td>NK group 2D</td>
</tr>
<tr>
<td>NKT</td>
<td>natural killer T</td>
</tr>
<tr>
<td>NNAl</td>
<td>4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol</td>
</tr>
<tr>
<td>NNK</td>
<td>4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone</td>
</tr>
<tr>
<td>NNN</td>
<td>N’-nitrosonornicotine</td>
</tr>
<tr>
<td>NO</td>
<td>nitric oxide</td>
</tr>
<tr>
<td>NP</td>
<td>nicotine polacrilex gum</td>
</tr>
<tr>
<td>NPCR</td>
<td>National Program of Cancer Registries</td>
</tr>
<tr>
<td>NPT</td>
<td>nocturnal penile tumescence</td>
</tr>
<tr>
<td>NPTTR</td>
<td>nocturnal penile tumescence and rigidity</td>
</tr>
<tr>
<td>NRT</td>
<td>nicotine replacement therapy</td>
</tr>
<tr>
<td>NSAIDs</td>
<td>nonsteroidal anti-inflammatory drugs</td>
</tr>
<tr>
<td>NSCLC</td>
<td>non-small-cell lung cancer</td>
</tr>
<tr>
<td>NSDUH</td>
<td>National Survey on Drug Use and Health</td>
</tr>
<tr>
<td>NTHI</td>
<td>nontypeable Haemophilus influenza</td>
</tr>
<tr>
<td>NV</td>
<td>neovascular</td>
</tr>
<tr>
<td>NYTS</td>
<td>National Youth Tobacco Survey</td>
</tr>
<tr>
<td>ODD</td>
<td>oppositional defiant disorder</td>
</tr>
<tr>
<td>OR</td>
<td>odds ratio</td>
</tr>
<tr>
<td>P. aeruginosa</td>
<td>Pseudomonas aeruginosa</td>
</tr>
<tr>
<td>PACT</td>
<td>Prevent All Cigarette Trafficking Act</td>
</tr>
<tr>
<td>PAD</td>
<td>peripheral arterial disease</td>
</tr>
<tr>
<td>PAF</td>
<td>population-attributable fraction</td>
</tr>
<tr>
<td>PAH</td>
<td>polycyclic aromatic hydrocarbon</td>
</tr>
<tr>
<td>PAI-1</td>
<td>plasminogen activator inhibitor-1</td>
</tr>
<tr>
<td>PAMPs</td>
<td>pathogen-associated molecular patterns</td>
</tr>
<tr>
<td>Pap</td>
<td>Papanicolaou</td>
</tr>
<tr>
<td>PARC</td>
<td>pulmonary-and activation-regulated chemokine</td>
</tr>
<tr>
<td>PBI</td>
<td>penile-brachial index</td>
</tr>
<tr>
<td>PCR</td>
<td>polymerase chain reaction</td>
</tr>
<tr>
<td>PDAY</td>
<td>Pathobiological Determinants of Atherosclerosis in Youth study</td>
</tr>
<tr>
<td>PHS</td>
<td>U.S. Public Health Service</td>
</tr>
<tr>
<td>PID</td>
<td>pelvic inflammatory disease</td>
</tr>
<tr>
<td>PM_{2.5}</td>
<td>particulate matter</td>
</tr>
<tr>
<td>PR</td>
<td>progesterone receptors</td>
</tr>
<tr>
<td>PRAMS</td>
<td>Pregnancy Risk Assessment Monitoring System</td>
</tr>
<tr>
<td>PRRs</td>
<td>pattern recognition receptors</td>
</tr>
<tr>
<td>PSA</td>
<td>prostate-specific antigen</td>
</tr>
<tr>
<td>PSAM</td>
<td>probability of smoking-attributable mortality</td>
</tr>
<tr>
<td>PVFE</td>
<td>present value of future earnings</td>
</tr>
<tr>
<td>QALYs</td>
<td>quality-adjusted life years</td>
</tr>
<tr>
<td>RA</td>
<td>rheumatoid arthritis</td>
</tr>
<tr>
<td>RAI</td>
<td>Reynolds American, Inc.</td>
</tr>
<tr>
<td>RCP</td>
<td>Royal College of Physicians</td>
</tr>
<tr>
<td>RCT</td>
<td>randomized clinical trial</td>
</tr>
<tr>
<td>RDFS</td>
<td>root-surface caries decayed/filled tooth surface</td>
</tr>
<tr>
<td>RDS</td>
<td>root-surface caries decayed tooth surface</td>
</tr>
<tr>
<td>RF</td>
<td>rheumatoid factor</td>
</tr>
<tr>
<td>RICO</td>
<td>Racketeer Influenced and Corrupt Organizations Act</td>
</tr>
<tr>
<td>RJR</td>
<td>R.J. Reynolds Tobacco Company</td>
</tr>
<tr>
<td>ROS</td>
<td>reactive-oxygen species</td>
</tr>
<tr>
<td>RPE</td>
<td>retinal pigment epithelium</td>
</tr>
<tr>
<td>RR</td>
<td>relative risk</td>
</tr>
<tr>
<td>RSV</td>
<td>respiratory syncytial virus</td>
</tr>
<tr>
<td>RT</td>
<td>response time</td>
</tr>
<tr>
<td>S. pneumonia</td>
<td>Streptococcus pneumoniae</td>
</tr>
<tr>
<td>SAB</td>
<td>spontaneous abortion</td>
</tr>
<tr>
<td>SAF</td>
<td>smoking-attributable fraction</td>
</tr>
<tr>
<td>SAM</td>
<td>smoking-attributable mortality</td>
</tr>
<tr>
<td>SAMHSA</td>
<td>Substance Abuse and Mental Health Services Administration</td>
</tr>
<tr>
<td>SAMMMEC</td>
<td>Smoking-Attributable Mortality, Morbidity, and Economic Costs</td>
</tr>
<tr>
<td>SCD</td>
<td>sudden coronary death</td>
</tr>
<tr>
<td>SCE</td>
<td>sister chromatid exchange</td>
</tr>
<tr>
<td>SEER</td>
<td>Surveillance, Epidemiology, and End Results</td>
</tr>
<tr>
<td>Acronym</td>
<td>Full Form</td>
</tr>
<tr>
<td>---------</td>
<td>-----------</td>
</tr>
<tr>
<td>SES</td>
<td>socioeconomic status</td>
</tr>
<tr>
<td>SF-12</td>
<td>Short Form 12</td>
</tr>
<tr>
<td>SF-36</td>
<td>Short Form 36</td>
</tr>
<tr>
<td>sFlt-1</td>
<td>soluble fms-like tyrosine kinase-1</td>
</tr>
<tr>
<td>S/G2/M</td>
<td>synthesis/gap2/mitosis</td>
</tr>
<tr>
<td>SIDS</td>
<td>sudden infant death syndrome</td>
</tr>
<tr>
<td>SLE</td>
<td>systemic lupus erythematosus</td>
</tr>
<tr>
<td>SLEDAI</td>
<td>Systemic Lupus Erythematosus Disease Activity Index</td>
</tr>
<tr>
<td>SNP</td>
<td>single nucleotide polymorphism</td>
</tr>
<tr>
<td>SOD2</td>
<td>superoxide dismutase 2</td>
</tr>
<tr>
<td>STI</td>
<td>sexually transmitted infection</td>
</tr>
<tr>
<td>SULT</td>
<td>sulfotransferase</td>
</tr>
<tr>
<td>TB</td>
<td>tuberculosis</td>
</tr>
<tr>
<td>TCDD</td>
<td>tetrachlorodibenzo-p-dioxin</td>
</tr>
<tr>
<td>TCR</td>
<td>T cell receptor</td>
</tr>
<tr>
<td>Th cell</td>
<td>T helper cell</td>
</tr>
<tr>
<td>TI</td>
<td>The Tobacco Institute, Inc.</td>
</tr>
<tr>
<td>TIA</td>
<td>transient ischemic attack</td>
</tr>
<tr>
<td>TIPS</td>
<td>Tips from Former Smokers</td>
</tr>
<tr>
<td>TIRC</td>
<td>Tobacco Industry Research Committee</td>
</tr>
<tr>
<td>TLR4</td>
<td>toll-like receptor 4</td>
</tr>
<tr>
<td>tPA</td>
<td>tissue plasminogen activator</td>
</tr>
<tr>
<td>TPSAC</td>
<td>Tobacco Products Scientific Advisory Committee</td>
</tr>
<tr>
<td>TRIPS</td>
<td>Trade-Related Aspects of Intellectual Property Rights</td>
</tr>
<tr>
<td>TRPA1</td>
<td>transient receptor potential cation channel, subfamily A, member 1</td>
</tr>
<tr>
<td>TST</td>
<td>tuberculin skin test</td>
</tr>
<tr>
<td>UGT</td>
<td>uridine-5'-diphosphate-glucuronosyltransferase</td>
</tr>
<tr>
<td>UICC</td>
<td>Union for International Cancer Control</td>
</tr>
<tr>
<td>UN</td>
<td>United Nations</td>
</tr>
<tr>
<td>UPRs</td>
<td>unfolded protein responses</td>
</tr>
<tr>
<td>USDHEW</td>
<td>U.S. Department of Health, Education, and Welfare</td>
</tr>
<tr>
<td>USDHHHS</td>
<td>U.S. Department of Health and Human Services</td>
</tr>
<tr>
<td>USEPA</td>
<td>U.S. Environmental Protection Agency</td>
</tr>
<tr>
<td>USGAO</td>
<td>U.S. General Accounting Office</td>
</tr>
<tr>
<td>USPSTF</td>
<td>U.S. Preventive Services Task Force</td>
</tr>
<tr>
<td>USRTC</td>
<td>U.S. Radiologic Technologist Cohort</td>
</tr>
<tr>
<td>VA</td>
<td>U.S. Department of Veterans Affairs</td>
</tr>
<tr>
<td>VDJ</td>
<td>variable, diversity, and joining gene segments recombination</td>
</tr>
<tr>
<td>WHI</td>
<td>Women’s Health Initiative</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
<tr>
<td>WTO</td>
<td>World Trade Organization</td>
</tr>
<tr>
<td>YPLL</td>
<td>years of potential life lost</td>
</tr>
<tr>
<td>YRBS</td>
<td>Youth Risk Behavior Survey</td>
</tr>
<tr>
<td>YRBSS</td>
<td>Youth Risk Behavior Surveillance System</td>
</tr>
</tbody>
</table>
## List of Tables and Figures

### Chapter 1
**Introduction, Summary, and Conclusions**

<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1</td>
<td>Four-level hierarchy for classifying the strength of causal inferences from available evidence</td>
<td>3</td>
</tr>
<tr>
<td>1.1A</td>
<td>The health consequences causally linked to smoking</td>
<td>4</td>
</tr>
<tr>
<td>1.1B</td>
<td>The health consequences causally linked to exposure to secondhand smoke</td>
<td>5</td>
</tr>
</tbody>
</table>

### Chapter 2
**Fifty Years of Change 1964–2014**

<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1</td>
<td>Adult per capita cigarette consumption and major smoking and health events, United States, 1900–2012</td>
<td>18</td>
</tr>
</tbody>
</table>

### Chapter 3

<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.1</td>
<td>Surgeon General's reports on smoking and health, 1964–2012</td>
<td>46</td>
</tr>
</tbody>
</table>

### Chapter 4
**Advances in Knowledge of the Health Consequences of Smoking: From 1964–2014**

<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.1</td>
<td>Conclusions from Surgeon General's reports on active cigarette smoking and cancer</td>
<td>70</td>
</tr>
<tr>
<td>4.2</td>
<td>Conclusions from Surgeon General's reports on active cigarette smoking and cardiovascular diseases</td>
<td>76</td>
</tr>
<tr>
<td>4.3</td>
<td>Conclusions from Surgeon General's reports on active cigarette smoking and respiratory diseases</td>
<td>77</td>
</tr>
<tr>
<td>4.4</td>
<td>Conclusions from Surgeon General's reports on active cigarette smoking and adverse reproductive outcomes or childhood neurobehavioral disorders</td>
<td>82</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.5</td>
<td>Conclusions from Surgeon General's reports on active cigarette smoking and other adverse health effects</td>
<td>87</td>
</tr>
<tr>
<td>4.6</td>
<td>Conclusions from Surgeon General's reports on exposure to secondhand smoke and cancer</td>
<td>90</td>
</tr>
<tr>
<td>4.7</td>
<td>Conclusions from Surgeon General's reports on exposure to secondhand smoke and cardiovascular diseases</td>
<td>91</td>
</tr>
<tr>
<td>4.8</td>
<td>Conclusions from Surgeon General's reports on exposure to secondhand smoke and respiratory effects in children</td>
<td>92</td>
</tr>
<tr>
<td>4.9</td>
<td>Conclusions from Surgeon General's reports on exposure to secondhand smoke and respiratory effects in adults</td>
<td>95</td>
</tr>
<tr>
<td>4.10</td>
<td>Conclusions from Surgeon General's reports on exposure to secondhand smoke and reproductive and developmental effects</td>
<td>98</td>
</tr>
<tr>
<td>4.11</td>
<td>Conclusions reached by the Advisory Committee to the Surgeon General in 1964</td>
<td>100</td>
</tr>
<tr>
<td>4.12</td>
<td>Conclusions from previous Surgeon General's reports related to smoking and all-cause mortality</td>
<td>102</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.1</td>
<td>Mortality rates for major diseases in the United States, 1900–2005</td>
<td>63</td>
</tr>
<tr>
<td>4.2</td>
<td>Age-adjusted mortality rates for all causes, United States, selected years, 1900–2010</td>
<td>64</td>
</tr>
<tr>
<td>4.3</td>
<td>Mortality rates from selected cancers among men in the United States, 1930–2008</td>
<td>65</td>
</tr>
<tr>
<td>4.4</td>
<td>Mortality rates from selected cancers among women in the United States, 1930–2008</td>
<td>66</td>
</tr>
</tbody>
</table>

### Chapter 5
**Nicotine**

<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.1</td>
<td>Animal studies on acute toxicity of nicotine</td>
<td>111</td>
</tr>
<tr>
<td>5.1</td>
<td>Venous blood concentrations of nicotine over time for various nicotine delivery systems</td>
<td>110</td>
</tr>
</tbody>
</table>
Table 6.1  Singular discoveries and major events in the cancer field and changing relative survival rates for persons with cancer in the United States, 1863–2006 144

Table 6.2  Ratio of brand coefficient of variation to replicate measurement coefficient of nicotine and tar variation per milligram (mg), per Massachusetts Machine Smoking Protocol, in rank order 156

Table 6.3S  Case-control studies on smoking and primary liver cancer S-3

Table 6.4S  Cohort studies on smoking and primary liver cancer S-12

Table 6.5S  Prospective studies of cigarette smoking and colorectal cancer incidence, published 2002–2009 S-21

Table 6.6S  Case-control studies of cigarette smoking and colorectal cancer incidence, published 2001–2008 S-26

Table 6.7S  Prospective studies of cigarette smoking and colorectal cancer mortality, published 2002–2009 S-28

Table 6.8S  Prospective cohort studies on the association between cigarette smoking and prostate cancer incidence and mortality S-30

Table 6.9S  Epidemiologic cross-sectional studies on the association between cigarette smoking and stage and histologic grade at diagnosis of prostate cancer S-45

Table 6.10S  Cohort studies on the association between cigarette smoking and risk of prostate cancer progression, case fatality, and all-cause mortality in men with prostate cancer S-48

Table 6.11S  Reports on levels of endogenous hormones and smoking in premenopausal women (n = 22) S-52

Table 6.12S  Reports on levels of endogenous hormones and smoking in postmenopausal women (n = 17) S-57

Table 6.13  Age-standardized estimates of the prevalence of current cigarette smoking for selected member states of the World Health Organization (WHO), 2009 218

Table 6.14S  Cohort study reports of the association between active cigarette smoking and risk of breast cancer, based on studies published before 2012 (n = 15) S-60

Table 6.15S  Case-control study reports of the association between active cigarette smoking and risk for breast cancer, based on studies published from 2000 to 2011 (n = 34) S-75

Table 6.16S  Evaluation of reports on exposure to active cigarette smoking for meta-analyses, based on cohort studies before 2012 and case-control studies published from 2000 to 2011 for meta-analyses, by location, study design, size of analytic sample, type of referent group, meta-analysis categories, and design or analysis issues (n = 65) S-109

Table 6.17S  Summary of meta-analyses for measures of active cigarette smoking for all studies combined and stratified by study design, based on cohort studies published before 2012 and case-control studies published from 2000 to 2011 S-118

Table 6.18S  Reports of premenopausal and postmenopausal relative risks (RRs) by study and meta-analysis RRs for the association of active smoking (ever, pack-years) with risk for breast cancer, based on cohort studies published before 2012 and case-control studies published from 2000 to 2011 (n = 20) S-120

Table 6.19S  Reports of estrogen receptor status relative risks (RRs) for the association of active cigarette smoking (ever, cigarettes/day) with risk for breast cancer, based on cohort studies published before 2012 and case-control studies published from 2000 to 2011 (n = 17) S-123

Table 6.20S  Reports on the association between active cigarette smoking and risk of a second primary contralateral breast cancer (n = 7) S-125

Table 6.21S  Modification of risk for breast cancer associated with smoking by NAT2 phenotype, based on two meta-analyses and one pooled analysis, stratified by menopausal status S-126

Table 6.22S  Reports on cohort studies of the association between exposure to secondhand smoke and relative risk (RR) for breast cancer incidence, based on studies published before 2012 included in the 2006 Surgeon General’s report (n = 7) S-127
Table 6.23S  Reports on case-control studies of the association between exposure to secondhand smoke and relative risk (RR) for breast cancer incidence, based on studies published before 2012 but not included in the 2006 Surgeon General’s report (n = 11)  S-132

Table 6.24S  Evaluation of reports on exposure to secondhand smoke among 171 nonsmokers, based on 10 cohort and 24 case-control studies of breast cancer published before 2012 for meta-analyses, by location, study design, analytic sample size, meta-analysis categories, and design or analysis issues (n = 39)  S-142

Table 6.25S  Summary of meta-analyses for the broadest categories of exposure to secondhand smoke (adult—any source, ever in lifetime, most comprehensive) for all studies of breast cancer combined and stratified by menopausal status, based on cohort and case-control studies published before 2012  S-148

Table 6.26S  Summary of meta-analyses for specific categories of exposure to secondhand smoke (spouse, home, workplace, childhood, childhood and adulthood) for all studies of breast cancer combined and stratified by menopausal status, based on cohort and case-control studies published before 2012  S-150

Table 6.27S  Comparison of relative risks (RRs) from selected summaries of meta-analyses for active smoking versus exposure to secondhand smoke for all studies of breast cancer combined and stratified by study design, based on cohort and case-control studies published before 2012  S-152

Table 6.28S  Associations between smoking and overall mortality in cancer patients  S-153

Table 6.29S  Associations between smoking and overall survival in cancer patients  S-167

Table 6.30S  Associations between smoking and cancer-related mortality  S-173

Table 6.31S  Associations between smoking and developing a second primary cancer in cancer patients  S-180

Table 6.32S  Associations between smoking and cancer recurrence  S-184

Table 6.33S  Associations between smoking and cancer response  S-189

Table 6.34S  Associations between smoking and treatment-related toxicity in cancer patients  S-191

Figure 6.1  Timeline of pivotal events in cancer prevention  145

Figure 6.2  Surveillance, Epidemiology, and End Results (SEER) age-adjusted incidence, selected sites, males, 1975–2010  146

Figure 6.3  Surveillance, Epidemiology, and End Results (SEER) age-adjusted incidence, selected sites, females, 1975–2010  147

Figure 6.4  Pathway for causation of cancer by carcinogens in tobacco smoke  148

Figure 6.5  Market share and total annual cigarette sales of filtered and unfiltered cigarettes in the United States, 1925–1993  152

Figure 6.6  Market share of total cigarettes sold per year, by tar yield (milligrams [mg]s of tar by Federal Trade Commission method), United States, 1967–1990  153

Figure 6.7  Ratio of the means of constituents in cigarette brands from Canada and Australia to the mean for an international sample of U.S.-style blended cigarettes manufactured by Philip Morris and sampled from late 2000 to early 2001  157

Figure 6.8  Mean and range of N’-nitrosonornicotine (NNN) and 4-(methylnitrosamino)-1-(3pyridyl)-1-butane none (NNK) yields per milligram (mg) of nicotine for brands reported to the Australian government, contrasted with the levels of NNN and NNK reported for a Philip Morris Marlboro brand cigarette identified as an Australian brand, in 1999  158

Figure 6.9  Death rates from all lung cancers, by smoking status, Cancer Prevention Study I (CPS-I) and Cancer Prevention Study II (CPS-II), 1959–1965 and 1982–1988  159

Figure 6.10  Standardized incidence of lung cancer, by gender and histology (age adjusted to 2000 U.S. population), 1973–2010  162

Figure 6.11  Incidence of lung cancer among U.S. men from various birth cohorts, by histologic type (adenocarcinoma, squamous cell carcinoma, and small and large cell carcinoma) and year of diagnosis, 1975–2000  164

Figure 6.12  Incidence of lung cancer among U.S. women from various birth cohorts, by histologic type (adenocarcinoma, squamous cell carcinoma, and small and large cell carcinoma) and year of diagnosis, 1975–2000  170
Figure 6.13  Unweighted mean percentage of all lung cancers that were adenocarcinoma, by gender and birth cohort for the available calendar years, United States, 1890–1955  175

Figure 6.14  Trends in incidence rates for lung cancer (age adjusted, world standard), by histologic type (squamous cell carcinoma, small cell carcinoma, and adenocarcinoma) and geographic area, 1980–1982 to 1995–1997  179

Figure 6.15  Age-specific rates of lung cancer death, by gender and age group, in the United States and Australia, 2000  182

Figure 6.16  Adenocarcinoma as a percentage of designated lung cancers in U.S. White men and women and Australian men and women, by various birth cohorts, 1890–1955  183

Figure 6.17  Estimated risk for liver cancer in current smokers compared with nonsmokers  190

Figure 6.18  Estimated risk for hepatocellular carcinoma in current smokers compared with nonsmokers among studies that controlled for confounding by primary etiological factors (viral hepatitis, consumption of alcohol)  191

Figure 6.19  Estimated risk for hepatocellular carcinoma in ever smokers compared with never smokers  192

Figure 6.20  Estimated risk for hepatocellular carcinoma in ever smokers compared with never smokers among studies that controlled for confounding by primary etiological factors (viral hepatitis, consumption of alcohol)  193

Figure 6.21  Estimated risk for hepatocellular carcinoma among persons without evidence for chronic viral hepatitis infection for current or ever smokers compared with never smokers  194

Figure 6.22  Estimated risk for hepatocellular carcinoma in former smokers compared with never smokers  195

Figure 6.23  Forest plot of relative risk for colorectal adenoma for current smokers versus never smokers  200

Figure 6.24  Forest plot of relative risk for adenomatous polyps for former smokers versus never smokers  201

Figure 6.25  Prospective cohort studies on the association between current cigarette smoking and prostate cancer mortality  207

Figure 6.26  Pathways to estrogen carcinogenesis  212

Figure 6.27  Pathways involved in estrogen metabolism  213

Figure 6.28  Forest plot showing association between ever smoking and risk for breast cancer, based on cohort studies published before 2012 and case-control studies published from 2000 to 2011 (n = 49)  227

Figure 6.29  Funnel plot for estimates in meta-analysis of ever smoking with risk for breast cancer, based on cohort studies published before 2012 and case-control studies published from 2000 to 2011 (n = 49)  228

Figure 6.30  Forest plot showing association between ever smoking and risk for breast cancer, based on cohort studies published before 2012 and case-control studies published from 2000 to 2011, excluding studies with design or analysis issues (n = 30)  230

Figure 6.31  Forest plot showing association between ever smoking and risk for breast cancer, based on the subset of cohort studies published before 2012 and case-control studies published from 2000 to 2011 with a no active-only referent group (n = 25)  232

Figure 6.32  Forest plot showing association between ever smoking and risk for breast cancer, based on the subset of cohort studies published before 2012 and case-control studies published from 2000 to 2011 with a no active/no passive exposure referent group (n = 14)  233

Figure 6.33  Forest plot showing association between current smoking and risk for breast cancer, based on the subset of cohort studies published before 2012 and case-control studies published from 2000 to 2011 (n = 25)  234

Figure 6.34  Forest plot showing association between former smoking and risk for breast cancer, based on the subset of cohort studies published before 2012 and case-control studies published from 2000 to 2011 (n = 25)  235

Figure 6.35  Forest plot showing association between 20 or more years of smoking duration and risk for breast cancer, based on the subset of cohort studies published prior to 2012 and case-control studies published from 2000 to 2011 (n = 19)  237
Figure 6.36  Forest plot showing association between 20 or more cigarettes/day and risk for breast cancer, based on the subset of cohort studies published before 2012 and case-control studies published from 2000 to 2011 (n = 18) 238

Figure 6.37  Forest plot showing association between 20 or more pack-years of smoking and risk for breast cancer, based on the subset of cohort studies published before 2012 and case-control studies published from 2000 to 2011 (n = 16) 239

Figure 6.38  Forest plot showing association between less than 20 years of age at smoking initiation and risk for breast cancer, based on the subset of cohort studies published before 2012 and case-control studies published from 2000 to 2011 (n = 22) 241

Figure 6.39  Forest plot showing the association between smoking before or during first full-term pregnancy and risk for breast cancer, based on the subset of cohort studies published before 2012 and case-control studies published from 2000 to 2011 (n = 22) 243

Figure 6.40  Forest plot showing the association between the most comprehensive measure of exposure to secondhand smoke and risk for breast cancer, based on the subset of cohort and case-control studies published before 2012 (n = 34) 266

Figure 6.41  Funnel plot showing estimates in the meta-analysis of the most comprehensive measure of exposure to secondhand smoke with risk for breast cancer, based on the subset of cohort and case-control studies published before 2012 (n = 34) 267

Figure 6.42  Forest plot showing the association between the most comprehensive measure of secondhand smoke and risk for breast cancer, based on the subset of cohort and case-control studies published before 2012, excluding studies with design or analysis issues (n = 23) 268

Figure 6.43  Funnel plot for estimates in the meta-analysis of the most comprehensive measure of exposure to secondhand smoke with risk for breast cancer, based on the subset of cohort and case-control studies published before 2012, excluding studies with design or analysis issues (n = 23) 269

Figure 6.44  Funnel plots for estimates in the meta-analysis of Adult—any source (n = 14) and Ever in lifetime (n = 20) measures of exposure to secondhand smoke that contributed to the Most comprehensive exposure category, based on the subset of cohort and case-control studies published before 2012 (n = 34) 270

Figure 6.45  Funnel plots showing estimates in the meta-analysis of premenopausal (n = 17) and postmenopausal (n = 17) status for the Most comprehensive measure of exposure to secondhand smoke with risk for breast cancer, based on the subset of cohort and case-control studies published before 2012 271

Figure 6.46  Forest plots showing the association between premenopausal (n = 12) and postmenopausal (n = 13) status for the Most comprehensive measure of exposure to secondhand smoke with risk for breast cancer, based on the subset of cohort and case-control studies published before 2012, excluding studies with design or analysis issues 273

Chapter 7  Respiratory Diseases

Table 7.1  Genome-wide association studies of chronic obstructive pulmonary disease (COPD) and COPD-related phenotypes 365

Table 7.2  Population-based cohort studies of cigarette smoking and asthma induction in children and adolescents S-203

Table 7.3  Studies of cigarette smoking and asthma induction in adults S-205

Table 7.4  Studies of cigarette smoking, exacerbation of asthma, and natural history in adults S-208

Table 7.5  Studies on tobacco use and tuberculosis (TB) infection S-211

Table 7.6  Studies on tobacco use and tuberculosis (TB) disease S-217

Table 7.7  Studies on tobacco use and recurrent tuberculosis (TB) S-241

Table 7.8  Studies on tobacco and tuberculosis (TB) mortality S-244
Table 7.9 Meta-analysis of the association between smoking and latent tuberculosis (TB) infection, progression to active disease, and mortality from active TB 384

Table 7.10S Studies of risk of cigarette smoking and idiopathic pulmonary fibrosis (IPF), 1990–2011 S-250

Figure 7.1 Venn diagram with overlapping circles indicating chronic bronchitis, emphysema, and asthma, overlaid by a rectangle indicating airflow obstruction 357

Figure 7.2 Age-adjusted prevalence of chronic obstructive pulmonary disease (COPD) among adults—Behavioral Risk Surveillance System, United States, 2011 358

Figure 7.3 Deaths due to chronic obstructive pulmonary disease among adult men and women, 1979–2007, United States 359

Figure 7.4 Age-adjusted mortality rate from chronic obstructive pulmonary disease among adults 25 years of age or older, by gender, United States, 1968–2010 361

Figure 7.5 Age-adjusted all-cause mortality rates per 1,000 person-years (95% confidence interval [CI]) for men and women 25–74 years of age in the United States by survey and Global Initiative For Chronic Obstructive Lung Disease classification 362

Figure 7.6 Changes in rates of death from chronic obstructive pulmonary disease over time among current women and men smokers in three time periods 363

Figure 7.7 Natural history of tuberculosis from exposure to mortality 378

Figure 7.8 Progression to active tuberculosis disease among persons exposed to M. tuberculosis 378

Figure 7.9 Forest plot for hospital admissions for respiratory disease following the implementation of a smokefree law or policy 390

Table 8.3 Average annual percentage change in age-adjusted death rates for all causes and cardiovascular diseases (CVDs), United States, 1968–2008 416

Table 8.4 Prevalence of cardiovascular diseases (CVDs), United States, 2008 416

Table 8.5 Mortality rates from coronary heart disease adjusted to the U.S. 2000 standard populations, in men and women 55 years of age and older in Cancer Prevention Study (CPS-I), CPS-II, and contemporary cohorts 425

Table 8.6S Detailed description of studies on smokefree laws and coronary events S-255

Table 8.7S Detailed description of studies on smokefree laws and cerebrovascular accidents S-281

Table 8.8S Detailed description of studies on the relationship between smokefree laws and other heart disease S-287

Figure 8.1 Death rates for heart disease in males by age and race/ethnicity, United States, 2008 417

Figure 8.2 Death rates for heart disease in females by age and race/ethnicity, United States, 2008 418

Figure 8.3 Overview of mechanisms by which cigarette smoking causes an acute cardiovascular event 420

Figure 8.4 Relative risk and excess death rate for coronary heart disease among men, by age group 424

Figure 8.5 Forest plot of studies examining the association between exposure to secondhand smoke and risk of stroke, stratified by study design 431

Figure 8.6 Forest plot for studies on the relationship between smokefree laws and coronary events 438

Figure 8.7 Metargression for reduction in risk of hospitalization (or death) associated with implementation of comprehensive smokefree laws and acute myocardial infarction by time since implementation 439

Figure 8.8 Forest plot for studies on smokefree laws and cerebrovascular accidents 440

Figure 8.9 Forest plot for studies on smokefree laws and other heart disease 441

Figure 8.10 Funnel plot for risk estimates used in the meta-analysis on the association between smokefree legislation and hospitalizations for cardiac diseases 442

Chapter 8 Cardiovascular Diseases

Table 8.1 Cardiac vascular diseases 414

Table 8.2 Age-adjusted death rates and percentage change for all causes and for cardiovascular diseases (CVDs), United States, 1968 and 2010 415
Chapter 9
Reproductive Outcomes

Table 9.1  Data sources for smoking prevalence during pregnancy 462

Table 9.2  Summary of a systematic review of maternal smoking during pregnancy and its relationship with specific congenital malformations 473

Table 9.3S  Summary of studies of orofacial clefts and maternal smoking, 2002–2011 S-297

Table 9.4S  Summary of studies of maternal smoking and clubfoot, 1999–2011 S-300

Table 9.5S  Summary of studies of maternal smoking and gastroschisis, 1999–2011 S-302

Table 9.6S  Summary of studies of maternal smoking and congenital heart defects, 1999–2011 S-304

Table 9.7S  Summary of studies of maternal smoking and craniosynostosis, 1999–2011 S-307

Table 9.8S  Summary of studies of maternal smoking and anorectal atresia, 1999–2011 S-308

Table 9.9  Key words used in the systematic literature review of prenatal smoking and neurobehavioral disorders among offspring 480

Table 9.10S  Studies on associations between prenatal smoking and disruptive behavioral disorders in children, 2000–2012 S-309

Table 9.11S  Studies on associations between prenatal smoking and anxiety and depression in children, 2000–2012 S-329

Table 9.12S  Studies on associations between prenatal smoking and Tourette syndrome in children, 2000–2011 S-332

Table 9.13S  Studies on associations between prenatal smoking and intellectual disability in children, 2000–2009 S-333

Table 9.14S  Association between maternal smoking and ectopic pregnancy, studies included in 2001–2010 Surgeon General’s reports and subsequently published through March 2013 S-335

Table 9.15S  Studies on the effect of maternal active smoking on spontaneous abortion (SAB) risk S-340

Table 9.16S  Experimental studies of the association between smoking and erectile dysfunction S-342

Table 9.17S  Cross-sectional studies of the association between smoking and the risk of erectile dysfunction S-343

Figure 9.1  Catecholamine response to hypoxia by nicotine-exposed and unexposed rats 468

Figure 9.2  Triple-risk model for sudden infant death syndrome (SIDS) 470

Chapter 10
Other Specific Outcomes

Table 10.1S  Summary of evidence from case-control studies on the association between smoking and age-related macular degeneration (AMD) S-347

Table 10.2S  Summary of evidence from cross-sectional studies on the association between smoking and age-related macular degeneration (AMD) S-356

Table 10.3S  Summary of evidence from prospective cohort studies on the association between smoking and age-related macular degeneration (AMD) S-362

Table 10.4S  Summary of evidence from other types of studies on the association between smoking and age-related macular degeneration (AMD) S-370

Table 10.5S  Studies on the association between active smoking and dental caries S-374

Table 10.6S  Studies on exposure to tobacco smoke and dental caries S-379

Table 10.7S  Studies on smoking and failure of dental implants S-383

Table 10.8S  Characteristics of studies included in the meta-analysis on smoking and diabetes S-393

Table 10.9  Stratified analyses of pooled relative risk (RR) for incident diabetes from smoking 543

Table 10.10  Conclusions about the adverse effects of tobacco use and exposure to tobacco smoke on infectious diseases, from previous Surgeon General’s reports 546

Table 10.11  Conclusions about the adverse effects of tobacco use and exposure to tobacco smoke on asthma, from previous Surgeon General’s reports 547
Table 10.12 Conclusions about the adverse effects of tobacco use and exposure to tobacco smoke on chronic obstructive pulmonary disease, from previous Surgeon General’s reports 548

Table 10.13 Pathogen-associated molecular patterns and their respective pattern recognition receptors 550

Table 10.14 Studies on the association between smoking and rheumatoid arthritis (RA) risk  S-400

Table 10.15 Studies on the association between smoking and rheumatoid arthritis (RA) severity  S-403

Table 10.16 Studies on the association between smoking and rheumatoid arthritis (RA) treatment response S-405

Table 10.17 Studies on the association between smoking and systemic lupus erythematosus (SLE) risk  S-406

Table 10.18 Studies on the association between smoking and systemic lupus erythematosus (SLE) severity and manifestations S-408

Table 10.19 Studies on smoking and systemic lupus erythematosus (SLE) treatment response S-409

Table 10.20 Characteristics of the studies on the effects of current smoking on Crohn’s disease or ulcerative colitis S-410

Table 10.21 Characteristics of the studies on the effects of former smoking on Crohn’s disease or ulcerative colitis S-411

Figure 10.1 Adjusted relative risk (RR) of diabetes, current smokers compared with nonsmokers 541

Figure 10.2 Log relative risk of diabetes for current smokers, funnel plots without (A) and with 225 (B) trim-and-fill procedure 542

Figure 10.3 Pooled relative risk of diabetes associated with various levels of smoking intensity 544

Figure 10.4 Overview of immune defects caused by smoking in the lungs 549

Figure 10.5 Diagram of innate and adaptive immunity 551

Figure 10.6 The respiratory epithelium 553

Figure 10.7 Relationship between smoking on or before the time of diagnosis and risk of Crohn’s disease 578

Figure 10.8 Relationship between smoking on or before the time of diagnosis and risk of ulcerative colitis 580

Figure 10.9 Relationship between smoking on or before the time of diagnosis and risk of Crohn’s disease or ulcerative colitis among case-control studies conducted in Asia 582

Chapter 11 General Morbidity and All-Cause Mortality

Table 11.1 Studies on the association between smoking and all-cause mortality  S-437

Table 11.2 Studies on the association between smoking and poor general health  S-439

Table 11.3 Studies on the association between smoking and relative risk of poor functional status  S-441

Table 11.4 Studies on the association between smoking and SF-36 or SF-12 scores  S-444

Table 11.5 Studies on the association between smoking and other measures of health and function  S-446

Table 11.6 Studies on the association between smoking and hospitalizations  S-448

Table 11.7 Studies on the association between smoking and outpatient visits  S-450

Table 11.8 Studies on the association between smoking and nursing home stays  S-451

Table 11.9 Studies on the association between smoking and costs  S-452

Table 11.10 Annual per capita spending on health care, by smoking status and age group (2008 dollars) S-453

Table 11.11 Studies on the association between smoking and workplace absenteeism (days absent)  S-454

Table 11.12 Studies on the association between smoking and relative risk (RR) of workplace absenteeism S-455
Table 11.13  All-cause mortality and five main causes of death by smoking status: death rates per 100,000 among men of Cancer Prevention Study II Nutrition Cohort, Health Professional Follow-Up Study, National Household Survey, National Institutes of Health-AARP Diet and Health Study, and Women's Health Initiative, 2000–2010 634

Table 11.14  All-cause mortality and five main causes of death by smoking status: death rates per 100,000 among women of Cancer Prevention Study II Nutrition Cohort, Health Professional Follow-Up Study, National Household Survey, National Institutes of Health-AARP Diet and Health Study, and Women's Health Initiative, 2000–2010 635

Figure 11.1  Survivorship lines of life tables for White males falling into three categories relative to the usage of tobacco as in Pearl, 1938 626

Figure 11.2  Relative risk for all-cause mortality among female current versus never-smoker by amount smoked at recruitment 637

Figure 11.3  Relative risk for all-cause mortality among female former versus current smokers by age at stopping 638

Figure 11.4  Survival after 35 years of age among smokers and nonsmokers 639

Figure 11.5  Survival after 60 years of age for smokers and never smokers 640

Figure 11.6  Survival probabilities for current smokers and never smokers for women and men 641

Chapter 12
Smoking-Attributable Morbidity, Mortality, and Economic Costs

Table 12.1  Relative risks for adult mortality from smoking-related diseases, adults 35 years of age and older, based on Cancer Prevention Study II, United States 652

Table 12.2  Annual prevalence of current smoking and former smoking among adults, 35 years of age and older, for selected years; National Health Interview Survey (NHIS), United States, 1965–2011 654

Table 12.3  Relative risks by smoking status and age group, adults 35 years of age and older, United States 658

Table 12.4  Annual deaths and estimates of smoking-attributable mortality (SAM) for adults 35 years of age and older, total and by gender, United States, 2010–2014 660

Table 12.5  Average annual smoking-attributable mortality (SAM) for males 35 years of age and older, total and by age group, United States, 2005–2009 661

Table 12.6  Average annual smoking-attributable mortality (SAM) for females 35 years of age and older, total and by age group, United States, 2005–2009 663

Table 12.7  Average annual smoking-attributable mortality (SAM) for adults 35 years of age and older, total and by gender, United States, 2005–2009: Cancer Prevention Study II (CPS-II) relative risks (RRs) vs. CPS-II/contemporary cohorts RRs 664

Table 12.8  Average annual perinatal deaths attributable to smoking, United States, 2005–2009 665

Table 12.9  Deaths, years of productive life lost, and value of lost productivity from coronary heart disease and lung cancer attributable to exposure to secondhand smoke among nonsmoking adults, 20 years of age and older, United States, 2006 666

Table 12.10  Number and percentage of cigarette smoking-attributable conditions among current and former smokers, by condition, United States, 2000 668

Table 12.11  Average annual value of lost productivity attributable to death from cigarette smoking, adults 35–79 years of age, United States, 2005–2009 671

Table 12.12  Aggregate health care expenditures attributable to cigarette smoking by type of service among adults, 19 years of age and older, United States, 2009 672

Table 12.13  Aggregate health care expenditures ($ in billions) attributable to cigarette smoking among adults, 35 years of age and older, by age group and gender, United States, 2012 673

Table 12.14  Smoking-attributable fraction (SAF) and aggregate health care expenditures attributable to cigarette smoking by source of fund, National Health Expenditure Accounts (NHEA), United States, 2010 675

Table 12.15  Smoking-attributable mortality, total and by gender, United States, 1965–2014 677
Figure 12.1  The relationship of relative risk (RR) to the population-attributable fraction at different prevalence levels 650

Figure 12.2  Changes over time in death rates from lung cancer and chronic obstructive pulmonary disease (COPD) 656

Figure 12.3  Trend in civilian deaths in smoking-material home fires, United States, 1980–2010 662

Chapter 13
Patterns of Tobacco Use Among U.S. Youth, Young Adults, and Adults

Table 13.1  Sources of national survey data on tobacco use, United States 704

Table 13.2  Cumulative percentages of recalled age at which a respondent who had ever smoked daily first used a cigarette and began smoking daily, by smoking status among adults (30–39 year of age); National Survey on Drug Use and Health 2012; United States 708

Table 13.3  Prevalence of current cigarette smoking among young people, by selected characteristics; National Survey on Drug Use and Health (NSDUH) 2012; United States 711

Table 13.4  Prevalence of current smoking among adults 18 years of age and older, by selected characteristics; National Survey on Drug Use and Health (NSDUH) 2012; United States 712

Table 13.5  Prevalence of intermittent and daily smoking among young people who are past-month cigarette users, by selected characteristics; National Survey on Drug Use and Health (NSDUH) 2012; United States 713

Table 13.6  Prevalence of intermittent and daily smoking among adults 18 years of age and older among past-month cigarette users, by selected characteristics; National Survey on Drug Use and Health (NSDUH) 2012; United States 714

Table 13.7  Prevalence of intermittent and daily smoking among adults 18 years of age and older, by selected characteristics; National Survey on Drug Use and Health (NSDUH) 2012; United States 715

Table 13.8  Percentage of current adult daily smokers, 18 years of age and older, who attempted to quit smoking during the past year or had an interest in quitting smoking, by selected characteristics; National Health Interview Survey (NHIS) 2010 and 2012; United States 717

Table 13.9  Percentage of ever cigarette smokers 18 years of age and older who have quit smoking (i.e., the quit ratio), by selected characteristics; National Health Interview Survey (NHIS) 2012, United States 718

Table 13.10  Prevalence of current smokeless tobacco use among young people, by selected characteristics; National Survey on Drug Use and Health (NSDUH) 2012; United States 731

Table 13.11  Prevalence of current smokeless tobacco use among adults 18 years of age and older, by selected characteristics; National Survey on Drug Use and Health (NSDUH) 2012; United States 732

Table 13.12  Prevalence of current cigar use among young people, by selected characteristics; National Survey on Drug Use and Health (NSDUH) 2012; United States 737

Table 13.13  Prevalence of current cigar use among adults 18 years of age and older, by selected characteristics; National Survey on Drug Use and Health (NSDUH) 2012; United States 738

Table 13.14  Prevalence of current use of multiple tobacco products by age group; National Survey on Drug Use and Health (NSDUH) 2012; United States 743

Table 13.15  Prevalence of current use of multiple tobacco products among young people, by selected characteristics; National Survey on Drug Use and Health (NSDUH) 2012; United States 744

Table 13.16  Prevalence of current use of multiple tobacco products among adults 18 years of age and older, by selected characteristics; National Survey on Drug Use and Health (NSDUH) 2012; United States 745

Table 13.17  Percent current use of tobacco by product, school level, and gender; National Youth Tobacco Survey 2011 and 2012; United States 746

Table 13.18  Percent current use of tobacco by product, school level, and race/ethnicity, National Youth Tobacco Survey 2011 and 2012; United States 748

Table 13.19  Percentage of tobacco product use in the past month among persons 18 years of age and older, 2002–2012 750

Table 13.20  Sources of data and prevalence of electronic nicotine delivery systems (ENDS); United States, 2012–2013 752
Figure 13.1  Per capita consumption different forms of tobacco in the United States, 1880–2011  705

Figure 13.2  Per capita consumption of noncigarette products in the United States, 1970–2011  706

Figure 13.3  Cigar consumption in the United States, 2000–2012  707

Figure 13.4  Trends in prevalence (%) of current cigarette smoking among adults, 18 years of age and older, by gender; National Health Interview Survey (NHIS) 1965–2012; United States  710

Figure 13.5  Percentage of ever cigarette smokers 18 years of age and older who had quit smoking (i.e., the quit ratio), by gender; National Health Interview Survey (NHIS) 1965–2012; United States  719

Figure 13.6  Percentage of ever cigarette smokers 18 years of age and older who had quit smoking (i.e., the quit ratio), by age group; National Health Interview Survey (NHIS) 1965–2012; United States  719

Figure 13.7  Percentage of ever cigarette smokers 18 years of age and older, who had quit smoking (i.e., the quit ratio), by race/ethnicity; National Health Interview Survey (NHIS) 1965–2012; United States  720

Figure 13.8  Trends over time in the prevalence of current cigarette smoking among high school students, by gender and by race/ethnicity; National Youth Risk Behavior Survey (YRBS) 1991–2011; United States  721

Figure 13.9  Prevalence of current cigarette smokers, by gender, calendar year, and birth cohort  722

Figure 13.10  Trends in prevalence (%) of current smoking among adults 18 years of age and older, by race/ethnicity; National Health Interview Survey (NHIS) 1965–2012, United States  723

Figure 13.11  Trends in prevalence (%) of current cigarette smoking among adults, by age group; National Health Interview Survey (NHIS) 1965–2012; United States  723

Figure 13.12  Trends in prevalence (%) of daily cigarette smoking among adults 18 years of age and older, by gender; National Health Interview Survey (NHIS) 1991–2012; United States  724

Figure 13.13  Trends in prevalence (%) of daily cigarette smoking among adults 18 years of age and older, by race/ethnicity; National Health Interview Survey (NHIS) 1991–2012; United States  725

Figure 13.14  Trends in prevalence (%) of daily cigarette smoking among adults, by age group; National Health Interview Survey (NHIS) 1991–2012; United States  726

Figure 13.15  Annual probabilities of initiating cigarette smoking, by gender, birth cohort, and age  727

Figure 13.16  Mean number of cigarettes smoked per day, by gender, year, and birth cohort  728

Figure 13.17  Annual probabilities of cigarette smoking cessation, by gender, age, and birth cohort  729

Figure 13.18  Trends over time in the prevalence (%) of current smokeless tobacco among high school students, by gender and by race/ethnicity (males only); National Youth Risk Behavior Survey (YRBS) 1995–2011; United States  733

Figure 13.19  Trends in prevalence (%) of smokeless tobacco use among adults 18 years of age and older, by gender and selected survey years; National Health Interview Survey (NHIS) 1987–2010; United States  734

Figure 13.20  Trends in prevalence (%) of smokeless tobacco use among adult males, 18 years of age and older, by race/ethnicity and selected survey years; National Health Interview Survey (NHIS) 1987–2010; United States  735

Figure 13.21  Trends in prevalence (%) of smokeless tobacco use among adult males 18 years of age and older, by age group and selected survey years; National Health Interview Survey (NHIS), 1987–2010; United States  736

Figure 13.22  Trends over time in prevalence (%) of current cigar smoking among high school students, by gender and race/ethnicity; National Youth Risk Behavior Survey (YRBS) 1997–2011; United States  739

Figure 13.23  Trends in prevalence (%) of cigar use among adults 18 years of age and older, by gender and selected survey years; National Health Interview Survey (NHIS) 1987–2010; United States  740

Figure 13.24  Trends in prevalence (%) of current cigar use among adult males 18 years of age and older, by race/ethnicity and selected survey years; National Health Interview Survey (NHIS) 1987–2010; United States  741
Chapter 14
Current Status of Tobacco Control

Table 14.1 Modified traditional tobacco products and novel tobacco products 781
Table 14.2 State cigarette excise taxes (dollars per pack) and sales tax rate applied to cigarettes 790
Table 14.3 Punitive damages in tobacco litigation 799
Table 14.4 Summary of selected state program components and outcomes 807
Table 14.5 Total state tobacco-related revenues (in millions of dollars)—United States, 1998–2010 809
Table 14.6 Five principles for community interventions 812
Table 14.7 Summary of studies examining effects of mass media campaigns on youth and adult smoking behavior, attitudes, knowledge, intentions, or cessation 815
Table 14.8 Years and locations for the World Conferences on Smoking and Health 818
Table 14.9 Global tobacco control MPOWER key findings, 2008 821
Table 14.10 Global tobacco control MPOWER key findings, countries 100% smokefree, 2009 824

Figure 14.1 Meeting of the 1964 Surgeon General’s Advisory Committee 774
Figure 14.2 Cigarette advertisements 775
Figure 14.3A Total tobacco incidents in top-grossing U.S. movies, by Motion Picture Association of America rating 776
Figure 14.3B Tobacco impressions delivered by top-grossing U.S. movies, by Motion Picture Association of America rating 776
Figure 14.4 Annual retail tobacco price index and per capita (18+) cigarette consumption—United States, 1900–2012 789
Figure 14.5 Number of municipalities and local laws covering smoking in workplaces, restaurants, and enclosed public places, generally, 1978–2013 793
Figure 14.6 Map of 100% smokefree laws, United States, May 31, 2013 794
Figure 14.7 Total funding for state tobacco control programs, 1986–2009 (adjusted to fiscal year 2010 dollars) 806
Figure 14.8 World Health Organization (WHO) selected key indicators for tobacco control policies, 2012 822

Chapter 15
The Changing Landscape of Tobacco Control
Current Status and Future Directions

Table 15.1 End game strategies discussed in the scientific literature 833
Figure 15.1 Predicted rates of smoking initiation and cessation for U.S. adults, University of Michigan Tobacco Prevalence and Health Effects Model 848
Figure 15.2 Projection of U.S. adult smoking prevalence rates under status quo scenario and California rate scenarios, 2005–2020 849
Figure 15.3 Simplified dynamic model of protobacco and antitobacco forces on patterns of tobacco use 850
Figure 15.4 Effects of a 100% reduction in the quit attempt rate, treatment use, and treatment effectiveness on smoking prevalence, 2008–2020 850

Chapter 16
A Vision for Ending the Tobacco Epidemic: Toward a Society Free of Tobacco-caused Death and Disease

Table 16.1 Total cigarette consumption, United States, 1900–2012 868
Figure 16.1 Total cigarette consumption, United States, 1900–2012 868
Figure 16.2 Potential patterns of use of combustible products (CP) and non-combustible products (NCP) 874
### Definitions and Alternative Nomenclature of Genetic Symbols Used in This Report

Throughout this report, genes are represented by their abbreviations in italics. In many cases, proteins and enzymes related to these genes have the same abbreviation, presented in roman type. Definitions, alternative genetic symbols, related proteins and enzymes, and polymorphisms and variant genotypes are listed alphabetically by gene abbreviation.

<table>
<thead>
<tr>
<th>Gene symbol used in this report</th>
<th>Definition</th>
<th>Alternative gene symbol</th>
<th>Related protein/enzyme</th>
<th>Polymorphism/variant genotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAT</td>
<td>α1-antitrypsin</td>
<td>SERPINA1</td>
<td>AAT</td>
<td>PI<em>S, PI</em>Z, PI MZ, PI 22, GLN6VAL (S), GLN6LYS (Z)</td>
</tr>
<tr>
<td>ADD</td>
<td>adducin 1 (alpha)</td>
<td>ADD1</td>
<td>ADD1</td>
<td>GLY460TRP</td>
</tr>
<tr>
<td>AGT</td>
<td>O6-alkylguanine–DNA alkyltransferase</td>
<td>AGT</td>
<td>AGT</td>
<td>ILE143VAL, GLY160ARG</td>
</tr>
<tr>
<td>AHR</td>
<td>aryl hydrocarbon receptor</td>
<td>AHR</td>
<td>AHR</td>
<td></td>
</tr>
<tr>
<td>AHR RR</td>
<td>aryl-hydrocarbon receptor repressor</td>
<td>AHR RR</td>
<td>AHR RR</td>
<td></td>
</tr>
<tr>
<td>AIB1</td>
<td>amplified in breast 1</td>
<td>NCOA3</td>
<td>AIB1</td>
<td></td>
</tr>
<tr>
<td>AKT</td>
<td>v-akt murine thymoma viral oncogene homolog 1</td>
<td>AKT</td>
<td>AKT</td>
<td></td>
</tr>
<tr>
<td>ATM</td>
<td>ataxia telangiectasia mutated</td>
<td>ATM</td>
<td>ATM</td>
<td></td>
</tr>
<tr>
<td>APC</td>
<td>adenomatous polyposis coli</td>
<td>APC</td>
<td>APC</td>
<td></td>
</tr>
<tr>
<td>APO2</td>
<td>tumor necrosis factor receptor superfamily, member 10a</td>
<td>APO2</td>
<td>APO2</td>
<td></td>
</tr>
<tr>
<td>APOE</td>
<td>apolipoprotein E</td>
<td>TNFRSF10A</td>
<td>APOE</td>
<td>*2</td>
</tr>
<tr>
<td>ARMS2</td>
<td>age-related maculopathy susceptibility 2</td>
<td>LOC387715 A69S</td>
<td>ARMS2</td>
<td>rs10490942, rs10490912, rs10490924</td>
</tr>
<tr>
<td>BAD</td>
<td>BCL2-associated agonist of cell death</td>
<td>BBC2, BCL2L8</td>
<td>BAD</td>
<td></td>
</tr>
<tr>
<td>BAX</td>
<td>BCL2-associated X protein</td>
<td>BCL2LA</td>
<td>BAX</td>
<td></td>
</tr>
<tr>
<td>BCL3</td>
<td>B-cell CLL/lymphoma 3</td>
<td>BCL3</td>
<td>BCL3</td>
<td></td>
</tr>
<tr>
<td>BCL2L8</td>
<td>BCL2-associated agonist of cell death</td>
<td>BAD</td>
<td>BCL2L8</td>
<td></td>
</tr>
<tr>
<td>BCL2LA</td>
<td>BCL2-associated X protein</td>
<td>BAX</td>
<td>BCL2L4</td>
<td></td>
</tr>
<tr>
<td>BHLHB5</td>
<td>basic helix-loop-helix family, member e22</td>
<td>BHLHE22</td>
<td>BHE22</td>
<td></td>
</tr>
<tr>
<td>BHLHE22</td>
<td>basic helix-loop-helix family, member e22</td>
<td>BHLHB5</td>
<td>BHLHB5</td>
<td></td>
</tr>
<tr>
<td>BICD1</td>
<td>bicaudal D homolog 1 (Drosophila)</td>
<td>BICD1</td>
<td>BICD1</td>
<td></td>
</tr>
<tr>
<td>BMP4 T538C</td>
<td>bone morphogenetic protein 4</td>
<td>BMP4</td>
<td>BMP4</td>
<td></td>
</tr>
<tr>
<td>BOLL</td>
<td>bol, boule-like</td>
<td>BOLL</td>
<td>BOLL</td>
<td></td>
</tr>
<tr>
<td>BRCA1</td>
<td>breast cancer 1, early onset</td>
<td>BRCA1</td>
<td>BRCA1</td>
<td></td>
</tr>
<tr>
<td>BRCA2</td>
<td>breast cancer 2, early onset</td>
<td>BRCC2</td>
<td>BRCA2</td>
<td>HIS372ASN (T27113G), ILE3412VAL (G93268A)</td>
</tr>
<tr>
<td>Gene symbol used in this report</td>
<td>Definition</td>
<td>Alternative gene symbol</td>
<td>Related protein/ enzyme</td>
<td>Polymorphism/ variant genotype</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>------------</td>
<td>-------------------------</td>
<td>-------------------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>BRCC2</td>
<td>breast cancer 2, early onset</td>
<td>BRCA2</td>
<td>BRCC2</td>
<td></td>
</tr>
<tr>
<td>BRMS1</td>
<td>breast cancer metastasis suppressor 1</td>
<td>BRMS1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C3</td>
<td>complement component 3 (C3)</td>
<td>C3</td>
<td></td>
<td>R102G, rs1047286, rs11569536, rs3745565, P314L</td>
</tr>
<tr>
<td>C7</td>
<td>complement component 7</td>
<td>CXCL10</td>
<td>C7</td>
<td></td>
</tr>
<tr>
<td>CARD15</td>
<td>nucleotide-binding oligomerization domain containing 2</td>
<td>NOD2</td>
<td>CARD15</td>
<td></td>
</tr>
<tr>
<td>CC2</td>
<td>complement component 2</td>
<td>CC2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CDKN2A</td>
<td>cyclin-dependent kinase inhibitor 2A</td>
<td>P16</td>
<td>CDKN2A</td>
<td></td>
</tr>
<tr>
<td>CFB</td>
<td>complement factor B</td>
<td>CFB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CFH</td>
<td>complement factor H</td>
<td>CFH</td>
<td></td>
<td>rs3753394, rs800292, rs1061147, rs1061170, rs380390, rs1329428, Y402H, rs1410996, rs2274700, T1277C, CAATTTAG (P1), CCGCTTAG (P2), rs1410996-AG, rs1410996-GG, (GG)rs10490924/ (TT), (TT)rs10490924/(CC), Y402H, YY, AA, CC, TT, CT, HH</td>
</tr>
<tr>
<td>CHRNA3</td>
<td>cholinergic receptor, nicotinic, α3</td>
<td>CHRNA3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHRNA5</td>
<td>cholinergic receptor, nicotinic, α5</td>
<td>CHRNA5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHRN54</td>
<td>cholinergic receptor, nicotinic, β4</td>
<td>CHRNA5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>COX2</td>
<td>mitochondrially encoded cytochrome c oxidase II</td>
<td>COX2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CRP</td>
<td>C-reactive protein</td>
<td>CRP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CXCL10</td>
<td>chemokine (C-X-C motif) ligand 10</td>
<td>C7</td>
<td>CXCL10</td>
<td></td>
</tr>
<tr>
<td>CYP17</td>
<td>cytochrome P450, family 17, subfamily A, polypeptide 1</td>
<td>CYP17</td>
<td>CYP17</td>
<td></td>
</tr>
<tr>
<td>CYP1A1</td>
<td>cytochrome P-450, family 1, subfamily A, polypeptide 1 (CYP1A1)</td>
<td>CYP1A1</td>
<td>*2A, *2C, m1/m2, *1, *2, MSPI</td>
<td></td>
</tr>
<tr>
<td>CYP1A2</td>
<td>cytochrome P-450, family 1, subfamily A, polypeptide 1</td>
<td>CYP1A2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYP1B1</td>
<td>cytochrome P450, family 1, subfamily B, polypeptide 1</td>
<td>CYP1B1</td>
<td>LEU/LEU, VAL/VAL, 119S</td>
<td></td>
</tr>
<tr>
<td>CYP2A6</td>
<td>cytochrome P-450, family 2, subfamily A, polypeptide 6</td>
<td>CYP2A6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYP2E1</td>
<td>cytochrome P450, family 2, subfamily E, polypeptide 1</td>
<td>CYP2E1</td>
<td>RSAI</td>
<td></td>
</tr>
<tr>
<td>DAT1</td>
<td>dopamine active transporter 1</td>
<td>SLC6A3</td>
<td>DAT1</td>
<td>+/-</td>
</tr>
<tr>
<td>Gene symbol used in this report</td>
<td>Definition</td>
<td>Alternative gene symbol</td>
<td>Related protein/ enzyme</td>
<td>Polymorphism/ variant genotype</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>------------</td>
<td>-------------------------</td>
<td>-------------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td><strong>DCC</strong></td>
<td>deleted in colorectal carcinoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>EGFR</strong></td>
<td>epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) onco homolog, avian)</td>
<td></td>
<td>EGFR</td>
<td></td>
</tr>
<tr>
<td><strong>ELN</strong></td>
<td>Elastin</td>
<td></td>
<td>ELN</td>
<td></td>
</tr>
<tr>
<td><strong>ELOVL4</strong></td>
<td>ELOVL fatty acid elongase 4</td>
<td></td>
<td>ELOVL4</td>
<td></td>
</tr>
<tr>
<td><strong>ENOS</strong></td>
<td>endothelial nitric oxide synthase</td>
<td>NOS3</td>
<td>ENOS, NOS3</td>
<td></td>
</tr>
<tr>
<td><strong>EPHB2</strong></td>
<td>EPH receptor B2</td>
<td>ERK</td>
<td>EPHB2</td>
<td></td>
</tr>
<tr>
<td><strong>EPHX</strong></td>
<td>epoxide hydrolase</td>
<td></td>
<td>EPHX</td>
<td></td>
</tr>
<tr>
<td><strong>EPHX1</strong></td>
<td>epoxide hydrolase 1, microsomal (xenobiotic)</td>
<td></td>
<td>EPHX1</td>
<td></td>
</tr>
<tr>
<td><strong>ERBB2</strong></td>
<td>v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2</td>
<td>HER2</td>
<td>ERBB2</td>
<td></td>
</tr>
<tr>
<td><strong>ERCC2</strong></td>
<td>excision repair cross-complementing rodent repair deficiency, complementation group 2</td>
<td>XPD</td>
<td>ERCC2</td>
<td></td>
</tr>
<tr>
<td><strong>ERCC4</strong></td>
<td>excision repair cross-complementing rodent repair deficiency, complementation group 4</td>
<td>XPF</td>
<td>ERCC4</td>
<td></td>
</tr>
<tr>
<td><strong>ERCC5</strong></td>
<td>excision repair cross-complementing rodent repair deficiency, complementation group 5</td>
<td>XPG</td>
<td>ERCC5</td>
<td></td>
</tr>
<tr>
<td><strong>ERCC6</strong></td>
<td>excision repair cross-complementing rodent repair deficiency, complementation group 6</td>
<td></td>
<td>ERCC6</td>
<td></td>
</tr>
<tr>
<td><strong>ERK</strong></td>
<td>extracellular signal-regulated kinase</td>
<td>EPHB2</td>
<td>ERK</td>
<td></td>
</tr>
<tr>
<td><strong>ESR1</strong></td>
<td>estrogen receptor 1</td>
<td></td>
<td>ESR1</td>
<td></td>
</tr>
<tr>
<td><strong>FAM13A</strong></td>
<td>family with sequence similarity 13, member A</td>
<td></td>
<td>FAM13A</td>
<td></td>
</tr>
<tr>
<td><strong>FBLN5</strong></td>
<td>fibulin 5</td>
<td></td>
<td>FBLN5</td>
<td></td>
</tr>
<tr>
<td><strong>FBXW7</strong></td>
<td>F-box and WD repeat domain containing 7, E3 ubiquitin protein ligase</td>
<td></td>
<td>FBXW7</td>
<td></td>
</tr>
<tr>
<td><strong>FUT2</strong></td>
<td>fucosyltransferase 2 (secretor status included)</td>
<td>SE</td>
<td>FUT2</td>
<td></td>
</tr>
<tr>
<td><strong>GADD45</strong></td>
<td>growth arrest and DNA-damage-inducible, alpha</td>
<td></td>
<td>GADD45</td>
<td></td>
</tr>
<tr>
<td>Gene symbol used in this report</td>
<td>Definition</td>
<td>Alternative gene symbol</td>
<td>Related protein/ enzyme</td>
<td>Polymorphism/ variant genotype</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>------------</td>
<td>-------------------------</td>
<td>------------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>GFI1</td>
<td>growth factor independent 1 transcription repressor</td>
<td>GFI1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GST</td>
<td>glutathione-S-transferase</td>
<td>GST</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GSTA1</td>
<td>glutathione S-transferase alpha 1</td>
<td>GSTA1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GSTA4</td>
<td>glutathione-S-transferase α4</td>
<td>GSTA4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GSTM1</td>
<td>glutathione-S-transferase μ1 (GSTM1)</td>
<td>GSTM1-1</td>
<td>GSTM1</td>
<td>A/B</td>
</tr>
<tr>
<td>GSTM3</td>
<td>glutathione S-transferase μ3 (brain)</td>
<td>GSTM3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GSTP1</td>
<td>glutathione S-transferase π1</td>
<td>GSTP1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GSTT1</td>
<td>glutathione-S-transferase θ1 (GSTT1)</td>
<td>GSTT1-1</td>
<td>GSTT1</td>
<td>DEL</td>
</tr>
<tr>
<td>HER2</td>
<td>human epidermal growth factor receptor 2</td>
<td>ERBB2</td>
<td>HER2</td>
<td></td>
</tr>
<tr>
<td>HHIP</td>
<td>hedgehog interacting protein</td>
<td>HHIP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIF1A</td>
<td>hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)</td>
<td>HIF1A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HLA</td>
<td>major histocompatibility complex</td>
<td>HLA-A</td>
<td>HLA</td>
<td>SE</td>
</tr>
<tr>
<td>HLA-DPB1</td>
<td>major histocompatibility complex, class II, DP beta 1</td>
<td>HLA-DPB1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HLA-DPB2</td>
<td>major histocompatibility complex, class II, DP beta 2 (pseudogene)</td>
<td>HLA-DPB2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HO-1</td>
<td>heme oxygenase (decycling) 1</td>
<td>HMOX1</td>
<td>HMOX1</td>
<td></td>
</tr>
<tr>
<td>HRAS</td>
<td>v-Ha-ras Harvey rat sarcoma viral oncogene homolog</td>
<td>C-HRAS</td>
<td>C-HRAS, HRAS1 proto-oncoprotein</td>
<td></td>
</tr>
<tr>
<td>HTRA1</td>
<td>HtrA (high temperature requirement factor A) serine peptidase 1</td>
<td>HTRA1</td>
<td></td>
<td>GG, rs11200638, AA</td>
</tr>
<tr>
<td>IBD1</td>
<td>nucleotide-binding oligomerization domain containing 2</td>
<td>IBD1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ICAM-1</td>
<td>intercellular adhesion molecule 1</td>
<td>ICAM-1</td>
<td></td>
<td>GLY241ARG</td>
</tr>
<tr>
<td>IGHMP2</td>
<td>immunoglobulin mu binding protein 2</td>
<td>IGHMP2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IKKβ</td>
<td>inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta</td>
<td>IKK</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-1β</td>
<td>interleukin-1β (IL-1β)</td>
<td>IL-1β</td>
<td>IL-1β</td>
<td></td>
</tr>
<tr>
<td>IL-12</td>
<td></td>
<td>IL-12</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-13</td>
<td></td>
<td>IL-13</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gene symbol used in this report</td>
<td>Definition</td>
<td>Alternative gene symbol</td>
<td>Related protein/ enzyme</td>
<td>Polymorphism/ variant genotype</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>------------</td>
<td>-------------------------</td>
<td>-------------------------</td>
<td>------------------------------</td>
</tr>
<tr>
<td>IL-4</td>
<td>interleukin-4</td>
<td>IL-4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-5</td>
<td>interleukin-5</td>
<td>IL-5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-6</td>
<td>interleukin-6</td>
<td>IL-6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-8</td>
<td>interleukin-8</td>
<td>IL-8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-10</td>
<td>interleukin-10</td>
<td>IL-10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-17A</td>
<td>interleukin-17A</td>
<td>IL-17A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-18</td>
<td>interleukin-18</td>
<td>IL-18</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-23</td>
<td>interleukin-23</td>
<td>IL-23</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-33</td>
<td>interleukin-33</td>
<td>IL-33</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IP-10</td>
<td>chemokine (C-X-C motif) ligand 10</td>
<td>C-7, CXCL10</td>
<td>CXL 10</td>
<td></td>
</tr>
<tr>
<td>IREB2</td>
<td>iron-responsive element binding protein 2</td>
<td>IREB2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IRF6</td>
<td>interferon regulatory factor 6</td>
<td>IRF6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>JNK-1</td>
<td>c-Jun N-terminal kinase 1</td>
<td>MAPK8</td>
<td>JNK-1</td>
<td></td>
</tr>
<tr>
<td>KRAS</td>
<td>K-ras (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog)</td>
<td>KRAS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LacZ</td>
<td>beta-galactosidase</td>
<td>LACZ</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LC3B</td>
<td>microtubule-associated protein 1 light chain 3 beta</td>
<td>LCB3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LGALS4</td>
<td>lectin, galactoside-binding, soluble, 4</td>
<td>LGALS4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LIG4</td>
<td>ligase IV, DNA, ATP-dependent</td>
<td>LIG4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LOC387715 A69S</td>
<td>age-related maculopathy susceptibility 2</td>
<td>ARMS2</td>
<td>LOC387715</td>
<td>GG, GT+TT, rs10490924, rs10490942</td>
</tr>
<tr>
<td>MAOA</td>
<td>monoamine oxidase A</td>
<td>MAOA</td>
<td></td>
<td>5'uVNTR</td>
</tr>
<tr>
<td>MAPK8</td>
<td>mitogen-activated protein kinase 8</td>
<td>JNK-1</td>
<td>MK08</td>
<td></td>
</tr>
<tr>
<td>mEH3</td>
<td>microsomal epoxide hydrolase (mEH) polymorphism in exon 3</td>
<td>mEH3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MEK</td>
<td>mitogen-activated protein kinase</td>
<td>MEK</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MGMT</td>
<td>O6-methylguanine-DNA methyltransferase</td>
<td>MGMT</td>
<td>LEU8APHE, ILE143VAL</td>
<td></td>
</tr>
<tr>
<td>MnSOD2</td>
<td>manganese superoxide dismutase 2</td>
<td>MnSOD2</td>
<td>VAL (wild type), ALA</td>
<td></td>
</tr>
<tr>
<td>MMP</td>
<td>matrix metallopeptidase</td>
<td>MMP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gene symbol used in this report</td>
<td>Definition</td>
<td>Alternative gene symbol</td>
<td>Related protein/ enzyme</td>
<td>Polymorphism/ variant genotype</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>------------</td>
<td>-------------------------</td>
<td>-------------------------</td>
<td>--------------------------------</td>
</tr>
<tr>
<td>MMP 9</td>
<td>matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)</td>
<td>MMP 9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MMP 12</td>
<td>matrix metallopeptidase 12 (macrophage elastase)</td>
<td>MMP 12</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MPO</td>
<td>myeloperoxidase</td>
<td>MPO</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MYH9</td>
<td>myosin, heavy chain 9, non-muscle</td>
<td>MYH9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MSX1</td>
<td>muscle segment homeobox 1</td>
<td>MSX1</td>
<td>CA, X1.1, X1.3, X2.1, X2.4, T2090G</td>
<td></td>
</tr>
<tr>
<td>MTHFR</td>
<td>methylenetetrahydrofolate reductase</td>
<td>MTHFR</td>
<td>677C→T, CC</td>
<td></td>
</tr>
<tr>
<td>NAT1</td>
<td>N-acetyltransferase 1</td>
<td>NAT1, ARY1</td>
<td>1088, 1095, AA vs. TT, AA vs. CC, T1095A, 1088A, 1088T→A, 1095C→A</td>
<td></td>
</tr>
<tr>
<td>NCOA3</td>
<td>nuclear receptor coactivator 3</td>
<td>AIB1</td>
<td>NCOA3</td>
<td></td>
</tr>
<tr>
<td>NOD2</td>
<td>nucleotide-binding oligomerization domain containing 2</td>
<td>CARD15</td>
<td>NOD2</td>
<td></td>
</tr>
<tr>
<td>NOS3</td>
<td>nitric oxide synthase 3 (endothelial cell)</td>
<td>ENOS</td>
<td>ENOS, NOS3</td>
<td>A(-922)G, SNP2, GLU298ASP, G894T</td>
</tr>
<tr>
<td>NOTCH1</td>
<td>notch1</td>
<td>NOTCH1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NPPA</td>
<td>natriuretic peptide A</td>
<td>NPAA</td>
<td>2238T→C</td>
<td></td>
</tr>
<tr>
<td>P16</td>
<td>cyclin-dependent kinase inhibitor 2A</td>
<td>CDKN2A</td>
<td>P16</td>
<td></td>
</tr>
<tr>
<td>P53</td>
<td>tumor suppressor</td>
<td>P53</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PI</td>
<td>glutathione S-transferase pi 1</td>
<td>SERPINA1</td>
<td>S, Z, ZZ</td>
<td></td>
</tr>
<tr>
<td>P17</td>
<td>polymerase (DNA directed), epsilon 3, accessory subunit</td>
<td>POLE3</td>
<td>P17</td>
<td></td>
</tr>
<tr>
<td>PIK3CA</td>
<td>phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha</td>
<td>PIK3CA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>polA</td>
<td>polymerase (DNA directed), alpha 1, catalytic subunit</td>
<td>POLA1</td>
<td>POLA</td>
<td></td>
</tr>
<tr>
<td>PTPN22</td>
<td>protein tyrosine phosphatase, non-receptor type 22</td>
<td>PTPN22</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RAD23B</td>
<td>RAD23 homolog B (S. cerevisiae)</td>
<td>RAD23B</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RAF</td>
<td>rapidly accelerated fibrosarcoma</td>
<td>RAF</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gene symbol used in this report</td>
<td>Definition</td>
<td>Alternative gene symbol</td>
<td>Related protein/ enzyme</td>
<td>Polymorphism/ variant genotype</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>-------------------------</td>
<td>-------------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>Rag1</td>
<td>recombination activating gene 1</td>
<td>Rag1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RAS</td>
<td>rat sarcoma</td>
<td>RAS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RASSF1A</td>
<td>Ras association (RalGDS/AF-6) domain family member 1 (A isoform)</td>
<td>RASSF1A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RUNX1</td>
<td>runt-related transcription factor 1</td>
<td>RUNX1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SE</td>
<td>fucosyltransferase 2</td>
<td>FUT2</td>
<td>SE</td>
<td>Rs4646903</td>
</tr>
<tr>
<td>SERPINA1</td>
<td>serpin peptidase inhibitor, clade A (α-1 antiproteinase, antitrypsin), member 1</td>
<td>AAT</td>
<td>SERPINA1</td>
<td>PI*Z, SZ</td>
</tr>
<tr>
<td>SERPINE2</td>
<td>serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 2), member 2</td>
<td>PI7</td>
<td>SERPINE2</td>
<td></td>
</tr>
<tr>
<td>SERPINA3</td>
<td>serpin peptidase inhibitor, clade A (α-1 antiproteinase, antitrypsin), member 3</td>
<td>SERPINA3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SOD2</td>
<td>superoxide dismutase 2</td>
<td>SOD2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SOX5</td>
<td>SRY (sex determining region Y)-box 5</td>
<td>SOX5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>STK11</td>
<td>serine/threonine protein kinase 11</td>
<td>STK11</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SULT</td>
<td>sulfotransferase</td>
<td>SULT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SULT1A1</td>
<td>sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1</td>
<td>SULT1L1</td>
<td></td>
<td>ARG/HIS, *HIS</td>
</tr>
<tr>
<td>TGF-α</td>
<td>transforming growth factor-α</td>
<td>TGF-α</td>
<td>TAQ1</td>
<td></td>
</tr>
<tr>
<td>TNFα</td>
<td>tumor necrosis factor (TNF superfamily, member 2) α</td>
<td>TNFα</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TGF-β</td>
<td>transforming growth factor-β</td>
<td>TGF-β</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TGF-β3</td>
<td>transforming growth factor-β3</td>
<td>TGF-β3</td>
<td>CA, x5.1, 5’UTR.1, T-24in4C, C641A, G15572</td>
<td></td>
</tr>
<tr>
<td>TNFRSF10A</td>
<td>tumor necrosis factor receptor superfamily, member 10a</td>
<td>TNFRSF10A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TNFRSF10C</td>
<td>tumor necrosis factor receptor superfamily, member 10c, decoy without an intracellular domain</td>
<td>TNFRSF10C</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TP53</td>
<td>tumor protein 53</td>
<td>TP53</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TP63</td>
<td>tumor protein 63</td>
<td>TP63</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TRPA1</td>
<td>transient receptor potential cation channel, subfamily A, member 1</td>
<td>TRPA1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>UGT1A7</td>
<td>UDP glucuronosyltransferase 1 family, polypeptide A7</td>
<td>UGT1A7</td>
<td></td>
<td>SNP1</td>
</tr>
<tr>
<td>VEGF</td>
<td>vascular endothelial growth factor</td>
<td>VEGFA</td>
<td>VEGF</td>
<td></td>
</tr>
<tr>
<td>Gene symbol used in this report</td>
<td>Definition</td>
<td>Alternative gene symbol</td>
<td>Related protein/ enzyme</td>
<td>Polymorphism/ variant genotype</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>--------------------------------------------------------</td>
<td>-------------------------</td>
<td>-------------------------</td>
<td>-----------------------------------------------------</td>
</tr>
<tr>
<td>XPC</td>
<td>xeroderma pigmentosum, complementation group C</td>
<td>XPC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>XPD</td>
<td>xeroderma pigmentosum. Complementation group D</td>
<td>ERCC2</td>
<td>XPD</td>
<td>LYS751GLN, GLN/GLN</td>
</tr>
<tr>
<td>XPF</td>
<td>xeroderma pigmentosum, complementation group F</td>
<td>ERCC4</td>
<td>XPF</td>
<td></td>
</tr>
<tr>
<td>XPG</td>
<td>xeroderma pigmentosum, complementation group G</td>
<td>ERCC5</td>
<td>XPG</td>
<td></td>
</tr>
<tr>
<td>XRCC1</td>
<td>x-ray repair complementing defective repair in Chinese hamster cells 1</td>
<td>XRCC1</td>
<td>XRCC1</td>
<td>ARG399GLN, ARG213HIS, ARG194TRP, ARG280HIS, C26602T, GLN632GLN, 194 ARG/ ARG</td>
</tr>
<tr>
<td>XRCC2</td>
<td>x-ray repair complementing defective repair in Chinese hamster cells 2</td>
<td>XRCC2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>XRCC3</td>
<td>x-ray repair complementing defective repair in Chinese hamster cells 3</td>
<td>XRCC3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>XRCC5</td>
<td>x-ray repair complementing defective repair in Chinese hamster cells 5</td>
<td>XRCC5</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Index

1964 report. See Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service (1964 report)
1971 report. See The Health Consequences of Smoking (1971 report)
1972 report. See The Health Consequences of Smoking (1972 report)
1975 report. See The Health Consequences of Smoking (1975 report)
1983 report. See The Health Consequences of Smoking–Cardiovascular Disease (1983 report)
1985 report. See The Health Consequences of Smoking–Chronic Obstructive Lung Disease in the Workplace (1985 report)
1990 report. See The Health Benefits of Smoking Cessation (1990 report)
1994 report. See Preventing Tobacco Use Among Young People (1994 report)
2001 report. See Women and Smoking (2001 report)
2012 report. See Preventing Tobacco Use Among Youth and Young Adults (2012 report)

A

AAT. See α-1-antitrypsin (AAT)

Accidents
active smoking, and evolution of conclusions regarding, 87
conclusions of Advisory Committee (1964), 101

Acrolein
cardiovascular disease, 421–422
effects on immunity, 560

Active cigarette smoking. See also Cigarette smoking
asthma, acute exacerbation of, 375
breast cancer
cigarette smoking status, 231, 233, 234, 235,
cigarettes smoked per day, 236–237, 238,
duration of cigarette smoking, 233–236, 237, 277
ever smoking status, 226–229, 227, 228, 230,
evolution of conclusions regarding, 67, 70
hormone receptor status, 245–247
menopausal status, 242–245
mortality, 276–277
no active versus no active/no passive smoking status, 229, 231, 232, 233,
pack-years of cigarette smoking, 237–240, 239
risk for, 215–225, 218
studies of, 215–225, 218
summary points, 254–255
timing of exposure to tobacco smoke, 240–242, 241, 243

Note: t following a number refers to a table; f following a number refers to a figure; S preceding number indicates supplement.
conclusions of Advisory Committee (1964), 67, 100–101t
dental caries, 534
evaluation for meta-analyses, studies on, S109–117t
evolution of conclusions regarding
adverse health effects, 68, 87–89t
cancer, 67, 70–75t
cardiovascular diseases, 67–68, 76t
reproductive outcomes or childhood neurobehavioral disorders, 68, 82–86t
respiratory diseases, 68, 77–81t
summary of meta-analyses, studies on, S118–119t
Adult coronary syndrome, described, 414t
Adult myeloid leukemia. See under Leukemia
Acute myocardial infarction (AMI)
described, 414t
smokefree laws, 437, 439f
smoker’s paradox, 426
smoking-attributable morbidity estimates, 667, 668t
Adaptive immunity, 546–550, 551
Addiction. See also Nicotine addiction
factors affecting, 784
physical abstinence syndrome, 30
Addition
withdrawal symptoms (physical abstinence syndrome), 30, 113
Adenocarcinoma of the colon and rectum, 198, 199. See also Colorectal cancer
Adenocarcinoma of the lung. See also Lung cancer
increase in smokers, 185, 186, 293
rates by countries, 177–178, 181f, 183f
rates of, in U.S., 161–178, 162f, 164–175f, 184–186
Adenotonsillectomy, 94t
ADHD. See Attention deficit hyperactivity disorder (ADHD)
Adiponectin levels, 421
Administrative rather than a scientific consensus, 22
Adolescents. See also Young adults
1994 Surgeon General’s Report, 50t
2012 Surgeon General’s Report, 51t
active smoking during childhood and adolescence, 81t
asthma and smoking, 372–373, 391, 392
cigarette smoking
current, 709, 711t
daily versus intermittent, 710, 713t
trends over time, 718, 721f
electronic cigarette use, 743, 746–747t, 748–749t
females
1980 Surgeon General’s Report, 48t
cigarette smoking, current, 718, 721f
measures of tobacco use, 763–764
nicotine and nervous system development, 121–122
nicotine exposure, 126
projected smoking-related deaths (2012), 666–667
smokeless tobacco use, current, 730, 731t
Adults
cigarette smoking
attempts to quit in the past year or interest in quitting, 716, 717t
current, 709, 710f, 712t, 720, 722f, 723f, 765
current, 1965–2012, 867
daily, trends over time, 720–724, 724f, 725f, 726f
daily consumption, 726, 728f
daily versus intermittent, 710–716, 714t, 715t
former, 653, 654t
quit ratio, 716–718, 718f, 719f, 720f
relative risks, 655–657, 658t
trends over time, 720–724, 722f, 723f, 724f
cigar use
current, 736, 738t
trends over time, 740, 740f, 741f, 742f
deaths, years of productive life lost, and value of lost productivity from CHD and lung cancer, and secondhand smoke, 2006, 665, 666f
disease outcomes, 657
former smokers, relative risks for, 655–657, 658t
health care expenditures attributable to cigarette smoking, 672–673, 673t
measures of tobacco use, 764–765
new and emerging products use, 743–750, 750t
nicotine and cognitive function, 122–123
patterns of tobacco use, 701–770
polytobacco use, current, 741, 745t
RR estimates, 655–657, 658t
smokeless tobacco use
current, 730, 732t
trends, 734, 734f
intermittent, 710–716, 714t
trends over time among males, 734, 735f
smoking-attributable mortality (2005–2009), 659–666, 661f, 663t
smoking-attributable mortality (2010–2014), 659, 660t
smoking prevalence, projections of, 847–851
smoking prevalence, reduction at end of twentieth century, 846
Advertising. See also Marketing; Media
American Medical Association journal, 20
bans and restrictions on, 796–798
change in cigarette advertising, following 1964 Surgeon General’s Report, 25–26
for cigarettes, 775f
conclusions on, 827
early twentieth century, 19
Fairness Doctrine, 24
for moist snuff, 706
Advertising Age, 26
Advisory Committee to 1964 Surgeon General’s Report
1964 meeting, 774
causation, criteria for, 22
members, selection of, 21, 22
Advocacy efforts for restricting tobacco use, 778–779
Advocacy Institute, 779
Affordable Care Act. See Patient Protection and Affordable Care Act of 2010
Aflatoxins, 187
African Americans. See Blacks or African Americans
Age-Related Eye Disease Study, 530
Age-related macular degeneration (AMD), 527–532, 584
active smoking, and evolution of conclusions regarding, 68, 88
advanced, 530, 531
atrophic, 527
conclusions on, 10
early-stage, 530
genetic factors, 531
geographic atrophy, 527, 528, 530
neovascular, 527, 530, 531
smoking, case-control studies on, S347–355
smoking, cross-sectional studies on, S356–361
smoking, linked to, 47
smoking, other studies on, S370–373
smoking, prospective studies on, S362–369
smoking and, generally, 528–532
Age stratification in smoking-attributable mortality, 655
AhR. See Aryl hydrocarbon receptor (AhR)
Airflow obstruction, and COPD classification, 356, 357, fh
Air Force tobacco control policies, 778
Airline smoking policies, 27
Airway remodeling, with asthma, 371
Alarmin, 547
Alaska Natives
prenatal smoking prevalence, 463
Albany Cardiovascular Health Center Study, 427
Alcohol use/abuse
breast cancer, 279–280
colorectal cancer, 197
liver cancer, 187
tuberculosis, 377, 379
Allergic symptoms, 47
α-1-antitrypsin (AAT)
augmentation therapy for COPD, 367
deficiency
COPD, 356, 361–362, 371, 391
emphysema, 367
Altria, 706
Alveolar macrophages, 554–555
Alzheimer’s disease, 123
AMA. See American Medical Association (AMA)
AMD. See Age-related macular degeneration (AMD)
American Cancer Society
Cancer Prevention Study II (CPS-II)
adult RR estimates, 655, 656, 6587
Nutrition Cohort, 655
relative risks for adult mortality from smoking-related diseases, 651–653, 6527
cigarette smoking and lung cancer, 21
coronary heart disease, 423, 4247
increasing cancer death rates, early twentieth century, 19
studies carried out by, 64
American Indians/Alaska Natives
cigarette smoking
attempts to quit in the past year or interest in quitting, 716, 717
current, 709, 712
daily versus intermittent, 710–716, 714, 715
quit ratio, 716, 718
kap use among adults, 736, 738
polytobacco use
current, among adults, 741
current, among young people, 741, 745
prenatal smoking prevalence, 463
smokeless tobacco use among adults, 730, 732
smokeless tobacco use among adults, 746
American Legacy Foundation, 777, 799
American Medical Association (AMA)
cigarette and alcohol advertising, 20
position on smoking during the 1960s, 26
American Productivity Audit, 631
American Recovery and Reinvestment Act (2009), 851
Americans for Non-Smokers Rights, 27
American Stop Smoking Intervention Study (ASSIST), 31
American Thoracic Society, 356, 357
American Tobacco Company, 17
AMI. See Acute myocardial infarction (AMI)
Androgens, 214
Androstenedione, 205
Angina pectoris
conclusions on, 10
described, 414
smokefree laws, 437
smokefree laws, studies on, S287–290
Angiogenesis and nicotine, 114–115, 116–117
Anorectal atresia
epidemiologic evidence, 476–477
evidence synthesis, 478
maternal smoking and, studies on, S308
maternal smoking during pregnancy, 473
Antibody-mediated autoimmunity, 558–559
Antitobacco effort, early twentieth century, 19
Anxiety and depression
conclusions on, 484, 499
epidemiologic evidence, 481–482
prenatal smoking and, studies on, S329–331
Aortic aneurysm
active smoking, and evolution of conclusions regarding, 68, 76
described, 414
nonsyphilitic, and 1971 Surgeon General’s Report, 46
smoking, linked to, 47
smokeless tobacco use, 428
APC gene, 198
Apoptosis of cells, 368
Arthritis. See Rheumatoid arthritis (RA)

Aryl hydrocarbon receptor (AhR)
- cardiovascular disease, 419
- cigarette smoke, component of, 560

Asbestos exposure
- 1974 Surgeon General’s Report, 47
- 1985 Surgeon General’s Report, 49

Asian Americans
- cigarette smoking
  - attempts to quit in the past year or interest in quitting, 716, 717
  - current, 709, 712
  - daily versus intermittent, 710–716, 714, 715
  - quit ratio, 716, 718
- cigar use, 736, 738
- diabetes among, 537
- polytobacco use
  - current, among adults, 741
  - current, among young people, 741, 745
  - smokeless tobacco use, 730, 732

Tobacco Use Among U.S. Racial/Ethnic Minority Groups
  (1998 report), 50

Australian Study of Health and Relationships, 495

Autoimmune disease. See also Rheumatoid arthritis (RA);
  Systemic lupus erythematosus (SLE)
- conclusions on, 11
- immune function, 545–571, 584

Autoimmunity
- antibody-mediated, 558–559
- cigarette smoke and, 567–568
- COPD, 368

Autotnate immunity, 568

Autophagy, 562

B

BACH (Boston Area Community Health) survey, 496

bacille Calmette-Guérin (BCG), 145

Bacterial infections and smoking, 562–563, 565–566

Bacterial meningitis, 562–563

Baltimore-Washington Infant Study, 476

Banzhaf, John F., III, 24

B[α]P. See Benzo[a]pyrene (B[a]P)

B cells
- antibody-mediated autoimmunity, 558–559
- COPD, 368

BCG (bacille Calmette-Guérin), 145

Beaver Dam Eye Study, 529–530, 531

Beclomethasone, 375

Behavioral counseling for prenatal smoking cessation, 463

Behavioral disorders of childhood. See Neurobehavioral disorders of childhood

Behavioral Risk Factor Surveillance System (BRFSS)
- morbidity and smoking, 627
- smoking prevalence, 653
Belgium, smokefree air laws in, 464
Benjamin, Regina
  2010 Surgeon General’s Report, 50t
  2012 Surgeon General’s Report, 51t
Benzo(a)pyrene (B(a)P)
  Canadian and Australian cigarettes, 157, 158f
  cardiovascular disease, 419
  cigarette smoke, in, 560
  colorectal cancer, 198, 199
  tobacco smoke, in, 155, 156t
Best Practices for Comprehensive Tobacco Control Programs
  (CDC), 806, 812, 814, 817
β-thromboglobulin, 421
BICD1 gene, 365t, 366
Bidis, 381
Bilateral trade and investment agreements, 826
Biliary cirrhosis, primary, 569
Birth certificates, and smoking prevalence during pregnancy, 461, 462, 463
Birth defects. See Congenital malformations
Birth weight
  1969 Surgeon General’s Report, 46t
  active smoking, and evolution of conclusions regarding, 84t
  conclusions of Advisory Committee (1964), 101t
  prenatal maternal smoking, effects of, 465
  secondhand smoke, 5f, 99t
Blacks or African Americans
  cardiovascular disease, 443
  cigarette smoking
    attempts to quit in the past year or interest in quitting, 716, 717t
    current, 709, 711t, 712t
    current, among adults, 720, 723t
    current, among high school students, 718, 721t
    daily, trends over time, 720–724, 725t
    daily versus intermittent, 710–716, 713t, 714t, 715t
    quit ratio, 716–718, 718t, 719t
  cigar use
    current, among adults, 736, 738t
    current, among young people, 735, 737t
    trends among adult males, 740, 741t
    trends among high school students, 736–740, 739t
  diabetes among, 537
  electronic cigarette use among youth, 743, 748–749t
  menthol cigarette marketing toward, 782–783
  polytobacco use
    current, among adults, 741
    current, among young people, 741, 744t, 745t
  smokeless tobacco use
    current, among adults, 730, 732t
    current, among high school students, 730–734, 733t
    current, among young people, 730, 731t
    trends among adult males, 734, 735t
Tobacco Use Among U.S. Racial/Ethnic Minority Groups
  (1998 report), 50t
Bladder cancer
  active smoking, and evolution of conclusions regarding, 70t
  age-adjusted incidence of, 146f, 147f
  bacille Calmette-Guérin (BCG), 145f
  conclusions of Advisory Committee (1964), 100t
  smoking, linked to, 4f
  Blindness and smoking, 4f
  Blue Cross and Blue Shield of Minnesota, 32
  Bone density, low, 89f, 244
  Boston Area Community Health (BACH) survey, 496
Brain
  cancer, 70t
  development, and nicotine, 8, 120, 126 (See also Neurocognitive development)
  Brandt, Allan M., 22
  BRCA1 gene, 217, 247, 248–249
  BRCA2 gene, 217, 247, 248–249
Breast and Prostate Cancer Cohort Consortium, 251
Breast cancer
  active smoking
    cigarette smoking status, 231, 233, 234f, 235f
    cigarettes smoked per day, 236–237, 238f
    duration of cigarette smoking, 233–236, 237f, 277
    ever smoking status, 226–229, 227f, 228f, 230f
    evolution of conclusions regarding, 67, 70t
    hormone receptor status, 245–247
    menopausal status, 242–245
    mortality and tobacco smoke, 276–277
    no active versus no active/no passive smoking status, 229, 231, 232f, 233f
    pack-years of cigarette smoking, 237–240, 239f
    risk for, 215–225, 218t
    secondhand smoke exposure, compared with, studies on, S152t
    summary points, 254–255
    timing of exposure to tobacco smoke, 240–242, 241f, 243f
    alcohol use, 279–280
    biologic plausibility of causal relationship with tobacco smoke, 283
    cigarette smoking, case-control studies on, S75–108t
    cigarette smoking, cohort studies on, S60–74t
    conclusions on, 8–9
    death rate, 209
    incidence by race/ethnicity, 209
    mortality and tobacco smoke, 275–277
    mortality rate of women in U.S., 1930–2008, 66, 66f
    potential etiologic mechanisms, 210–214, 212f, 213f
    premenopausal and postmenopausal relative risk, studies on, S120–122t
    risk factors and confounding variables, 224–225, 279–280
    risk for, with NAT2 phenotype, studies on, S126t
    secondhand smoke exposure
      active smoking, compared with, studies on, S152t
      breast cancer mortality, 277
      case-control studies on, S132–141t
cohort studies on, S127–131t
covariates, adjustment for, 265
evaluation for meta-analyses, studies on, S142–147t
evolution of conclusions regarding, 69, 90t
genotype interaction, 274
measures of exposure to, 263–264
mortality and tobacco smoke, 277
most comprehensive measures, 265, 266f, 267f, 268f, 269f
most comprehensive measures ever in lifetime, 267–269, 270f
premenopausal and postmenopausal comparison, 269, 271f, 272, 273f
previous Surgeon General’s reports, 257–263
risk for, 255–257
summary and review, 274–275
summary of meta-analyses, studies on, S148–149t
summary of meta-analyses for specific categories of exposure, studies on, S150–151t
in utero exposure, 272, 274
second primary breast cancer, 247
second primary breast cancer and active cigarette smoking, studies on, S125t
suggestive association with smoking, 292, 293
tamoxifen, 145f
Breathe California of Sacramento-Emigrant Trails, 775
BRFSS. See Behavioral Risk Factor Surveillance System (BRFSS)
Brigham and Women’s Hospital, 33
British Doctors Study
all-cause mortality, 636, 637, 639f, 640f
lung cancer death rates, 159
multiple diseases, smoking linked to, 64
prostate cancer mortality, 208
tuberculosis, 381
British Medical Journal, 29
British Women’s Heart and Health Study, 242
Bronchitis
children, and parental smoking, 47t
chronic (See also Chronic obstructive pulmonary disease (COPD))
chronic obstructive lung disease, type of, 356, 357f
conclusions of Advisory Committee in 1964, 100t
prevalence of, 357, 358f
smoking, 625
smoking as important cause of, 3
smoking-attributable morbidity estimates, 667, 668f
Bronchus-associated lymphoid tissue (BALT), 368
Bronchus cancer
mortality rate in U.S., 1900–2005, 63f, 65
mortality rate of men in U.S., 1930–2008, 65f, 66
mortality rate of women in U.S., 1930–2008, 66, 66f
smoking, linked to, 4f
Brundtland, Gro Harlem, 818, 820, 875
Buerger’s disease (thromboangiitis obliterans), 428
Bulgaria, smoking-attributable mortality in, 691
Burney, Leroy E.
cigarette smoking as cause of lung cancer, 45
cigarette smoking as etiological factor in lung cancer, 21
Public Health Service, role of, 23
Buses, smoking on, 27

C

C3 gene, 528
Cadmium, as fetal toxin, 472
Calcium levels, and colorectal cancer, 197
Califano, Joseph A., Jr.
antismoking campaign, 27
Office on Smoking and Health, 6
California Environmental Protection Agency (Cal/EPA)
active cigarette smoking and breast cancer, 215, 216
nicotine, 471
secondhand smoke and breast cancer, 256, 257
Californians for Non-Smokers Rights, 27
California Teachers Study
breast cancer and active cigarette smoking, 217, 219–220
breast cancer and no active versus no passive smoking, 229
breast cancer and secondhand smoke, 259, 260, 263
duration of cigarette smoking, 235
California Tobacco Control Program, 779
Camel Snus, 706
Campaign Against Cancer and Heart Disease (CLUE II), 202
Canada
adenocarcinoma of the lung, 181f
cigarette differences, 155, 157, 157f
lung cancer, 177, 178
small cell carcinoma of the lung, 180f
squamous cell carcinoma of the lung, 179f
warning labels in, 855
Canadian Expert Panel on Tobacco Smoke and Breast Cancer Risk
active cigarette smoking, 215–216
secondhand smoke, 257
Canadian National Breast Screening Study
breast cancer and active cigarette smoking, 216
duration of cigarette smoking, 233
Cancer. See also specific types of cancer, e.g., lung cancer
animal studies for carcinogenicity of nicotine, 115
conclusions on, 8–9, 293
5-year survival rate, 143, 144f
The Health Consequences of Smoking–Cancer (1982 report), 48f
human studies for carcinogenicity of nicotine, 115–116
induction mechanisms, in tobacco smoke, 148–151, 148f
major events in cancer field, 1863–2006, 143, 144f
mortality
cancer-related mortality and smoking, studies on, S173–179t
conclusions on, 870
increasing death rates, early twentieth century, 19, 20
mortality from, 1964–2014, 17
mortality rate in U.S., 1900–2005, 63f, 65
mortality rate of men in U.S., 1930–2008, 65f, 66
mortality rate of women in U.S., 1930–2008, 66, 66f,
overall mortality in cancer patients, studies on, S153–166t
smoking-attributable mortality (1965–2014), 676–678, 677t
smoking-attributable mortality for adults (2005–2009), 659–662, 661f, 663t, 664t
smoking-attributable mortality for adults (2010–2014), 659, 660t
smoking-attributable mortality (1965–2014), 676–678, 677t
smoking-attributable mortality for adults (2005–2009), 659–662, 661f, 663t, 664t
smoking-attributable mortality for adults (2010–2014), 659, 660t
nicotine exposure, 113–116
patients and survivors, adverse outcomes in, 9, 284–291, 292, 293
prevention, major events in, 143, 145f
recurrence
cancer patient adverse outcomes, 290, 291, 293
cancer recurrence, studies on, S184–188t
cigarette smoking and second primary cancers in cancer patients, 287–288
second primary breast cancer, 247
smoking by cancer patients and survivors, 285
relative risks, adults, 657, 658t
secondhand smoke
effects of, 28
 evolution of conclusions regarding, 68, 69, 90t
smoking
associated with, 4t, 562–563
 cancer recurrence, studies on, S184–188t
cancer response, studies on, S189–190t
cigarette smoking and survival times, 287
 evolution of conclusions regarding, 67, 70–75t
immunity, 570
lost productivity, 670, 671t
morbidity, 667, 668, 668t
overall mortality in cancer patients, studies on, S153–166t
overall survival in cancer patients, studies on, S167–172t
second primary cancer, studies on, S180–183t
smoking-attributable mortality (1965–2014), 676–678, 677t
smoking-attributable mortality for adults (2005–2009), 659–662, 661f, 663t, 664t
smoking-attributable mortality for adults (2010–2014), 659, 660t
treatment-related toxicity, studies on, S191–200t
treatment
response and cigarette smoking, 288
toxicity and cigarette smoking, 288–289
treatment-related toxicity, studies on, S191–200t
Cancer Intervention and Surveillance Modeling Network (CISNET), 160, 847
Cancer Prevention Study I (CPS-I)
counter smoking, and evolution of conclusions regarding,
active smoking, and evolution of conclusions regarding,
aortic aneurysm, 428
conclusions of Advisory Committee (1964), 101t
conclusions on, 10, 444
implications, 445
lower tar and nicotine cigarettes, 48t
mechanisms causing
atherogenesis, 419–420
endothelial function, 421
inflammation, 422–423
overview of, 419, 420f
prothrombotic effects of smoking, 421–422
mortality
death rate by smoking status, 634t, 635f, S455t, S458t
death rates for females, by age and race/ethnicity, 417, 418f
death rates for males, by age and race/ethnicity, 417, 417f
mortality decline, 1968–2010, 413, 415f, 416–417, 416t
mortality from, 1964–2014, 17
mortality rate in U.S., 1900–2005, 63f, 65
smoking-attributable mortality (1965–2014), 676–678,
677t
smoking-attributable mortality for adults (2005–2009),
659–662, 661t, 663t, 664t
smoking-attributable mortality for adults (2010–2014),
659, 660t
value of lost productivity attributable to death from
cigarette smoking, 670, 671t
nicotine, 116–117
peripheral arterial disease, 428
pipes and cigars, 428–429
prevalence of, 416t, 417
racial/ethnic disparities, 442–443
relative risks, adults, 657, 658t
risk reduction, 429–430
secondhand smoke
conclusions on, 444
evolution of conclusions regarding, 69, 91t
smokefree laws, 435
stroke, 430–434, 431t
smokefree laws, impact of, 435–443, 438f, 439f, 440f, 441f,
442f, S287–290t
smoking-attributable morbidity, 669
tobacco use, and evolution of evidence, 418
types of, 414–415t
Women and Smoking (2001 report), 50t
Cardiovascular system
congenital heart defects, 119, 473t, 475–476, 479, 499
oral contraceptive use by smokers, 47t
Carmona, Richard
2004 Surgeon General’s Report, 50t
2006 Surgeon General’s Report, 50t
Carolina Breast Cancer Study
active smoking, 226
secondhand smoke, 261, 263
smoking, 222
Case-control studies
age-related macular degeneration, S347–355t
breast cancer, 221–224, S26–27t, S75–108t, S132–141t
colorectal cancer, S26–27t
liver cancer, 53–11t
stroke risk factors, 433
Cataracts
2004 Surgeon General’s Report, 50t
evolution of conclusions regarding, 68, 88t
smoking, linked to, 4f
Catecholamine response to hypoxia by rats, 468f
Causation/causal inferences
application of criteria in reports, 52–53
breast cancer, 281–283
cancer patient adverse outcomes, 289–290
causal inferences, strength hierarchy for, 53
criteria for, in 1964 Surgeon General’s Report, 21, 22
development of criteria for 1964 Surgeon General’s Report,
51–52
strength hierarchy for, 3, 3t, 53
CC16 (Clara cell secretory protein 16), 367
CD8+ T cells, 368
CD (cluster differentiation) 40 receptor, 422
CDC. See Centers for Disease Control and Prevention (CDC)
CDKN2A gene, 150
Celebrezze, Anthony J., 23
Cells, apoptosis of, 368
Center for Indoor Air Research, 32
Center for Tobacco Products (FDA), 33
Centers for Disease Control and Prevention (CDC)
Best Practices for Comprehensive Tobacco Control
Programs, 806, 812, 814, 817
Communicable Disease Center, 23
Initiatives to Mobilize for the Prevention and Control of
Tobacco Use program, 805
National Tobacco Control Program, 805
Office on Smoking and Health, 55
School Health Policies and Programs Study, 793
serious medical conditions caused by smoking, 625
Smoking-Attributable Mortality, Morbidity, and Economic
Costs (SAMMEC) system, 649
smoking-attributable mortality estimates, 688
Centers for Medicare & Medicaid Services, 222
Central nervous system defects, 477
Ceramide, 368
Cerebrovascular disease and stroke
1971 Surgeon General’s Report, 46t
active smoking, and evolution of conclusions regarding, 68,
76t
conclusions on, 10
current, former, and never smokers, 427–428
described, 415t
mortality
death rate by smoking status, 634t, 635t, S457t, S458t
death rates, 1968–2008, 415t
smoking-attributable mortality for adults (2005–2009),
659–662, 661t, 663t
smoking-attributable mortality for adults (2010–2014),
659, 660t
relative risks, adults, 657, 658t
secondhand smoke, 5f, 430–434, 431f
secondhand smoke, and evolution of conclusions regarding,
69, 91t
smokefree laws, 437, 440f
smokefree laws and cerebrovascular accidents, studies on,
S281–286t
smoking, linked to, 4f
smoking-attributable morbidity estimates, 667, 668t
Cervical cancer
active smoking, and evolution of conclusions regarding, 67,
70t
age-adjusted incidence of, 147f
The Health Consequences of Smoking (2004 report), 50t
human papilloma virus, 145f
secondhand smoke, and evolution of conclusions regarding,
69, 90t
smoking, linked to, 4f
Cessation. See Smoking cessation; Tobacco cessation, clinical and educational approaches

CYP gene, 528

CHARGE (Cohorts for Heart and Aging Research in Genomic Epidemiology), 364

CHD. See Coronary heart disease (CHD)

Chemically reactive intermediates, 561–562

Chewing tobacco. See Smokeless tobacco

Children. See also Adolescents; Infants; Neurobehavioral disorders of childhood

active smoking

child development, 68, 82t

childhood and adolescence, during, 81t

evolution of conclusions regarding, 68, 82–83t, 84t, 86t

asthma and smoking, 92t, 372–373, 391, 392, S457t, S458t

intellectual disability

conclusions, 484, 499

maternal smoking effects, epidemiologic evidence, 482–483

maternal smoking and, studies on, S334–335t, S334t

maternal active smoking, and evolution of conclusions regarding, 86t

neurobehavioral disorders, 479–484, 499

neurocognitive development, 469–470

parental smoking, and 1986 Surgeon General’s Report, 49t

secondhand smoke

developmental effects, 28, 69, 98–99t

health consequences, 5f

respiratory effects, 69, 92–94t

Children’s Health Insurance Program Reauthorization Act, 789, 869

Cholesterol, 419

CHRNA3 gene, 364, 365t, 366

CHRNA5 gene, 364, 365t, 366

Chromosome 19q, 364, 365t

Chronic bronchitis. See under Bronchitis

Chronic diseases

etiological research, 21–22

nonneoplastic bronchopulmonary diseases, 46t

smoking, linked to, 4f

Chronic obstructive lung disease (COLD). See also Chronic obstructive pulmonary disease (COPD); The Health Consequences of Smoking–Chronic Obstructive Lung Disease (1984 report)

1984 Surgeon General’s report, 49t

1985 Surgeon General’s report, 49t

Genetics of Chronic Obstructive Lung Disease (GenKOLS), 363

Global Initiative for Chronic Obstructive Lung Disease, 356, 362f

Chronic obstructive pulmonary disease (COPD). See also Bronchitis, chronic; Emphysema

active smoking, and evolution of conclusions regarding, 68, 78t

antibody-mediated autoimmunity in, 558–559

asthma, overlap of clinical features with, 373

B cells in, 558–559

chapter 7 conclusions, 370–371, 391

COLD morbidity and mortality, 49t

comorbidities, 355

conclusions on, 9

dead by smoking status, 634t, 635t, S457t, S458t

death rates, 655, 656f

epidemiology of, 356–358, 357f, 358f

gender differences

gender effects, 358–359

gender-specific manifestations, 359–360

gender-specific morbidity and mortality, 360, 361f, 362f, 363f

prevalence, 359

genetics and genomics of, 361–367, 365f

lower tar and nicotine cigarettes, 48t

mortality

increased risk of, 65–66, 869

mortality from, 1964–2014, 17

smoking-attributable mortality for adults (2005–2009), 659–662, 661t, 663t

smoking-attributable mortality for adults (2010–2014, 659, 660t

pathogenesis, 367–370

prevalence of, 357, 358f, 359

relative risks, adults, 657, 658t

secondhand smoke, and evolution of conclusions regarding, 96t

smoking and, 4f, 563, 566

smoking-attributable morbidity, 668–669

T cells in, 558

Cigarette Labeling and Advertising Act of 1965, 46t

Cigarettes. See also Electronic cigarettes

addictiveness, 782, 801, 803

additives to, 154

Canadian and Australian differences, 155, 157, 157f, 158f, 185

changes in, and adenocarcinoma, 176

changes in, and increased risk, 186

changes in, and lung cancer, 151–152

deposition of smoke in the respiratory tract, 184

disease epidemic attributable to, 845

filtered and unfiltered, sales of, 152, 153f

filters and changes in smoking patterns, 184–185

filters and increase in adenocarcinoma, 293

flavorings, 783, 825–826

lower tar and nicotine, 48t

lower tar yields, 152–153, 153f

marketing of, 774

mentholated, 782–783

per capita consumption (1900–2012), 17, 18f, 19, 25, 31

per capita consumption (1963–2012), 846, 867

prevalence of use, 845

retail prices, effects of, 788–798, 789f, 791–792, 799

toxicants in, 154–155, 156f

venous blood concentrations, 110f

911
Cigarette smoke. See also Secondhand smoke
autoimmunity, 567–568
chemical components of, 550–552, 559–562
immune system, 552–559, 553f, 559–562, 563–564, 571
inflammation induced by, 563–564
Cigarette smoking. See also Active cigarette smoking; Smoking
definition of, 734
prevalence of, 710–716, 713
patterns of, 709–716
prevalence over time, 720–724, 724f, 725f, 726f
definition of, 764
demographic disparities in, 867
former
annual prevalence of, 653, 654f
health care expenditures attributable to, adults, 672–673, 673f
relative risks, adults, 655–657, 658f
health care expenditures attributable to, adults, 672–673, 673f
history by birth cohorts, 722f, 722f
intermittent
definition of, 713f, 715f, 765
measures of, 765
patterns of, 709–716
prevalence of, 710–716, 713f, 714f, 715f
trends over time, 720–724, 724f, 725f, 726f
definition of, 764
demographic disparities in, 867
Cigars
1973 Surgeon General’s Report, 47f
cardiovascular disease, 428–429
definition of, 734
filtered cigars, 707, 707f
little cigars, 47f, 706–707, 706f, 707f
types of, 734
Cigar use
current among adults, 736, 738f
among young people, 735, 737f
definition of, 735, 766
measures of, 766
patterns of, 734–740
trends, 705, 705f, 706–707, 706f, 707f
trends among adult males, 740, 741f
trends among high school students, 736–740, 739f
trends over time, 736–740, 739f, 740f, 741f, 742f
Cipollone v. Liggett Group, Inc., 32
Cirrhosis of the liver
active smoking, and evolution of conclusions regarding, 88f
biliary, primary, 569
conclusions of Advisory Committee (1964), 101f
liver cancer, 187
CISNET (Cancer Intervention and Surveillance Modeling
Network), 160, 847
Civil Aeronautics Board, 27
Clara cell secretory protein 16 (CC16), 367
Clean Air Act Extension of 1970, 29
Clean indoor air policies, 792–795
conclusions on, 827
forms of, 792
numbers of laws, 793f
Cleft lip. See also Orofacial clefts
description, 473
epidemiologic evidence, 473–474
Cleft palate. See also Orofacial clefts
description, 473
epidemiologic evidence, 473–474
Clinical approach to reduce tobacco use, 50f
Clopidogrel, 422
Clubfoot (idiopathic talipes equinovarus)
conclusions on, 479, 499
evidence synthesis, 478
maternal smoking and, studies on, S300–301f
maternal smoking during pregnancy, 473f
nicotine, 119
CLUE II (Campaign Against Cancer and Heart Disease), 202
Cluster differentiation (CD) 40 receptor, 422
CO. See Carbon monoxide (CO)
Cochrane Review, 811
Cognitive function
decline in, measuring, 629
neurocognitive development, 8, 120, 126, 469–470
nicotine, 120–125
The Health Consequences of Smoking—50 Years of Progress

Coherence of association, as causation criterion, 21
Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE), 364
Cohort studies
  breast cancer
    active smoking, 217–218, 220
    no active versus no active/no passive smoking, 231
    secondhand smoke exposure, 258, 259, 260, S127–131t
    smoking and, 217–221, S60–74t
  colorectal cancer, 202
  erectile dysfunction, 495–496
  liver cancer, S12–20t
  lung cancer death rates and smoking prevalence, 159–160
  prostate cancer incidence and mortality, S30–44t
COLD (chronic obstructive lung disease), 49t. See also Chronic obstructive pulmonary disease (COPD)
Collaborative Breast Cancer Study, 223, 226
Collaborative Group on Hormonal Factors in Breast Cancer
  active cigarette smoking, 215, 216
  active smoking and breast cancer mortality, 276
  alcohol use and breast cancer, 279
Colleges and universities, smokefree, 793
Colon cancer. See also Colorectal cancer
  adenocarcinoma, 198
  aspirin, 145f
Colorectal cancer
  active smoking, and evolution of conclusions regarding, 67, 71t
  adenomatous polyps, 197, 198–199, 200f, 201f, 203, 204
  age-adjusted incidence of, 143, 146f, 147f
  causal association with smoking, 292, 293
  cigarette smoking, case-control studies on, S26–27t
  cigarette smoking, studies on, S21–25t
  conclusions on, 8, 870
  mortality
    mortality and cigarette smoking, studies on, S28–29t
    mortality rate of men in U.S., 1930–2008, 65f
    mortality rate of women in U.S., 1930–2008, 66f
  risk factors and protective factors, 197
  smoking, linked to, 4f
Columbus, Christopher, 17
COMMIT intervention, 811–812
Communicable Disease Center, 23
Community interventions, 811–812
Community Preventive Services Task Force on smokefree policies, 794, 795
Complications of Age-related Macular Degeneration Prevention Trial, 530
Comprehensive approach to reduce tobacco use
devvelopment of, 805
Reducing Tobacco Use (2000 report), 50t
Comprehensive Smokeless Tobacco Health Education Act of 1986, 6
COM-THL genotype, 274
Conclusions. See within specific topics
Concurrent use. See Polytobacco use
Confronting the Tobacco Epidemic in a New Era of Trade and Investment Liberalization (WHO), 826
Congenital heart defects
  conclusions on, 479, 499
  epidemiologic evidence, 475–476
  evidence synthesis, 479
  maternal smoking and, studies on, S304–306t
  maternal smoking during pregnancy, 473t
  nicotine, 119
Congenital malformations, 471–479. See also specific malformations, e.g., orofacial clefts
  active smoking, and evolution of conclusions regarding, 83t
  biologic basis for, 471–472
  conclusions on, 10, 479, 499
  epidemiologic evidence, 473–478
  anorectal atresia, 476–477
  clubfoot, 474–475
  congenital heart defects, 475–476
  craniolacunar, 476
  gastrochisis, 475
  genetic polymorphisms, 477–478
  orofacial clefts, 473–474
  other defects, 477
  evidence synthesis, 478–479
  implications, 479
  literature review description, 472–473
  methodologic considerations, 473
  nicotine, 119
  overview, 471
  secondhand smoke, and evolution of conclusions regarding, 98f
  smoking, linked to, 4f
Congestive heart failure, 414f
Congressional Budget Office, 630–631
Consistency of association
  breast cancer, 281–282
  cancer patient adverse outcomes, 289
  causation, criterion for, in 1964 Surgeon General’s Report, 21
Consumer Demand Roundtable, National Tobacco Cessation Collaborative, 804
Consumer Products Safety Act of 1972, 29
Contingency management interventions for smoking cessation in pregnancy, 464
Conwood, 706
Cooper, Theodore
  1975 Surgeon General’s Report, 47f
  1976 Surgeon General’s Report, 47f
COPD. See Chronic obstructive pulmonary disease (COPD)
COPDgene study, 360
Copenhagen City Heart Study
  active smoking and breast cancer mortality, 277
  asthma, 375
Coronary artery disease. See Coronary heart disease (CHD)
 Coronary heart disease (CHD)
  1967 Surgeon General’s Report, 46t
  active smoking, and evolution of conclusions regarding, 67–68, 76t
  conclusions on, 10
described, 413, 414t
  mortality
  death rate by smoking status, 634t, 635t, S457t, S458t
death rates, 1968–2008, 415t
  deaths attributable to smoking, 424–425
  mortality rates, 423–424, 425t
  relative risk and excess death rate, 423, 424t
  smoking-attributable mortality (1965–2014), 676–678, 677t
  smoking-attributable mortality for adults (2005–2009), 659–662, 661t, 663t, 664t
  smoking-attributable mortality for adults (2010–2014), 659, 660t
  value of lost productivity attributable to death from cigarette smoking, 670, 671t
  relative risks, adults, 657, 658t
  secondhand smoke
  causal link to, 5f
deaths, years of productive life lost, and value of lost productivity, 665, 666t
evolution of conclusions regarding, 69, 91t
smokefree laws and coronary events, studies on, S255–280t, S291t
smoking, linked to, 4f

Corticosteroids
  asthma, 375
  COPD, 367
  inhaled, 375
  oral, 367, 375
Cortisol, 214
Cotinine
  acute coronary syndrome, 436
  genotoxicity, 114
  nicotine toxicokinetics, 110–111
Council for Tobacco Research, 20, 32
CPS-I. See Cancer Prevention Study I (CPS-I)
CPS-II. See Cancer Prevention Study II (CPS-II)
Craniostenosis
  epidemiologic evidence, 476
  evidence synthesis, 478
  maternal smoking and, studies on, S307t
  maternal smoking during pregnancy, 473t
C-reactive protein (CRP)
  cardiovascular disease and inflammation, 422
  COPD biomarker, 367
Crohn’s disease, 562–563, 576, 584
  current smoking, studies on, S410–417t
  current smoking and, 577–579, 578–579t
  epidemiology of, 579–581
  former smoking, studies on, S427–429t
  former smoking and, 581, 582f
  incidence of, 576
  risk factors for, 576, 578–579f
  smoking and
  biologic basis, 576–577
  dose-response, 582–583
  evidence synthesis, 583
  implications, 583
Crotonaldehyde, 422
CRP. See C-reactive protein (CRP)
Cryptorchidism
  causal link to, 5f
deaths, years of productive life lost, and value of lost productivity, 665, 666t
evolution of conclusions regarding, 69, 91t
smokefree laws and coronary events, studies on, S255–280t, S291t
smoking, linked to, 4f

Current cigar use
  among adults, 736, 738t
  among young people, 735, 737t
  definition of, 735, 766
  measures of, 766
Current smokeless tobacco use
  among adults, 730, 732t
  among high school students, 730–734, 733f
  among young people, 730, 731t
  definition of, 765
  measures of, 765
Current smoking
  annual prevalence of, 653, 654t
daily versus intermittent, 709–716, 714t, 715t
  definition of, 708–709, 712f, 764
  health care expenditures attributable to, adults, 672–673, 673t
  and IBD, 577–581
  measures of, 765
  prevalence of, 693t–697t, 708–709, 710, 710f, 711t, 712t, 713t, 714t, 718, 720, 721f, 722f
  projected number of smoking-related deaths, 693t–697t
Current tobacco use, defined, 742
Cutis laxa, 363, 371, 391
CVD. See Cardiovascular disease (CVD)
CXCR2 chemotactic receptor, 419, 420
CYP1A1 enzyme, 210, 211, 247, 251–252
CYP1A2 enzymatic activity, 422
CYP1B1 enzyme, 251–252
Cystic fibrosis, 569
Cytomegalovirus, 540
D

Daily smoking
  definition, 709, 713f, 715t, 765
  history by cohorts, 726, 728f
  measures of, 765
  patterns, 709–716
  prevalence, 710–716, 713f, 714f, 715t
  trends over time, 720–724, 724f, 725f, 726f


Data sources for tobacco use, 703–704, 704t
Death. See Mortality and mortality rates
Dendritic cells, 556–557
Dental care, spending on, 532
Dental caries
active smoking, studies on, S374–378t
active smoking and, 534
secondhand smoke and, 534
smoking and, 533–535
tobacco smoke exposure, studies on, S379–382t
Dental disease, 532–537, 584
active smoking, and evolution of conclusions regarding, 68, 87t
conclusions on, 10–11
costs of, 532
smoking and
conclusions on, 532, 535
evidence synthesis, 535
implications, 535
Dental implant failure
smoking, studies on, S383–392t
smoking and, 535–537
Department of Defense (DoD)
smokefree policies, 795
tobacco, stance on, 778
Department of Health, Education, and Welfare, 6
Department of Health and Human Services, 13. See also Ending the Tobacco Epidemic: A Tobacco Control Strategic Action Plan for the U.S. Department of Health and Human Services (Strategic Action Plan)
Dependence. See Nicotine addiction
Desmosine, 367
Diabetes, 537–545
active smoking, and evolution of conclusions regarding, 68, 87t
conclusions on, 11, 584, 870
fasting glucose thresholds, 538–539
prevalence of, 537
relative risks, adults, 657, 658t
risk in smokers compared with nonsmokers, 540, 541t, 542t
smoking and, 4t, 538–540, 543–544t, 544–545
smoking and, conclusions on, 870
smoking and, studies in meta-analysis on, S393–399t
smoking-attributable morbidity, 669–670
smoking-attributable mortality for adults (2005–2009), 659–662, 661t, 663t
smoking-attributable mortality for adults (2010–2014), 659, 660t
smoking cessation and, 540
type 2, 540
Diet and colorectal cancer, 197
Disease. See also specific diseases
2010 Surgeon General’s Report, 50t, 871
adult outcomes, 657
cigarette-attributable disease epidemic, 845
Disruptive behavioral disorders
c oncclusions, 484, 499
maternal smoking effects, epidemiologic evidence, 480–481
prenatal smoking and, studies on, S309–328t
Dissolvable tobacco products (DTPs), 780, 781t, 782
DMF index, 533
DMFS index, 533
DMFT index, 533
DNA adducts
breast cancer, 210–211
carcinogenesis, 149
DNA repair genes and breast cancer, 253
Doctors Ought to Care, 27
DoD. See Department of Defense (DoD)
Dopamine, 113
DTPs (dissolvable tobacco products), 780, 781t, 782
Dual use. See Polytobacco use
Ductal carcinoma in situ, 145t
Duke, James B., 17
DuVal, Merlin K., 47t
Dynamic model of forces on patterns of tobacco use, 851

E

E1 (estrone), 212, 212t, 213, 213t, 214
E2 (estradiol), 212, 212t, 213, 213t, 214
E3 (estriol), 213
Economic approach to reduce tobacco use, 50t
Economic costs. See also Smoking-Attributable Mortality, Morbidity, and Economic Costs (SAMMEC)
dental care, spending on, 532
hospitalizations, 630
medical services utilization, 629–631
morbidity and smoking, 629–631
nursing home stays, 630
outpatient visits, 630
smoking, studies on, S453t
smoking-attributable
by age and gender, 672–673, 673t
annual costs, 679
formula for estimating, 674
by source of funds, 673–674, 675t
by type of medical services, 671–672, 672t
updated estimates of, 670–674
smoking status and age group, studies on, S453t
workplace absenteeism, 457–458t, 631, S454t
Ectopic pregnancy (EP), 484–487
biologic basis, 484–485
conclusions on, 10, 487, 499
epidemiologic evidence, 485–486
evidence synthesis, 486–487
implications, 487
literature review description, 485
maternal smoking and, studies on, S335–339t
smoking, linked to, 4t
ED. See Erectile dysfunction (ED)
Educational approach to reduce tobacco use. See Tobacco cessation, clinical and educational approaches
Edwards, Charles C., 47t
EHR (electronic health records), 804
Elastase:antielastase hypothesis for emphysema, 367
Elders, M. Joycelyn, 50t
Electronic cigarettes
determining health risks and benefits of, 873
electronic nicotine delivery systems, ENDS, 780, 781t
marketing of, 780
use of
current, 743, 746–747t, 748–749t
patterns of, 742–743, 746–747t, 748–749t, 750
prevalence of, 750, 752–760t
sources of data, 752–760t
Electronic health records (EHR), 804
Electronic nicotine delivery systems (ENDS), 752–760t, 780, 781t
ELN gene, 363
Emotional function and health status, 628
Emphysema. See also Chronic obstructive pulmonary disease (COPD)
chronic obstructive lung disease, type of, 356, 357f/
conclusions of Advisory Committee (1964), 100t
defined, pathologically, 367
prevalence of, 357, 358f/
smoking, 625
smoking-attributable morbidity estimates, 667, 668t
End game strategies (for ending tobacco epidemic), 852–857, 858, 872
as framework, 874
mentioned, 845, 849
on tobacco control interventions, impact of, 851
smoking, linked to, 4
smoking and, studies on, S342–344t
Endgame strategies (for ending tobacco epidemic), 852–857, 858, 872
Ending the Tobacco Problem: A Blueprint for the Nation (Institute of Medicine), 13
on interventions, 851
mentioned, 845
recommendations in, 869
vision of, 859
Endocannabinoids, 113
Endogenous opiates, 113
Endometrial cancer, 71t
Endothelium, vascular, 421
ENDS (electronic nicotine delivery systems), 752–760t, 780, 781t
England. See also under British
estimates of smoking-attributable mortality, 691
lung cancer, 177–178
Environmental Protection Agency (EPA)
creation of, 29
tobacco smoke classification as human carcinogen, Group A, 29
Environmental tobacco smoke. See Secondhand smoke
Environmental Tobacco Smoke: Measuring Exposures and Assessing Health Effects (National Academy of Science), 28
EP. See Ectopic pregnancy (EP)
EPA. See Environmental Protection Agency (EPA)
Epidemic. See Tobacco epidemic
Epidemiology
causation, proving, in 1964 report, 51–52
chronic diseases, focus on, 21–22
evidence, 529–532
key measures, 704
Epigenetic changes in cancer progression, 150
Erectile dysfunction (ED), 489–498
2004 Surgeon General’s Report, 490
active smoking, and evolution of conclusions regarding, 68, 84t
biologic basis, 490–491
chapter 9 conclusions, 499
clinical evidence, 491–492
histopathology, 492
penile tumescence studies, 491
vascular hemodynamics of the penis, 491–492
vascular morphology, 492
conclusions on, 10
epidemiologic evidence, 494–498
case series, 494
cohort studies, 495–496
cross-sectional studies, 495
dose-response relationships, 496
other risk factors, 496–497
smoking cessation, effects of, 497–498
evidence synthesis, 498
experimental evidence, 493–494
animal studies, 494
human studies, 493
implications, 498
literature review description, 494
overview, 489–490
risk for, and smoking, studies on, S343–344t
smoking, linked to, 4f/
smoking and, studies on, S342–344t
ERs. See Estrogen receptors (ERs)
Esophageal cancer
1971 Surgeon General’s Report, 46t
active smoking, and evolution of conclusions regarding, 71t
age-adjusted incidence of, 146f, 147f/
conclusions of Advisory Committee (1964), 100t
smokeless tobacco, 116
smoking, linked to, 4f/
tobacco smoke carcinogens, 151
Estradiol (E2), 212, 212f, 213, 213f, 214
Estriol (E3), 213
Estrogen and breast cancer, 212–213, 212f, 213f, 214
Estrogen receptors (ERs)
  breast cancer, 245–247
  breast cancer mortality, 277
  status of, and active cigarette smoking, studies on, S123–124f
Estrogens (E1), 212, 212f, 213, 213f, 214
Ethics, and proving causation, 51, 52
Europe. See also specific countries
  adenocarcinoma of the lung, 181f
  small cell carcinoma of the lung, 180f
  squamous cell carcinoma of the lung, 179f
European Prospective Investigation into Cancer and Nutrition cohort, 149
Evidence. See within specific topics
EX (adult cessation campaign), 813
Excise taxes
  conclusions on, 827
Exercise performance, 47t
Expert Committee on Addiction-Producing Drugs (WHO), 30
Externalizing disorders, described, 481
Eye disease. See also Age-related macular degeneration (AMD)
  blindness, 4f
  cataracts, 4f, 50f, 68, 88t
  conclusions on, 10
  evolution of conclusions regarding, 88t
  glaucoma, 88t
  tobacco amblyopia, 88t, 101t

Federal Food, Drug and Cosmetic Act of 1938, amendments to, 29
Federal tax rates on cigarettes, 789
Federal Trade Commission (FTC)
  Advisory Committee to 1964 Surgeon General’s Report, selection of members for, 22
  on cigarette advertising, 774
Females. See also Reproductive outcomes; Women and Smoking (2001 report)
  all-cause mortality and main causes of death by smoking status, 633, 635f, S458t
  cardiovascular disease death rates, 417, 418f
  cigarette smoking attempts to quit in the past year or interest in quitting, 716, 717f
  cessation, 726, 729f
  current, 709, 710f, 711f
  current, among adults, 720, 722f
  current, among high school students, 718, 721f
  daily, trends over time, 720–724, 724f
  daily consumption, 726, 728f
  daily versus intermittent, 710, 713f, 714f
  probability of initiating, 725–726, 727f
  quit ratio, 716–718, 718t, 719f
  cigar use
    current, among adults, 736, 738f
    current, among young people, 735, 737f
    trends among adults, 740, 740f
    trends among high school students, 736–740, 739f
  deaths, years of productive life lost, and value of lost productivity from CHD and lung cancer due to secondhand smoke, 665, 666t
  early-onset COPD, 360, 370, 371, 391
  electronic cigarette use among youth, 743, 746–747t
  health care expenditures attributable to cigarette smoking, adults, 672–673, 673t
  The Health Consequences of Smoking, 1977–1978, 47t
  The Health Consequences of Smoking for Women (1980 report), 48t
  health effects of smoking, 7
  hormones in postmenopausal women and smoking, studies on, S57–59t
  hormones in premenopausal women and smoking, studies on, S52–56t
  polytobacco use
    current, among adults, 741, 745t
    current, among young people, 741, 744t
  relative risks, adults, 657, 658t
  smokeless tobacco use
    current, among high school students, 730–734, 733f
    current, among young people, 730, 731f
    current, trends over time, 730–734, 733f
    trends, 734, 734f
  smoking-attributable mortality (1965–2014), 676–678, 677t
  smoking-attributable mortality for adults (2005–2009), 659–662, 663t, 664t
smoking-attributable mortality for adults (2010–2014), 659, 660
smoking cessation, 726, 729
smoking history, 724–726, 727f, 728, 729f
smoking prevalence, 461

Fertility. See also Reproductive outcomes
secondhand smoke, and evolution of conclusions regarding, 98t
smoking, linked to, 4f

Fetal death. See also Stillbirths
active smoking, and evolution of conclusions regarding, 84t
secondhand smoke, and evolution of conclusions regarding, 98t

Fetal effects. See also Birth weight
growth restriction, 46f, 118, 465–466
lower tar and nicotine cigarettes, 48t
maternal smoking, 28
nicotine exposure, 118, 126
secondhand smoke, 272, 274

Fibrinogen, 422
Fibrinolytic therapy, 426
Films. See Movies
Filtered cigars, 706–707, 707f
Finasteride, 145f
Finland, smoking-attributable mortality in, 691
Fires, residential
smoking-attributable mortality, total and by gender (1965–2014), 676–678, 677f
trends in civilian deaths in, 659, 662f
Five Day Plan for smoking cessation, 30
Flavorings in cigarettes
ban on, 783
WTO disputes, 825–826
Flow-mediated dilation of blood vessels, 421
Follicle-stimulating hormone, 214
Food and Drug Administration (FDA)
actions to date, 785–787
Advisory Committee to 1964 Surgeon General’s report, selection of members for, 22
FDA regulation of tobacco products, 33, 875
menthol cigarettes, action on, 783
R.J. Reynolds Tobacco Co. v. U.S. Food and Drug Administration, 785, 787
tobacco epidemic end game, potential actions supporting, 854

Former cigarette smoking
annual prevalence of, 653, 654f
health care expenditures attributable to, adults, 672–673, 673t
relative risks, adults, 655–657, 658t
4-Corners Breast Cancer Study, 261
4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), 177
4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK)
Canadian and Australian cigarettes, 157, 158f
carcinogenesis, 115, 149
nicotine replacement therapy, 116
tobacco smoke, in, 155, 156f

Frailty, defined, 629
Framework Convention Alliance (FCA), 821–822
Framingham Heart Study
CHD mortality rate, decline in, 413
COPD susceptibility genes, 365, 365f
coronary heart disease, 64
peripheral arterial disease and smoking, 428
sudden cardiac death, 427
Framingham Offspring Study, 428
“Frank Statement” of 1954, by the tobacco industry, 20
French National BRCA1/2 carrier cohort, 249
FTC. See Federal Trade Commission (FTC)
Functional status, poor, and smoking, studies on, S441–443f
Future of tobacco control. See Tobacco epidemic

G

Gallbladder cancer, 196
Gamma-aminobutyric acid (GABA), 113
Gastroeschis
c onsiderations on, 479, 499
epidemiologic evidence, 475
evidence synthesis, 478
maternal smoking and, studies on, S302–303t
maternal smoking during pregnancy, 473t
nicotine, 119

Gender differences. See also Females; Males
COPD, effects of, 358–359
COPD, manifestations of, 359–360
COPD morbidity and mortality, 360, 361f, 362f, 363f
COPD prevalence, 359
tuberculosis, 379

Gene Environment Interaction and Breast Cancer in Germany study, 223–224
Gene promoter hypermethylation, 148f, 150–151
General sales taxes, 788
Genetics. See also specific genes
breast cancer, 247–253
COPD
common genetic determinants, 363–364, 365f
COPD-related phenotypes, 364, 366
gene expression studies, 366
protein biomarkers, 366–367
rare genetic syndromes, 356, 361–363, 371, 391
lung cancer, 149–150
mutations and cancer, 149–151
polymorphisms
epidemiologic evidence, 477–478
evidence synthesis, 479
susceptibility to congenital malformations, 471

Genetics of Chronic Obstructive Lung Disease (GenKOLS), 363
Genome-wide association studies (GWAS)
COPD susceptibility, 364, 365f, 366
noncommunicable diseases, 65
Gestational age and smokeless tobacco, 465–466
GINA (Global Initiative for Asthma), 375
Glucoma, 88f
Global Burden of Disease project, 54
Global Initiative for Asthma (GINA), 375
Global Initiative for Chronic Obstructive Lung Disease (GOLD)
all-cause mortality rates, by age, 362f
COPD classification, 356
Global Smokefree Partnership (GSP), 822
Global Study of Sexual Attitudes and Behaviors, 495
Global Youth Tobacco Survey, 820
Glutamate, 113
Glutathione S-transferases
breast cancer, 247, 252
prostate cancer, 205
Graphic warning labels, requirements for, 785–786, 787
Graves’ hyperthyroidism, 569
Gray, Nigel, 818
Greece, estimates of smoking-attributable mortality in, 691
Group Against Smoking Pollution, 27
GSP (Global Smokefree Partnership), 822
GST1M1 gene
breast cancer, 210, 211, 247, 252
colorectal cancer, 198, 199
GSTP1 gene, 252
GSTT1 gene
breast cancer, 252
colorectal cancer, 198
Gum, nicotine polacrilex, 110f, 429
GWAS. See Genome-wide association studies (GWAS)

H

Haemophilus influenza, nontypeable (NTHi), 566
Harmful and potentially harmful constituents (HPHCs) in
  tobacco products, 786
HBV. See Hepatitis B virus (HBV)
HCC. See Hepatocellular carcinoma (HCC)
HCV. See Hepatitis C virus (HCV)
Health and Retirement Study, 627, 629, 630
Health behaviors and health status, 629
Health benefits and health status, 629
The Health Benefits of Smoking Cessation (1990 report)
  bladder cancer, 70t
  fertility, 83t
  leukemia (acute), 72t
  liver cancer, 72t, 187
  lung function level, 80t
  male sexual function, 84t
  pancreatic cancer, 74t
  respiratory illnesses, acute, 79t
  subject and highlights, 50t
Health care expenditures and costs. See Economic costs
Health Care Financing Administration, 222
Health claims in advertising, 19

Health communication interventions, 812–814
Health consequences. See also specific disease or symptom
  autoimmune disease, 545–571, 584
  conclusions from previous Surgeon General’s Reports, 528, 532, 546f, 547t, 548f, 576
  dental disease, 532–537, 584
eye disease, 527–532, 584
  immune function, 545–571, 584
  secondhand smoke, causal links to, 3, 5f
  smoking, causal links to, 3, 4f
The Health Consequences of Involuntary Exposure to Tobacco Smoke (2006 report), 103t
  all-cause mortality, 103t
  breast cancer, 256, 257–258, 260
cancer, 68, 69, 90t
  cardiovascular disease, 69, 91t, 419, 429, 435
  cardiovascular diseases, 69, 91t
  cigarette per capita consumption, 18f
  meta-analysis of evidence, 54
  neurocognitive development effects, 469
  reproductive and developmental effects, 69, 98–99t
  respiratory effects in adults, 95–97t
  respiratory effects in children, 69, 92–94t
  secondhand smoke, 870
  subject and highlights, 50t
  workplace smoking restrictions, 795
The Health Consequences of Involuntary Smoking (1986 report)
  acute respiratory illness in children, 93t
  cigarette per capita consumption, 18f
  COPD, 96f
  lung cancer, 90t
  lung growth and pulmonary function in children, 93t
  middle ear disease and adenotonsillectomy, 94t
  odor and irritation, 97t
  passive smoking, adverse effects of, 28, 68, 69
  respiratory symptoms in children, 92t
  subject and highlights, 49f
  tobacco industry attempts to diminish impact of, 29
The Health Consequences of Smoking (1971 report)
  National Clearinghouse for Smoking and Health, 55
  subject and highlights, 46f
The Health Consequences of Smoking (1972 report)
  secondhand smoke
    coronary heart disease, 91t
    first consideration of, 68
    hazards of, 26–27
    lung function in adults, 96t
    odor and irritation, 97t
    subject and highlights, 47f
The Health Consequences of Smoking (1973 report)
  congenital malformations, 83t
  subject and highlights, 47f
The Health Consequences of Smoking (1974 report), 47t
The Health Consequences of Smoking (1975 report), 47t
The Health Consequences of Smoking (2004 report)
active smoking
  adverse health effects, 87–89
  breast cancer, 217, 254
  breast cancer mortality, 276
  cancer, 70–75
  cardiovascular diseases, 76
  reproductive outcomes, and childhood neurobehavioral
disorders, 68, 82–86
  respiratory diseases, 68, 77–81
  all-cause mortality, 103
  asthma in adults, 374–375
  asthma in children and adolescents, 372–373
  bladder cancer, 70
  brain cancer, 70
  breast cancer, 70, 217, 254
  cardiovascular disease, 76
  cervical cancer, 70
  CHD deaths attributable to smoking, 424–425
  colorectal cancer, 71, 198
  conclusions from, 528, 532
  congenital malformations, 471
  ectopic pregnancy, 484
  endometrial cancer, 71
  esophageal cancer, 71
  fetal growth, 465
  health status, 627
  idiopathic pulmonary fibrosis, 386
  kidney cancer, 71
  laryngeal cancer, 72
  leukemia (acute), 72
  liver cancer, 72, 187
  lung cancer, 73
  oral cavity and pharyngeal cancer, 74
  pancreatic cancer, 74
  prostate cancer, 75, 205
  spontaneous abortion, 487
  stomach cancer, 75
  strength of evidence classification, standardization of, 67
  subject and highlights, 50, 870
  workplace absenteeism, 631
The Health Consequences of Smoking: 1968 Supplement to the
1967 Public Health Service Review (1968 report)
  all-cause mortality, 102, 637
  subject and highlights, 46
The Health Consequences of Smoking: 1969 Supplement to the
  atherosclerosis and peripheral vascular disease, 76
  fetal death, stillbirth, and infant mortality, 84, 467
  subject and highlights, 46
The Health Consequences of Smoking: A Public Health Service
Review (1967 report)
  all-cause mortality, 102
  cerebrovascular disease, 76
  lung cancer, 73
  peptic ulcer, 89
  subject and highlights, 46
The Health Consequences of Smoking–Cancer (1982 report)
active smoking, 67
  breast cancer mortality, 276
  congestive heart failure, 76
  kidney cancer, 71
  lung cancer, 68, 73, 90
  oral cavity and pharyngeal cancer, 74
  pancreatic cancer, 74
  subject and highlights, 48
The Health Consequences of Smoking–Cardiovascular Disease
(1983 report)
  abdominal aortic aneurysm, 76
  atherosclerosis and peripheral vascular disease, 76
  subject and highlights, 48
The Health Consequences of Smoking–Chronic Obstructive
Lung Disease (1984 report)
  acute respiratory illnesses in children, 93
  asthma in adults, 95
  asthma in children, 92
  COPD, 78, 359
  lung function in adults, 96
  lung growth and pulmonary function in children, 93
  odor and irritation, 97
  respiratory diseases, 68
  secondhand smoke, 68–69
  subject and highlights, 49
The Health Consequences of Smoking–Chronic Obstructive
Lung Disease in the Workplace (1985 report), 49
The Health Consequences of Smoking for Women (1980 report)
  all-cause mortality, 102
  child development, 82
  congenital malformations, 83
  COPD, 359
  fertility, 83
  laryngeal cancer, 72
  subject and highlights, 48
The Health Consequences of Smoking–Nicotine Addiction
(1988 report)
  nicotine addiction, 30, 109
  subject and highlights, 49
The Health Consequences of Smoking: Selected Chapters from
1971 through 1975 (1976 report), 47
The Health Consequences of Smoking: The Changing Cigarette
(1981 report), 48
The Health Consequences of Using Smokeless Tobacco (1986
report)
  lung cancer, 257
  subject and highlights, 49
Health Information Technology Economic and Clinical Health
HITECH Act, 804, 851
Health insurance
  Medicaid and Medicare, 674, 675
  private, 674, 675
  State Children's Health Insurance Program, 707
Health professionals, smoking by, 24–25
Health Professionals Follow-up Study, 495, 655
Health status
measures of, and smoking, studies on, S446–447t
measures of general health and well-being, 629
poor, and smoking, studies on, S439–440t
poor physical or mental function, 628–629
self-reported poor or fair health, 628
smoking and, 625
HealthStyles Survey, 750
Healthy People 2010 smoking reduction goal, 848
Healthy People 2020 smoking reduction goal, 846, 849, 851
Healthy smoker effect, and asthma, 371
Heart. See Cardiovascular system; Congenital heart defects
Heart attack. See Acute myocardial infarction (AMI)
Heart disease. See Cardiovascular disease (CVD); Coronary heart disease (CHD)
Heavy metals, as fetal toxins, 472
Helicobacter pylori and peptic ulcer, 89f
Hepatocellular carcinoma, 197
hepatoma, 145f
liver cancer, 187, 188–189, 193, 196
Hepatitis C virus (HCV)
hepatocellular carcinoma, 196
liver cancer, 187, 188–189, 193, 196
Hepatocellular carcinoma (HCC). See also Liver cancer
causal association with smoking, 293
hepatitis C virus, 196–197
risk factors, 187
risk for current or ever smokers compared with never smokers, without hepatitis, 189, 194f
risk for current smokers compared with nonsmokers, controlled for confounding factors, 189, 191f
risk for ever smokers compared with never smokers, 189, 192f
risk for ever smokers compared with never smokers, controlled for confounding factors, 189, 193f
risk for former smokers compared with never smokers, 189, 195f
Hepatoma, 145f
HER2 (human epidermal growth factor receptor 2), 246, 247
Heroin addiction, methadone treatment for, 30
HHIP gene, 364, 365f, 366
High-density lipoprotein cholesterol, 419
High school students. See also Adolescents
cigarette smoking, current, 718, 721f, 867
cigar use, 736–740, 739f
dropouts, tobacco use prevalence among, 846
electronic cigarette use, 743, 746–747t, 748–749t
smokeless tobacco use, 730–734, 733f
Hill, Austin Bradford, 52
Hill & Knowlton advertising firm, 20
Hip fractures
active smoking, and evolution of conclusions regarding, 88t
smoking, linked to, 4t
Hispanics or Latinos
1998 Surgeon General’s Report, 50t
cardiovascular disease, 443
Cigarette smoking
attempts to quit in the past year or interest in quitting, 716, 717t
current, 709, 711t, 712t
current, among adults, 720, 723f
current, among high school students, 718, 721f
daily, trends over time, 720–724, 725f
daily versus intermittent, 710–716, 713t, 714t, 715t
quit ratio, 716–718, 718t, 719f
cigar use
current, among adults, 736, 738t
current, among young people, 735, 737t
trends among adult males, 740, 741f
trends among high school students, 736–740, 739f
diabetes, 537
electronic cigarette use among youth, 743, 748–749t
polytobacco use among young people, 741, 744t, 745t
smokeless tobacco use
current, among adults, 730, 732t
current, among high school students, 730–734, 733f
current, among young people, 730, 731t
trends among adult males, 734, 735f
Tobacco Use Among U.S. Racial/Ethnic Minority Groups
(1998 report), 50t
Historical trends in tobacco use, 705–707
HITECH (Health Information Technology Economic and Clinical Health) Act, 804, 851
HIV (human immunodeficiency virus), 569
Hoffman, Frederick L., 19
Home fires
smoking-attributable mortality (1965–2014), 676–678, 677f
trends in civilian deaths in, 659, 662f
Hormone replacement therapy (HRT)
breast cancer, 214
colorectal cancer, 197
Hormones
breast cancer, 212–214, 212f, 213f
hormone receptors and breast cancer, 245–247, 277, S123–124t
postmenopausal women and smoking, studies on, S57–59f
premenopausal women and smoking, studies on, S52–56t
Hospitalization
morbidity and smoking, 630
smoking, studies on, S448–449t
Hospitals, smoking in, 777, 795
How Tobacco Smoke Causes Disease—The Biologic and Behavioral Basis for Smoking-Attributable Disease (2010 report)
cancer patients and survivors, 284
cardiovascular disease, 419, 429, 435
congenital malformations, 471
coronary heart disease, 425
disease causation, conclusions regarding, 67
nicotine addiction, 109, 112–113
pathophysiology of nicotine addiction, 112–113
recommendations in, 869
subject and highlights, 50t

921
HPHCs (harmful and potentially harmful constituents) in tobacco products, 786
HPV. See Human papillomavirus (HPV)
HRAS gene, 150
HRT. See Hormone replacement therapy (HRT)
HTRA1 gene, 531
Human epidermal growth factor receptor 2 (HER2), 246, 247
Human immunodeficiency virus (HIV), 569
Human papilloma virus (HPV)
cervical cancer, 145
vaccine, 145
Hungary, estimates of smoking-attributable mortality in, 691
Hypertension
CVD risk factor, 17
secondhand smoke, 430
Hyperthyroidism, 569
Hypospadias, 477
Hypoxia, catecholamine response to, by rats, 468
I

IBD. See Inflammatory bowel disease
Idiopathic pulmonary fibrosis
biological evidence, 386–387
cigarette smoking, studies on, S250–252t
conclusions on, 10, 388, 392
epidemiologic evidence, 387–388
Idiopathic talipes equinovarus. See Clubfoot (idiopathic talipes equinovarus)
“If You Must Smoke...” campaign, 24
IgE (immunoglobulin E), 558
IgG (immunoglobulin G), 368
IL-1B (interleukin-1B), 422
IL-4 (interleukin 4), 372
IL-5 (interleukin 5), 372
IL-6 (interleukin-6), 422
IL-8 (interleukin 8), 368
IL-13 (interleukin 13), 372
IL-17 (interleukin-17), 560
Immune function, 545–571
1972 Surgeon General’s Report, 47t
adaptive, 546–550, 551t, 559, 563–564
asthma, 371–372
autoimmunity
antibody-mediated, 558–559
cigarette smoke and, 567–568
COPD, 368
autoinmate, 568
cancer, 570
cigarette smoke and, 552–559, 553t, 571
cigarette smoke-induced inflammation, 563–564
components of cigarette smoke and, 559–562
conclusions on, 11, 584
diseases associated with smoking, 562–571
effects of components of cigarette smoke on, 559–562
innate, 546–550, 551t, 559, 563–564
literature review, 545–546
maternal smoking during pregnancy, 570–571
morbidity and smoking, 627
nicotine, 117
smoking, linked to, 4t, 7
smoking and, 550–552, 563, 569, 570
smoking and, in lungs, 546, 549
smoking by cancer patients and survivors, 285
tuberculosis, 377
Immune surveillance, 549–550
Immunoglobulin, 558
Immunoglobulin E (IgE), 558
Immunoglobulin G (IgG), 368
IMPACT (Initiatives to Mobilize for the Prevention and Control of Tobacco Use) program, 805
Implications. See within specific topics
Inadequate evidence
causal inferences, strength hierarchy for, 3t, 53
tuberculosis disease, risk for, and secondhand smoke, 386, 392
tuberculosis infection, risk for, and secondhand smoke, 386, 392
tuberculosis infection, risk for, and smoking, 385, 392
Infant mortality
active smoking, and evolution of conclusions regarding, 84t
neonatal death, 46t
secondhand smoke, and evolution of conclusions regarding, 98t
Infants. See also Birth weight
maternal active smoking, and evolution of conclusions regarding, 86t
neurocognitive development, 469–470
relative risks in SAMMEC methodology, 657, 659
Infections and smoking
bacterial, 562–563, 565–566
respiratory, 562–563, 564
viral, 562–563, 564–565
Infectious diseases. See also specific diseases, e.g., influenza
conclusions from previous reports, 545, 546t
etiological research, 21
mortality rate in U.S., 1900–2005, 63t, 65
Inflammation
asthma, 371, 372
cardiopulmonary disease, 419, 422–423
COPD, 367–368
immune mechanisms of, 563–564
lung cancer, 151
smoking by cancer patients and survivors, 285
Inflammatory bowel disease, 576–583
conclusions on, 11, 584
current smoking and, 577–581
epidemiology of, 579–581
former smoking and, 581
incidence of, 576
prevalence of, 576
risk factors for, 576
The Health Consequences of Smoking (2004 report), 50
smoking, linked to, 4
Koop, C. Everett
1982 Surgeon General's Report, 48
1983 Surgeon General's Report, 48
1984 Surgeon General's Report, 49
1985 Surgeon General's Report, 49
1986 Surgeon General's Report, 49
1988 Surgeon General's Report, 49
1989 Surgeon General's Report, 49
nicotine addiction, 30
smokefree public places, 28
smokeless tobacco use, request for report on, 779
Korean Cancer Prevention Study, 381
Korean National Health Insurance Corporation study, 202
KRAS gene
colorectal cancer, 198
lung cancer, 150, 151
Krimpen Study (The Netherlands), 494, 495

Langmuir, Alexander, 23
Large cell carcinoma of the lung, 162, 164–174
Laryngeal cancer
active smoking, and evolution of conclusions regarding, 72
gender-adjusted incidence of, 146, 146f, 147f
conclusions of Advisory Committee (1964), 100
smoking, linked to, 4
smoking as a cause of, 3
Latinos. See Hispanics or Latinos
Learning and education. See Tobacco cessation, clinical and educational approaches
Legacy Tobacco Documents Library, University of California at San Francisco, 32
Legislation. See also Smokefree legislation and policies
Children's Health Insurance Program Reauthorization Act, 789
Cigarette Labeling and Advertising Act of 1965, 46
Clean Air Act Extension of 1970, 29
Comprehensive Smokeless Tobacco Health Education Act of 1986, 6
conclusions on, 827
Consumer Products Safety Act of 1972, 29
Family Smoking Prevention and Tobacco Control Act (See Tobacco Control Act of 2009)
Federal Cigarette Labeling and Advertising Act of 1965, 3, 23–24
Federal Food, Drug and Cosmetic Act of 1938, amendments to, 29
flavoring ban, 783
Health Information Technology Economic and Clinical Health (HITECH) Act, 804, 851
municipality and local laws, number of, 793f
Patient Protection and Affordable Care Act of 2010, 464, 632, 804
prenatal smoking, impact on, 464
Prevent All Cigarette Trafficking (PACT) Act, 797
Public Health Cigarette Smoking Act of 1969, 3, 24
Racketeer Influenced and Corrupt Organizations Act (RICO), 32
Safe Drinking Water Act of 1974, 29
smokefree and tobacco-free legislation, 792–795, 794
Toxic Substances Control Act of 1976, amendments to, 29
Leukemia
2004 Surgeon General's Report, 50
acute, active smoking, and evolution of conclusions regarding, 67, 72
acute myeloid leukemia
active smoking, and evolution of conclusions regarding, 67, 72
age-adjusted incidence of, 146f, 147f
smoking, linked to, 4
mortality rate of men in U.S., 1930–2008, 65f
Leukocyte levels, 422
Life expectancy. See also Mortality and mortality rates
1968 Surgeon General's Report, 46
decreased, linked to smoking, early twentieth century, 19
Life Span Study of Japanese atomic bomb survivors, 637
Lifestyle factors and colorectal cancer, 197
Litigation. See Tobacco product litigation
Little, Clarence Cook, 20
Little cigars
1973 Surgeon General's Report, 47
consumption of, 706–707
Liver cancer. See also Hepatocellular carcinoma (HCC)
active smoking, and evolution of conclusions regarding, 67, 72
age-adjusted incidence of, 146, 146f, 147f
causal association with smoking, 188, 196, 292, 293
conclusions on, 8, 870
mortality rate of men in U.S., 1930–2008, 65f
risk factors, 187
risk for current smokers compared with nonsmokers, 189, 190f
smoking, case-control studies on, S3–11
smoking, cohort studies on, S12–20
smoking, linked to, 4
Liver disease
cirrhosis, 88f, 101f, 187, 569
liver fibrosis, 188
Long Island Breast Cancer Study Project
active smoking and breast cancer mortality, 277
breast cancer and smoking, 220
smoking-related DNA adducts, 211
Low birth weight. See Birth weight
Lung cancer
1964 Surgeon General's Report, 46
1967 Surgeon General's Report, 46
active smoking, and evolution of conclusions regarding, 73

924
adenocarcinoma of the lung
increase in smokers, 185, 186, 293
rates by countries, 177–178, 181f, 183f
rates of, in U.S., 161–178, 162f, 164–175f, 184–186
age-adjusted incidence of, 143, 146, 146f, 147f
cigarette changes, 151–152, 293
conclusions of Advisory Committee (1964), 100t
conclusions on, 8, 293
consensus, scientific, 45
epidemic of, 846
epidemiology of, 867
increased risk of, 869
mortality
death rate by smoking status, 634t, 635t, S457t, S458t
death rates, 655, 656f
deaths avoided, 867
increased risk of, 869
mortality rate in U.S., 1900–2005, 63f, 65
mortality rate of men in U.S., 1930–2008, 65f, 66
mortality rate of women in U.S., 1930–2008, 66, 66f,
secondhand smoke, 665, 666t
smoking-attributable mortality (1965–2014), 676–678,
677t
smoking-attributable mortality for adults (2005–2009),
659–662, 661f, 663f, 664f
smoking-attributable mortality for adults (2010–2014),
659, 660t
U.S. and Australia, 178, 182f
women, 48t
nonsmoking wives of smoking husbands, 48t
productivity loss due to cigarette smoking, 670, 671f
rate increase, early twentieth century, 19, 20
relative risks, adults, 657, 658t
risk increase, 158–161, 159f
secondhand smoke
causal linkage to, 5f, 28
deaths, years of productive life lost, and productivity loss
depending on, 665, 666f
effects of, 28
evolution of conclusions regarding, 68, 90t
secondary cancer, as, 287
small cell carcinoma of the lung
rates by countries, 179f
rates of in U.S., 161, 162f, 163, 164–174f
smoking, linked to, 4f
smoking as a cause of, 3
smoking-attributable morbidity, 667, 668t
smoking behavior changes, impact of, 847
squamous cell carcinoma of the lung
decline in smokers, 185, 186, 293
rates by countries, 177–178, 179f
rates of in U.S., 161–163, 162f, 164–174f, 176, 185, 186
synergistic effect of smoking and asbestos exposure, 47f
tobacco smoke carcinogens, 151
types of, changes in, 161–186, 162f, 164–175f, 179–183f, 293
women
1980 Surgeon General’s Report, 48f
2001 Surgeon General’s Report, 50t
Lung function
active smoking, and evolution of conclusions regarding, 80t
adrenaline, 779, 782f
adults, secondhand smoke, and evolution of conclusions
regarding, 96t
children, secondhand smoke, and evolution of conclusions
regarding, 93f
secondhand smoke, 5f
Lung Health Study
cardiovascular disease, 429
carcinogen, for, 429
nicotine, for carcinogenicity, 115
Lung Health Trial, 426
Lungs. See also Chronic obstructive pulmonary disease
(COPD); Lung cancer; Lung function
development of, and nicotine, 119–120
immune defects caused by smoking, 546, 549f
infections associated with smoking, 562–563
lung repair, and COPD, 368

M

Macrophages
alveolar, 554–555
cardiovascular disease and inflammation, 422–423
COPD, 367–368
Macular degeneration. See Age-related macular degeneration
(AMD)

Males
all-cause mortality and main causes of death by smoking
status, 633, 634t, S457t
cardiovascular disease death rates, 417, 417f
cigarette smoking
trends among adults, 736–740, 739f
trends among high school students, 735, 737f
trends among young people, 735, 737f

Males
all-cause mortality and main causes of death by smoking
status, 633, 634t, S457t
cardiovascular disease death rates, 417, 417f
cigarette smoking
trends among adults, 736, 738f
trends among high school students, 735, 737f
trends among young people, 735, 737f
trends among high school students, 736–740, 739f

Males
all-cause mortality and main causes of death by smoking
status, 633, 634t, S457t
cardiovascular disease death rates, 417, 417f
cigarette smoking
trends among adults, 736, 738f
trends among high school students, 735, 737f
trends among young people, 735, 737f
trends among high school students, 736–740, 739f
debates, years of productive life lost, and value of lost
depends on, 151, 151
productivity from CHD and lung cancer due to secondhand
smoke, 665, 666t
electronic cigarette use among youth, 743, 746–747
health care expenditures attributable to cigarette smoking,
adults, 672–673, 673f
polytobacco use
  current, among adults, 741, 745
  current, among young people, 741, 744
relative risks, adults, 657, 658
sexual function (See also Erectile dysfunction (ED))
  active smoking, and evolution of conclusions regarding,
    68, 84
  conclusions on, 10
  smoking, linked to, 4
smokeless tobacco use
  current, among high school students, 730–734, 733
  current, among young people, 730, 731
  current, trends over time, 730–734, 733
  trends, 734, 735
  trends, among adults, 734, 735
smoking-attributable mortality (1965–2014), 676–678, 677
  smoking-attributable mortality for adults (2005–2009),
    659–662, 661
  smoking-attributable mortality for adults (2010–2014), 659,
    660
  smoking cessation, 726, 729
  smoking history, 724–726, 727
Malnutrition, and tuberculosis, 377
Mammography, 280
Marketing. See also Advertising
  cigarettes, 774
  definition of, 796
  electronic cigarettes, 780
  Joe Camel marketing campaign, 32
  marketing regulations, 784
  menthol cigarettes, 782–783
Marlboro Snus, 706
Massachusetts Benchmark Study, 154–155, 156
Massachusetts General Hospital, 33
Massachusetts Male Aging Study, 496, 497, 498
Mass media, 813, 814, 815–816, 827, 848
Mast cells, 557
Master Settlement Agreement of 1998. See also American
  Legacy Foundation
  cigarette per capita consumption, 18
  current smoking among youth since, 718
  description, 798
  funding for states, 31–32
  report conclusions, 54
  support for tobacco control programs from, 799–800, 805
Maternal (prenatal) smoking. See also Reproductive outcomes
  1969 Surgeon General’s Report, 46
  1971 Surgeon General’s Report, 46
  immune system function, 570–571
  prevalence, 461, 463–464
Matrix metalloproteinase 9 (MMP-9)
  cardiovascular disease and inflammation, 422
  COPD, 367
Matrix metalloproteinase 12 (MMP-12), 367–368, 369
Matrix metalloproteinases (MMPs)
  cardiovascular disease and inflammation, 423
  COPD, 367–368
MD Anderson Cancer Center, 33
Mecamylamine, 117
Media. See also Advertising
  broadcast media, and Fairness Doctrine application to
    cigarette advertising, 24
  mass media, 813, 814, 815–816, 827
  mass media campaigns, 848, 852
  print media, tobacco industry as revenue source for, 26
Medicaid, 674, 675
Medical Research Council Trial of Assessment and Management
  of Older People in the Community in the United Kingdom,
    530
Medicare, 674, 675
MEH3 high-metabolizer genotypes, 199
Men. See Males
Meningitis, bacterial, 562–563
Menopause
  breast cancer, 213
  breast cancer risk and smoking, 242–245
  ever smoking status, 244–245
  hormones in postmenopausal women and smoking, studies
    on, S57–59
  hormones in premenopausal women and smoking, studies
    on, S52–56
  pack-years of smoking, 245
  premenopausal and postmenopausal relative risk for breast
    cancer, studies on, S120–122
  premenopausal and postmenopausal secondhand smoke
    exposure and breast cancer, 269, 271f, 272, 273
Mentholated cigarettes, 782–783
MEPS survey, 673, 674
Meta-analysis, defined, 54
Methadone treatment for heroin addicts, 30
Middle ear disease, 5, 94
Middle school students, and electronic cigarette use, 743,
  746–747, 748–749
Midwest (U.S. region)
  cigarette smoking among adults
    current, 709, 712
    intermittent and daily, 710–716, 714f, 715f
  cigarette smoking among young people
    current, 709, 711
    intermittent and daily, 710, 713
  cigar use
    current, among adults, 738
    current, among young people, 737
  polytobacco use
    current, among adults, 745
    current, among young people, 744
  smokeless tobacco use
    current, among adults, 730, 732
    current, among young people, 730, 731
Military
  smokefree policies, 795
  smoking in, 778, 846
  tobacco-free areas, 777
Million Women Study
all-cause mortality, 636–637, 637f, 638f, 639
breast cancer and alcohol use, 279
breast cancer and secondhand smoke, 258, 260
Mini-Mental State Examination, 629
Minnesota litigation against the tobacco industry, 32
Minors, sale of tobacco products to, 785, 796
MMP-9. See Matrix metalloproteinase 9 (MMP-9)
MMP-12 (matrix metalloproteinase 12), 367–368, 369
MMPs. See Matrix metalloproteinases (MMPs)
MnSOD genotype, 274
Models
of future tobacco use, 847–851
Modified risk tobacco products, regulations on, 784, 785, 786, 787
Moist snuff. See Smokeless tobacco
Monocyte chemoattractant protein-1, 422
Mononuclear cells, 554–555
Moraxella catarrhalis, 566
Morbidity and smoking. See also Smoking-Attributable Mortality, Morbidity, and Economic Costs (SAMMEC)
biologic basis, 627
conclusions on, 11, 632, 642, 870
COPD, 49f
COPD, gender-specific, 360
economic costs, estimates of, 667–676, 668f
epidemiologic evidence, 627–628
evidence synthesis, 631–632
general morbidity, 626–627
health status, 628–629
implications, 632–633
medical services utilization and cost, 629–631
workplace absenteeism, 631, S454f, S455–456f
Morphological constitution of smokers, 101f
Mortality and mortality rates. See also Perinatal mortality; Smoking-Attributable mortality (SAM); Smoking-Attributable Mortality, Morbidity, and Economic Costs (SAMMEC); Sudden infant death syndrome (SIDS)
age-adjusted, in U.S. (1900–2010), 64f, 65
all-cause
age and COPD GOLD classification, 360, 362f
cigarette smoking by cancer patients, 286–287
conclusions on, 11, 641, 642, 867
main causes of death by smoking status, 633, 634f, 635f, 645f
smoking, studies on, S437–438f
smoking and, 102–103f
temporal trends in relative risk, 637–638, 637f, 638–639, 638f
temporal trends in survival, 637, 638–639, 639f, 640f, 641f
breast cancer and tobacco smoke, 275–277
cancer mortality and cigarette smoking, 870
cancer mortality and cigarette smoking by cancer patients, 287
cancer patient adverse outcomes, 290, 291, 293
cancers among men, in U.S., 1930–2008, 65f, 66
cancers among women, in U.S., 1930–2008, 66, 66f
cardiovascular disease, 413, 415f, 416–417, 416f, 417f
changes in, 1964–2014, 17
COPD, 357–358, 359f, 371, 391
COPD, by gender and age, 360, 361f
coronary heart disease, 423–424, 425f
current smokers with COPD, 360, 363f
lung cancer, increasing risk for, 158–161, 159f
lung cancer in U.S. and Australia, 178, 182f
major diseases in U.S., 1900–2005, 63f, 65–66
pipe and cigar smokers, 47f
prostate cancer and current smoking, 206–208, 207f
from tobacco use, by 2015, 847
tobacco users and nonusers, 625, 626f
tuberculosis and tobacco, 383
young adults, 867, 869
Motion Picture Association of America voluntary rating system, 873
Mouth. See Oral cavity cancer
Movies
impact of smoking incidents in, 813
tobacco impressions delivered by top-grossing U.S., 776f
tobacco incidents in, 774–775, 776f, 777, 797–798, 872–873
MPOWER components, 818, 819
key findings, 821f
Turkey, success in, 820
MSA. See Master Settlement Agreement of 1998
Multiple Risk Factor Intervention Trial (MRFIT), 426
Multiple sclerosis, 569
Multiple tobacco products, use of. See Polytobacco use
Multiple use definition of, 744f, 745f
prevalence of, 847
Mycobacterial infections and smoking, 566
*Mycobacterium tuberculosis* chapter 7 conclusions, 385, 392
conclusions on, 9
TB, cause of, 384, 385
tuberculosis, progression to, 376, 377, 378f

type 1 immunity, 566

N

*N*-acetyltransferase 1 (*NAT1*)
metabolism of, and breast cancer, 250–251
smoking and breast cancer, 247
*N*-acetyltransferase 2 (*NAT2*)
breast cancer, 210, 211, 281
breast cancer and active smoking, 247–248, 252, 253
breast cancer and secondhand smoke, 274
colorectal cancer, 198
*N*-acetyltransferase (NAT) polymorphisms, 250–251
NACHRs (nicotinic acetylcholine receptors). See Nicotinic acetylcholine receptors (nAChRs)
Nasal irritation, from secondhand smoke, 5f
Nasal sinus cavity cancer, 69, 90f
Nasopharyngeal carcinoma, 69, 90t
*NAT1.* See *N*-acetyltransferase 1 (*NAT1*)
*NAT2.* See *N*-acetyltransferase 2 (*NAT2*)
National Academy of Science, 28
National Birth Defects Prevention Study (NBDPS) on folic acid levels, 472
heart defects, 476
National Cancer Institute (NCI), 31
National Cancer Institute (NCI), Cancer Intervention and Surveillance Modeling Network, 847
National Center for Health Statistics, 659
National Clearinghouse for Smoking and Health creation of, 24 early Surgeon General’s reports, 55 scientific conclusions and public policy formation, separation of, 56
National Death Index, 655
National Emphysema Treatment Trial, 360
National Health and Nutrition Examination Survey (NHANES) CHD mortality rate, decline in, 413 COPD diagnosis, 357 data from, 463 health care costs, 630 methodologic issues, 653
National Health and Nutrition Examination Survey I (NHANES I), 360
National Health and Nutrition Examination Survey III (NHANES III) COPD mortality rates, 360 coronary heart disease and secondhand smoke, 426 tobacco smoke and breast cancer mortality, 278
National Health Expenditure Accounts, 674, 675t
National Health Interview Survey (NHIS) adult RR estimates, 656 cigarette smoking, defined, 764 cigarette smoking among adults current smoking, 709, 710t, 720, 723t, 849, 851 daily, trends over time, 720–724, 724t, 725t quit ratio, 716–718, 718t, 719t, 720t cigar use trends adult males, 740, 741t, 742t/ adults, 740, 740t COPD prevalence, 356 current cigarette smoking, defined, 765 current cigar smoking, defined, 766 current use of smokeless tobacco, defined, 765 methodologic issues, 653 smokeless tobacco use among adults trends, 734, 734t trends among males, 734, 735t smoking-attributable health care expenditures by source of funds, 673 smoking prevalence during pregnancy, 462 validity, 763, 764 National Institutes of Health (NIH) NIH-AARP Diet and Health Study adult RR estimates, 655 all-cause mortality, 636 State-of-the-Science Conference on Tobacco Use, 803 National Maternal and Infant Health Survey, 462 National Mortality Followback Survey, 427 National Nativality Survey, 461, 462 National Pregnancy and Health Survey, 462 National Survey of Family Growth, 462 National Survey on Drug Use and Health (NSDUH) overview and methods, 703, 704t, 762, 764 age when smoking began, 708, 708t current cigarette smoking among adults, 709, 712t, 851 among young people, 709, 711t defined, 708–709, 712t, 764, 765 current cigar use among adults, 736, 738t among young people, 735, 737t defined, 735, 737t, 766 current smokeless tobacco use among adults, 730, 732t among young people, 730, 731t defined, 765 current use of multiple tobacco products among adults, 741, 745t among young people, 741, 744t multiple use, defined, 744t, 745t patterns of, 740, 743t daily cigarette smoking among adults, 710, 714t, 715t, 716 among young people, 710, 713t defined, 709, 713t, 715t, 765 intermittent cigarette smoking among adults, 714t, 715t, 716 among young people, 713t defined, 709, 713t, 715t, 765 validity, 764 National Tobacco Cessation Collaborative’s Consumer Demand Roundtable, 804 National Tobacco Control Program, 805 National Youth Risk Behavior Survey (YRBS) overview and methods, 703, 704t current cigarette smoking among high school students, 718, 721t current cigar smoking among high school students, 736–740, 739t current smokeless tobacco use among high school students, 730–734, 733t validity, 763 National Youth Tobacco Survey (NYTS), 742, 746–747t, 748–749t Native Americans. See American Indians/Alaska Natives NAT (*N*-acetyltransferase) polymorphisms, 250–251 Natural killer cells, 556
The Health Consequences of Smoking —50 Years of Progress

The Health Consequences of Smoking —50 Years of Progress

NBDPS. See National Birth Defects Prevention Study (NBDPS)
NCI (National Cancer Institute), 31
Neonates. See Infants
The Netherlands, estimates of smoking-attributable mortality in, 691
The Netherlands Cohort Study on Diet and Cancer, 202
Neuberger, Maurine, 23
Neurobehavioral disorders of childhood, 479–484
bioxic basis, 479
conclusions on, 10, 484, 499
epidemiologic evidence, 480–483
anxiety and depression, 481–482
disruptive behavioral disorders, 480–481
intellectual disability, 482–483
schizophrenia, 482
Tourette syndrome, 482
evidence synthesis, 483–484
implications, 484
literature review description, 480
Neurocognitive development
brain development, and nicotine, 8, 120, 126
infancy and early childhood, 469–470
nervous system development, and nicotine, 121–123
Neutrophil elastase, 367
Neutrophil levels, 422
Neurontin, 48
Newsweek
1964 Surgeon General’s Report, 23
tobacco industry as revenue source for, 26
New York Public Library, 23
NF-xB. See Nuclear factor kappa B (NF-xB)
NHANES. See National Health and Nutrition Examination Survey (NHANES)
NHANES I (National Health and Nutrition Examination Survey I), 360
NHANES I Epidemiologic Follow-up Study, 630
NHANES III. See National Health and Nutrition Examination Survey III (NHANES III)
NHIS. See National Health Interview Survey (NHIS)
NHS. See Nurses’ Health Study (NHS)
NicoDerm CQ patch, 110f
Nicotine
1972 Surgeon General’s Report, 47f
acute toxicity, 111–112, 111f, 125, 126
cancer patients and survivors, 285
cardiovascular disease, 419, 420, 420f, 443
conclusions on, 8
effects on immunity, 560
genotoxicity, 114
health consequences of exposure
cancer, 113–116
cardiovascular diseases, 116–117
cognitive function, 120–125
immune function, 117
lung development, 119–120
reproductive health outcomes, 117–119
long-term use, 126
reductions to, as part of tobacco epidemic end game, 854
SIDS, 469
stillbirths, 467–468
toxicokinetics, 109–111, 110f
venous blood concentrations for various delivery systems, 110f
yields in cigarettes, 154, 155, 156f
Nicotine addiction
1986 Surgeon General’s Report, 49f
1988 Surgeon General’s Report, 49f, 109
2010 Surgeon General’s Report, 109, 112–113
addiction, recognition as, 30–31
cigarettes as delivery devices, 782, 801, 803
COPD susceptibility, 364
geneic association, 149
pathophysiology of, 112–113
physical abstinence syndrome, 30
recognition as an addiction, 30–31
smoking initiation by youth, 30–31
tobacco products, 782, 784
tobacco smoke, prolonged exposure to, 148
trajectory of, 113
Nicotine nasal spray, 110f
Nicotine polacrilex gum, 110f, 429
Nicotine replacement therapy (NRT)
addiction risk, 112
cancer risk, 114
carcinogenesis, 116
cardiovascular disease, 429–430
cigarette per capita consumption, 18f
fetal growth restriction, 118
smoking cessation, 30
for smoking cessation during pregnancy, 463–464
Nicotinic acetylcholine receptors (nAChRs)
cancer patients and survivors, 285
cognitive function, 121
nicotine effects, 111, 112, 113
stillbirth and perinatal mortality, 467
Nicotrol patch, 110f
NIH. See National Institutes of Health (NIH)
Nitric oxide, 421, 422
Nixon, Richard M., 30
NK cells, 556
NKT cells, 556
NNAL (4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanol), 177
N’-nitrosonornicotine (NNN)
Canadian and Australian cigarettes, 157, 158f
esophageal cancer, 151
nicotine replacement therapy, 116
tobacco smoke, in, 155, 156f
NNK. See 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK)
NNN. See N’-nitrosonornicotine (NNN)
Nocturnal penile tumescence (NPT), 491
NOD2, 576
Noncombustible tobacco products
  establishing benefits and risks of, 873–874
  as part of tobacco epidemic end game, 854
  prevalence of use, 846
Nonsmokers
  nicotine and cognitive function, 121
  rights movement, 18f, 777
Nonsteroidal anti-inflammatory drugs (NSAIDs), 197
Norepinephrine, 113
Nornicotine, 110
North Central (U.S. region) cigarette smoking among adults
  attempts to quit in the past year or interest in quitting, 716, 717t
  quit ratio, 716, 718t
Northeast (U.S. region)
cigarette smoking among adults
  attempts to quit in the past year or interest in quitting, 716, 717t
  current, 709, 712t
  intermittent and daily, 710–716, 714t, 715t
  quit ratio, 716, 718t
cigarette smoking among young people
  current, 709, 711t
  intermittent and daily, 710, 713t
cigar use
  current, among adults, 736, 738t
  current, among young people, 737t
polytobacco use
  current, among adults, 745t
  current, among young people, 744t
smokeless tobacco use
  current, among adults, 730, 732t
  current, among young people, 730, 731t
Norway, estimates of smoking-attributable mortality in, 691
Norwegian Counties Study, 426
Norwegian-Swedish Cohort Study
  breast cancer and active smoking, 220
  breast cancer and secondhand smoke, 258, 260
Nurses Health Study I
  active smoking and breast cancer mortality, 276–277
  breast cancer and secondhand smoke, 259, 260
  breast cancer and smoking, 219
  duration of cigarette smoking, 234, 277
  smoking before or during first pregnancy, 242
Nurses Health Study II, 219
Nursing homes
  morbidity and smoking, 630
  smoking, studies on, S451t
NYTS (National Youth Tobacco Survey), 742, 746–747t, 748–749t

O

Obesity and prostate cancer, 205
Occupational Safety and Health Administration, creation of, 29
Ochsner, Alton, 19
ODD (oppositional defiant disorder), 481
Odor and irritation of secondhand smoke, 5f, 97t
Office of Environmental Health Hazard Assessment, Cal/EPA, 471
Office on Smoking and Health, U.S. Dept. of Health, Education, and Welfare, 6
Ontario Women’s Diet & Health Study
  breast cancer and secondhand smoke, 261
  breast cancer and smoking, 222
Ontario Women’s Health Study
  breast cancer and secondhand smoke, 261
  breast cancer and smoking, 222
Oppositional defiant disorder (ODD), 481
Oral cavity cancer
  1971 Surgeon General’s Report, 46t
  active smoking, and evolution of conclusions regarding, 74t
  conclusions of Advisory Committee (1964), 100t
  smokeless tobacco, 116
  smoking, linked to, 4f
Oral contraceptives, 47t
Oral contraceptives, 47t
Orofacial clefts
  cleft lip, 473–474
  cleft palate, 473–474
  conclusions on, 479, 499
  evidence synthesis, 478
  maternal smoking and, studies on, S297–299t
  maternal smoking during pregnancy, 471, 473t
  nicotine, 119
  serum folate levels and, 472
  smoking, linked to, 4f
Oropharyngeal cancer, 143, 146f, 147t
Osteoporosis, 244. See also Bone density, low
Outpatient visits
  morbidity and smoking, 630
  smoking, studies on, S450t
Ovarian cancer
  active smoking, and evolution of conclusions regarding, 74t
  mortality rate of women in U.S., 1930–2008, 66f
The Health Consequences of Smoking—50 Years of Progress

Oxford Vegetarian Study, 202
Oxidants, 561–562
Oxidative stress
  morbidity and smoking, 627
  smoking by cancer patients and survivors, 285

P

P16 methylation, 150–151
P53 tumor suppressor gene, 198
Pacific Islanders, 50
Packaging, plain, 855
PACT (Prevent All Cigarette Trafficking) Act, 797
PAD. See Peripheral arterial disease (PAD)
PAF. See Population-attributable fraction (PAF)
PAF (platelet activating factor), 421
PAHs. See Polycyclic aromatic hydrocarbons (PAHs)
PAI-1 (plasminogen activator inhibitor-type 1), 421, 422
PAMPs (pathogen-associated molecular patterns), 546–547, 550
Pancreatic cancer
  active smoking, and evolution of conclusions regarding, 67, 74t
  age-adjusted incidence of, 146t, 147t
The Health Consequences of Smoking (2004 report), 50t
mortality rate of men in U.S., 1930–2008, 65t, 66
mortality rate of women in U.S., 1930–2008, 66, 66t
smokeless tobacco, 116
smoking, linked to, 4t
PARC/CCL-18 (pulmonary and activation-regulated chemokine), 367
Parental smoking, 47t. See also Maternal (prenatal) smoking; Secondhand smoke
Parkinson's disease, 123
Passive smoking. See Secondhand smoke
Pathobiologic Determinants of Atherosclerosis in Youth study, 428
Pathogen-associated molecular patterns (PAMPs), 546–547, 550
Patient Protection and Affordable Care Act of 2010
  morbidity and smoking, 632
  results of, 851
  section 4107, 464
tobacco cessation, 804, 869–870, 874
Pattern recognition receptors (PRRs), 546–547, 550
PBI (penile-brachial index), 491–492
Peer review of Surgeon General reports, 55
Penile-brachial index (PBI), 491–492
Peptic ulcer
  active smoking, and evolution of conclusions regarding, 68, 89t
  conclusions of Advisory Committee (1964), 101t
Perinatal mortality
  advances in understanding of, 467–469
  nicotine, 118–119
  smoking-attributable mortality (1965–2014), 676–678, 677t
  smoking-attributable mortality (2010–2014), 659, 660t
Periodontal disease and smoking, 4t, 532, 562–563
Peripheral arterial disease (PAD). See also Peripheral vascular disease
described, 415t
tobacco use, 428
Peripheral vascular disease. See also Peripheral arterial disease (PAD)
  1971 Surgeon General's Report, 46t
  1973 Surgeon General's Report, 47t
active smoking, and evolution of conclusions regarding, 68, 76t
smoking, linked to, 4t
Peroxynitrite, 422
Persons with alcohol and substance abuse disorders
tobacco use among, 846
Persons with mental illness
tobacco use among, 846
Pertschuk, Michael, 823
Pesticide, nicotine as, 112
Pharyngeal cancer
  active smoking, and evolution of conclusions regarding, 74t
  nasopharyngeal carcinoma, 69, 90t
  oropharyngeal cancer, 143, 146t, 147t
smoking, linked to, 4t
Philip Morris, United States v., 32, 800–803
PHS. See Public Health Service (PHS)
Physical abstinence syndrome (withdrawal symptoms)
adiction, feature of, 30
nicotine addiction, 113
Physical inactivity and colorectal cancer, 197
Physicians’ Health Study
  age-related macular degeneration, 530
  colorectal cancer, 202
PIK3CA gene, 150
PI MZ genotype, 362–363
Pipes and pipe smoking
  1973 Surgeon General's Report, 47t
  cardiovascular disease, 428–429
trends in, 705, 705t, 706t
PI*S allele, 362
PI*Z allele, 361–362
Plain packaging, 855
Plasminogen activator inhibitor-type 1 (PAI-1), 421, 422
Platelet activating factor (PAF), 421
Platelet factor 4, 421, 422
Platelets
  cardiovascular disease, 421, 422
defined, 415t
Pneumonectomy, increasing rates of, early twentieth century, 19
Pneumonia
  2004 Surgeon General's Report, 50t
active smoking, and evolution of conclusions regarding, 79t
children, and parental smoking, 47t
relative risks, adults, 657, 658t
secondhand smoke, and evolution of conclusions regarding, 93f
smoking and, 4f, 566
smoking-attributable mortality for adults (2005–2009), 659–662, 661f, 663f
smoking-attributable mortality for adults (2010–2014), 659, 660
Polacrilex (nicotine gum), 110f, 429
Polio, 874
Polycyclic aromatic hydrocarbons (PAHs)
      fetal toxins, 472
      immunity, 560
Polyps, adenomatous, 197, 198–199, 200f, 201f, 203, 204
Polytobacco use
      adults, 741, 745f, 847
      patterns, 740–741, 743f
      prevalence of, 740, 743f
      young people, 741, 744f, 847
Population Assessment of Tobacco and Health Study, 786
Population-attributable fraction (PAF)
      estimation of, 649
      formula for, 650
      relative risk (RR) and, 650, 650f
Portugal, estimates of smoking-attributable mortality in, 691
PRAMS (Pregnancy Risk Assessment Monitoring System), 462, 463, 662
Prednisolone, 375
Preeclampsia, 466–467
Pregnancy.
      See also Fetal effects; Maternal (prenatal) smoking;
      Reproductive outcomes
      complications
      active smoking, and evolution of conclusions regarding, 85f
      secondhand smoke, and evolution of conclusions regarding, 99f
      The Health Consequences of Smoking (1973 report), 47f
      nicotine, 117–119
      preterm delivery, 46f, 118
      smoking before or during first pregnancy, 242, 243f, 280–281
Pregnancy Risk Assessment Monitoring System (PRAMS), 462, 463, 662
Prematurity.
      See Preterm delivery
Prenatal conditions
      smoking-attributable mortality (2010–2014), 659, 660f
Prenatal smoking.
      See Maternal (prenatal) smoking
President’s Office of Science and Technology, 22
Preterm delivery
      1969 Surgeon General’s Report, 46t
      nicotine, 118
Prevent All Cigarette Trafficking (PACT) Act, 797
Preventing Tobacco Use Among Young People (1994 report)
      active smoking during childhood and adolescence, 81f
      nicotine addiction, 31, 109
      subject and highlights, 50t
Preventing Tobacco Use Among Youth and Young Adults (2012 report)
      cigarette advertising, 797
      COMMIT, 811
      data sources, 703
      depictions of smoking in movies, 775, 797–798
      evidence-based strategies, 871
      sale of tobacco products to underage youth, 796
      subject and highlights, 51t
      on youth initiation and prevalence rates, 851, 869
Prevention
      need for, 846
Prevention and Public Health Fund, 869–870
Prices. See also Taxes
      price increases, effects of, 869
      price increases as part of comprehensive tobacco control strategy, 848
      retail prices of cigarettes, effects of, 788–798, 798f, 791–792, 799
      tobacco price index and per capita cigarette consumption, 799f
Primary biliary cirrhosis, 569
Prisons, smokefree policies in, 795
Private health insurance, 674, 675f. See also Insurance
Procedural science, era of, 22
Proctor, Robert N., 22
Productivity, loss of
      1985 Surgeon General’s Report, 49f
      CHD and lung cancer attributable to secondhand smoke, 665, 666f
      smoking-attributable economic costs, 670, 671f, 870
      workplace absenteeism, 631, S454f, S455–456f
Progesterone and breast cancer, 214
Progesterone receptors (PRs)
      breast cancer, 245–246
      breast cancer mortality, 277
PRORRI (angiogenic molecule), 485
Proline-glycine-proline, 367
Prostacyclin, 421
Prostate cancer
      active smoking, and evolution of conclusions regarding, 75f
      conclusions on, 8
      finasteride, 145f
      incidence and mortality, and cigarette smoking, prospective cohort studies on, S30–44f
      mortality from, 206–208, 207f
      mortality rate of men in U.S., 1930–2008, 65f
      progression, case fatality, and all-cause mortality, and cigarette smoking, studies on, S48–51f
      PSA test, 204
      risk factors, 204–205
      smoking, no causal relationship with, 209, 292, 293
      stage and grade, 208
      stage and histologic grade at diagnosis and cigarette smoking, studies on, S45–47f
Prostate-specific antigen (PSA) test, 204
PRRs (pattern recognition receptors), 546–547, 550
Prudential Insurance Company, 19
PSA (prostate-specific antigen) test, 204
Pseudomonas aeruginosa, 566
Public beliefs
  denormalization of tobacco use, 31–33
  public smoking, restricting, 29
  smoking hazards, following 1964 Surgeon General’s Report, 25
Public health
  cigarette smoking, effect of, 7
  criteria for interpreting epidemiologic evidence, 52
  prevalence of public smoking, 774
Public Health Cigarette Smoking Act of 1969
  broadcast media advertising of cigarettes, 24
  passage of, 3
Public Health Service (PHS)
  1971 Surgeon General’s Report, 55
  National Clearinghouse on Smoking and Health, creation of, 24
Public policy formation and scientific conclusions, separation between, 56
Pulmonary and activation-regulated chemokine (PARC/CCL-18), 367
Pulmonary disease. See Respiratory disease

Q

Quality of life and health status, 629
Quit attempts (attempts to quit)
  definition of, 765
  measures of, 765
  in past year, 716, 717t
  proven treatments, use of, 846
  rate projections, 848
Quitlines, 813–814
Quit Now smoking cessation program, 30
Quit ratio
  overall, 716, 718t
  trends over time, 716–718, 719f, 720f
Quitting cigarettes. See Smoking cessation
Quitting “cold turkey,” 846

R

RA. See Rheumatoid arthritis (RA)
Racketeer Influenced and Corrupt Organizations Act (RICO), 32
Radiation therapy
  second primary cancers, 288
  toxicity and cigarette smoking, 288–289
RAS oncogene, 198
Reactive-oxygen species (ROS), 421, 422, 423
Reagan, Ronald W., 28
Reasons for Geographic and Racial Differences in Stroke study, 443
Rectal cancer, 198. See also Colorectal cancer
Reduced potency, defined, 238
Reducing the Health Consequences of Smoking—25 Years of Progress (1989 report)
  all-cause mortality, 102t, 636
  cerebrovascular disease, 76t
  endometrial cancer, 71t
  fetal death, stillbirth, and infant mortality, 84t
  kidney cancer, 71t
  subject and highlights, 49f
Reducing Tobacco Use (2000 report)
  dental diseases, 87t
  subject and highlights, 50t
  tobacco trade, 823
Regulated Market Model for tobacco, 853
Regulatory approach to reduce tobacco use, 50t. See also Legislation
Relative risk (RR)
  adult estimates, 655–657, 658t
  adult mortality from smoking-related diseases, based on CPS-II, 651–653, 652t
  infant RRs, 657–659
  population-attributable fraction, 650, 650f
Reproductive outcomes, 461–499. See also Maternal (prenatal) smoking
  active smoking, and evolution of conclusions regarding, 68, 82–86t
  advances in understanding of tobacco and, 464–470
  fetal growth, 465–466
  neurocognitive development, 469–470
  preeclampsia, 466–467
  SIDS, 469
  stillbirth and perinatal mortality, 467–469
  conclusions on, 10, 499
  nicotine, 117–119
  overview, 461
  secondhand smoke, 5f, 69, 98–99t
  secondhand smoke, and evolution of conclusions regarding, 69, 98–99t
  smoking, linked to, 4f
  smoking cessation, 463–464
  surveillance, 461–463
  updated evidence reviews, 471–499
  congenital malformations, 471–479
  ectopic pregnancy, 484–487
  evidence summary, 498–499
  male sexual function, 489–498
  neurobehavioral disorders of childhood, 479–484
  spontaneous abortion, 487–489
Women and Smoking (2001 report), 50t
Research, expanding, 875
Residential fires
  smoking-attributable mortality (1965–2014), 676–678, 677t
  trends in civilian deaths in, 659, 662f
Respiratory disease. See also Chronic obstructive pulmonary disease (COPD)
1971 Surgeon General’s Report, 46t
active smoking
   childhood and adolescence, during, 81t
   evolution of conclusions regarding, 68, 77–81t, 79t
conclusions of Advisory Committee (1964), 100t
conclusions on, 9–10, 391–392
maternal smoking, and evolution of conclusions regarding, 86t
secondhand smoke
   adults, 95–97t
   causal link to, 5f
   children, 69, 92–94t
   evolution of conclusions regarding, 93t
smoking, linked to, 4f
smoking-attributable mortality (1965–2014), 676–678, 677t
smoking-attributable mortality for adults (2005–2009), 659–662, 661t, 663t, 664t
smoking-attributable mortality for adults (2010–2014), 659, 660t
value of lost productivity attributable to death from cigarette smoking, 670, 671t
Respiratory epithelium, 553f, 554
Respiratory illnesses, acute. See also Influenza; Pneumonia; Tuberculosis (TB)
1971 Surgeon General’s Report, 46t
active smoking, and evolution of conclusions regarding, 79t
infections and smoking, 564
secondhand smoke, and evolution of conclusions regarding, 93t
Retinoic acid, 368
Reynolds American, 706
Rheumatic disorders associated with smoking, 562–563
Rheumatoid arthritis (RA)
   conclusions on, 11, 584
   immunologic dysregulation, 562–563
   risk for and smoking, studies on, S400–402t
   severity and smoking, studies on, S403–404t
   smoking, linked to, 4f
   smoking and, 572–574
   treatment response and smoking, studies on, S405t
Richmond, Julius B.
   1979 Surgeon General’s Report, 47t, 48t
   1980 Surgeon General’s Report, 48t
   1981 Surgeon General’s Report, 48t
   smoking as public health concern, 28
RICO (Racketeer Influenced and Corrupt Organizations Act), 32
R.J. Reynolds Tobacco Co.
   nicotine and cognitive function, 124
   R.J. Reynolds Tobacco Co. v. U.S. Food and Drug Administration, 785, 787
tobacco industry, litigation against, 32
Roemer, Ruth, 818
Roll your own tobacco products, trends in, 705, 705f, 706f
Romania, estimates of smoking-attributable mortality in, 691
ROS (reactive-oxygen species), 421, 422, 423
Roswell Park Cancer Institute, 33
Royal College of Physicians, 21
S

SAB. See Spontaneous abortion (SAB)
SAF. See Smoking-attributable fraction (SAF)
Safe Drinking Water Act of 1974, 29
SAM. See Smoking-attributable mortality (SAM)
SAMHSA (Substance Abuse and Mental Health Services Administration), 703
SAMMEC. See Smoking-Attributable Mortality, Morbidity, and Economic Costs (SAMMEC)
Satcher, David
   1998 Surgeon General’s Report, 50t
   2000 Surgeon General’s Report, 50t
   2001 Surgeon General’s Report, 50t
   on lack of progress in tobacco control, 869
Schick Centers for the Control of Smoking, 30
Schizophrenia
   childhood, 482
   conclusions on, 484, 499
   nicotine and cognitive function, 123–124
School Health Policies and Programs Study, 793
Scientific conclusions
   Master Settlement Agreement (1988), 54
   public policy formation, separation from, 56
   scientific transparency, 55
Scientific consensus
   cigarette smoking as cause of lung cancer, 45
   Surgeon General’s reports, 55
Scientific evidence
   review methods and developing conclusions from, 53–55
   tobacco industry countering, 20
Scientific transparency, 55
Scotland
   lung cancer, 177–178
   national smokefree air laws, 464
Secondhand smoke. See also Cigarette smoke
   1972 Surgeon General’s Report, 47t
   1975 Surgeon General’s Report, 47t
   1986 Surgeon General’s Report, 49t
   2006 Surgeon General’s Report, 50t
   breast cancer
   breast cancer mortality, 277
covariates, adjustment for, 265
genotype interaction, 274
measures of exposure to, 263–264
mortality, 277
most comprehensive measures, 265, 266f, 267f, 268f, 269f
most comprehensive measures ever in lifetime, 267–269, 270f
premenopausal and postmenopausal comparison, 269, 271f, 272, 273f
previous Surgeon General’s reports, 257–263
risk for, 255–257
summary and review, 274–275
in utero exposure, 272, 274
cardiovascular disease, 419, 422, 435, 443, 444
coronary heart disease, 425–426
deaths, years of productive life lost, and value of lost productivity from CHD and lung cancer attributable to, 665, 666f
deaths attributable to, 659
dental caries, 534
evolution of conclusions regarding cancer, 68, 69, 90f
cardiovascular diseases, 69, 91f
reproductive and developmental effects, 69, 98–99f
respiratory effects in adults, 68–69, 95–97f
respiratory effects in children, 69, 92–94f
health consequences, 5f, 7, 777
hypertension, 430
Kessler on, 801–802
meta-analysis of evidence, 54
orofacial clefts, 474
prevalence of exposure to, 792
smokefree policies and, 794
smokefree policies and respiratory outcomes, 389, 390f
smoking-attributable mortality (1965–2014), 676–678, 677f
smoking-attributable mortality for adults (2005–2009), 659–662, 661f, 663f
smoking-attributable mortality for adults (2010–2014), 659, 660f
stroke, 430–434, 431f, 870
tuberculosis, 381–382
SEER (Surveillance, Epidemiology, and End Results) data
age-adjusted incidence of cancers, 143, 146, 146f, 147f
lung cancer types in U.S., 161–176, 162f, 164–175f
Seavers, Maurice H., 30
Selection bias, 279
Selenium levels, 205
Self-paid smoking-attributable health care expenditures, 674, 675f
Serotonin, 113
SERPINA1 gene, 361, 362
SERPINE2 gene, 364
SES. See Socioeconomic status (SES)
Sexual minorities
tobacco use prevalence, 846
S-glutathionylation, 561
Short Form 12
health status and smoking, 628
smoking, studies on, S444–445f
Short Form 36
health status and smoking, 628–629
smoking, studies on, S444–445f
SIDS. See Sudden infant death syndrome (SIDS)

Simulation models
for smoking prevalence, 847–851
Single nucleotide polymorphisms (SNPs)
COPD susceptibility, 364
DNA repair genes and breast cancer, 253
Skull. See Craniosynostosis
SLE. See Systemic lupus erythematosus (SLE)
Small cell carcinoma of the lung
rates by countries, 179f
rates of in U.S., 161, 162f, 163, 164–174f
Smallpox, 874
SmokeEnders program, 30
Smokefree environment
eye calls for, 28
extending protections of, 875
policies and respiratory outcomes, 389, 390f
public smoking, restricting, 28–29
secondhand smoke, 389, 390f, 794
Smokefree legislation and policies, 792–795. See also
Legislation; Tobacco control
angina pectoris, 437, S287–290t
asthma, 389
cardiovascular disease, 435–443, 438f, 439f, 440f, 441f, 442f, 444, S287–290t
cerebrovascular disease and stroke, 437, 440f, S281–286t
conclusions on, 442, 444, 827
coronary heart disease, S255–280f, S291f
Global Smokefree Partnership, 822
impact of, 852
map of, 794f
overview, 777–778
as part of comprehensive tobacco control strategy, 848
Scotland and Belgium, 464
socioeconomic status, 445
state policies, 794f, 795
sudden cardiac death, 292–293t, 437, S292–293t
youth access, regulations on, 796
Smokeless tobacco
age targeting, 782
carcinogenesis, 115–116
fetal growth restriction, 118, 465–466
The Health Consequences of Using Smokeless Tobacco (1986 report), 49t
Parkinson’s disease, 123
preterm delivery, 118
reproductive health outcomes, 118
Smoking and Health (1979 report), 48t
snus, 117, 118, 706
stillbirths, 118, 468–469
venous blood concentrations, 110f
Smokeless tobacco use
current
among adults, 730, 732t
among high school students, 730–734, 733f
among young people, 730, 731f
definition of, 765
measures of, 765
patterns of, 730–734
  trends, 705–706, 705, 706
  trends among adults, 734, 734
  trends over time, 730–734, 733, 733, 735, 736

Smoker's paradox, 426
Smokewatchers program, 30

Smoking and Health
(1979 report)
abdominal aortic aneurysm, 76
all-cause mortality, 102
behavioral aspects of smoking, 30
child development, 82
chronic respiratory symptoms, 79
congenital malformations, 83
Coronary heart disease, 68, 76
lung cancer, 73
oral cavity and pharyngeal cancer, 74
pregnancy complications, 84
sudden infant death syndrome, 86

Smoking and Health in the Americas
(1992 report), 50

Smoking and Health: Report of the Advisory Committee to the
Surgeon General of the Public Health Service
(1964 report)
accidents, 87
acute respiratory illnesses, 79
administrative rather than a scientific consensus, 22
Advisory Committee members, selection of, 21, 22
all-cause mortality, 102
asthma, 77
birth weight, low, 84
bladder cancer, 70
cardiovascular disease, 418, 419
chronic respiratory symptoms, 79
cigarette per capita consumption, 18
conclusions of Advisory Committee, 67, 100–101
COPD, 68, 78
coronary heart disease, 76
esophageal cancer, 71
eye diseases, 88
laryngeal cancer, 72
liver cirrhosis, 88
lung cancer, 73
lung function, 80
male sexual function, 84
methodology for, 21–22
oral cavity and pharyngeal cancer, 74
peptic ulcer, 89
public health action, as, 34
release of, 3
remedial action and change following, 23–26
respiratory diseases, 68
significance of, 45
stomach cancer, 75
studies contributing to, 64
subject and highlights covered, 46

Smoking-attributable fraction (SAF)
formula, 687
methodologic issues, 651
by source of funds, 674, 675

Smoking-attributable mortality (SAM). See also Mortality and mortality rates
adults (2005–2009), 659–666, 661, 663, 664
adults (2010–2014), 639, 660
conclusions on, 679
estimates (2000–2004), 649
findings, 692, 693–697
implications, 679
infants (2005–2009), 659–666
methodologic issues, 651–653
methodology, 650–651, 691–692
other methods to calculate, 687–688
overall approach, 650
projected among youth (2012), 666–667
rationale for use, 649
recent estimates in other countries, 690–691
recent estimates in United States, 688–690
relative risks based on CPS-II, 651–653, 652
summary, 678
total (1965–2014), 676–678, 677

Smoking-Attributable Mortality, Morbidity, and Economic Costs
(SAMMEC). See also Economic costs; Morbidity and smoking;
Mortality and mortality rates
adult disease outcomes, 657
adult RR estimates, 655–657, 658
age stratification, 655
all-cause mortality, 633
conclusions on, 11–12
current methodology, 649
deaths attributable to exposure to secondhand smoke, 659
infant RRs, 657–659
methodologic issues, 651–653
past publications, 651–653, 652
2013 update, 649, 655–659

Smoking behavior. See also Cigarette smoking
1979 Surgeon General's Report, 30
breast cancer risk
cigarette smoking status, 231, 233, 234, 235
Cigarettes smoked per day, 236–237, 238
duration of cigarette smoking, 233–236, 237, 277
ever smoking status, 226–229, 227, 228, 230
hormone receptor status, 245–247
menopausal status, 242–245
no active versus no active/no passive smoking status, 229, 231, 232
pack-years of cigarette smoking, 237–240, 239
timing of exposure to tobacco smoke, 240–242, 241
complexity of, 34
duration, self-reporting of, 160–161
factors influencing, 48

936
hormone receptor status and cigarettes smoked per day, 246
intensity, and COPD susceptibility, 364
low levels of cigarette consumption and cardiovascular risk, 443
low tar and nicotine cigarettes, 186
menopause and breast cancer, 244–245
prevalence, decline in, 283–284
socioeconomic status, 176–177
studies on effects of mass media campaigns on, 815–816
Smoking cessation. See also Tobacco cessation, clinical and educational approaches
cancer patient outcomes, 290, 291
cardiovascular disease, 429, 444
coronary heart disease, 426–427
and diabetes, 540
erectile dysfunction, 497–498
The Health Benefits of Smoking Cessation (1990 report), 50
health professionals, 24–25
history by cohorts, 726, 729
interest in quitting smoking, 716, 717
interventions, 48
need for expansion of, 875
nicotine replacement therapy for, 30
peripheral arterial disease, 428
predicted rates of, 848
during pregnancy, 463–464
programs for, 30
quitlines, 813–814
quit ratio
overall, 716, 718
interest in quitting smoking, 716, 717
interest in quitting or attempts to quit in past year, biologic basis, 487
conclusions on, 10, 489, 499
epidemiologic evidence, 487–489
evidence synthesis, 489
implications, 489
literature review description, 487
maternal smoking and, studies on, 340–341
S-nitrosylation, 561
SNPs. See Single nucleotide polymorphisms (SNPs)
Snuff. See Smokeless tobacco
Snus (smokeless tobacco)
Camel/Marlboro Snus, 706
fetal growth restriction, 118
immune system, 117
reproductive health outcomes, 118
Socioeconomic status (SES)
smokefree policies and cardiovascular disease, 445
smoking behavior, 176–177
tobacco use prevalence, relationship to, 846
tuberculosis, 379
SOD2 (superoxide dismutase), 252–253
Soldiers
cigarettes use by, 846
South (U.S. region)
cigarette smoking among adults
attempts to quit in past year or interest in quitting, 716, 717
current, 709, 712
intermittent and daily, 710–716, 714, 715
quit ratio, 716, 718
Smoking cessation.
South African Demographic and Health Survey, 379
SOX5 gene, 364
Spain, estimates of smoking-attributable mortality in, 691
Specificity of association, as criterion for causation, 21
SpiroMeta consortium studies, 364
Spontaneous abortion (SAB), 487–489
1969 Surgeon General's Report, 46
biologic basis, 487
conclusions on, 10, 489, 499
epidemiologic evidence, 487–489
evidence synthesis, 489
implications, 489
literature review description, 487
maternal smoking and, studies on, 340–341
Squamous cell carcinoma of the head and neck, 150
Squamous cell carcinoma of the lung
decline in smokers, 185, 186, 293
dates by countries, 177–178, 179
rates of in U.S., 161–163, 162, 164–174, 176, 185, 186
Standards on tobacco products, 783–784, 785
State Children's Health Insurance Program, 707
The State of Tennessee, Austin v., 854
State-of-the-Science Conference on Tobacco Use, 803
States
cigarette excise taxes, 790
smokefree policies, 794, 795
State Attorney General cases, 798–800
tobacco cessation program components, 807–808
control programs, 804–817, 806, 807, 875
tobacco products, ability to ban, 854
tobacco-related revenues, 809–810
Statin drugs, 17
Surgeon General’s Report

Steinfeld, Jesse L.
1971 Surgeon General’s Report, 46t
1972 Surgeon General’s Report, 47t
passive smoking, 26
Stem cells, for lung repair in COPD, 368
Stewart, William H.
1967 Surgeon General’s Report, 46t
1968 Surgeon General’s Report, 46t
1969 Surgeon General’s Report, 46t
Stillbirths
1969 Surgeon General’s Report, 46t
active smoking, and evolution of conclusions regarding, 84t
advances in understanding of, 467–469
nicotine, 118
secondhand smoke, and evolution of conclusions regarding, 98t
STK11 gene, 150
Stomach cancer
2004 Surgeon General’s Report, 50t
active smoking, and evolution of conclusions regarding, 75t
age-adjusted incidence of, 146, 146t, 147f
conclusions of Advisory Committee (1964), 100t
mortality rate in U.S., 1900–2005, 63f
mortality rate of men in U.S., 1930–2008, 65f, 66
mortality rate of women in U.S., 1930–2008, 66, 66f
smoking, linked to, 4f
Strategic Action Plan. See Ending the Tobacco Epidemic:
A Tobacco Control Strategic Action Plan for the U.S.
Department of Health and Human Services (Strategic Action
Plan) (U.S. Department of Health and Human Services)
Strength of association/evidence
breast cancer, 282–283
cancer patient adverse outcomes, 289–290
causation, criterion for, in 1964 report, 21
standardization of, in 2004 report, 67
Streptococcus pneumoniae, 566
Stroke. See Cerebrovascular disease and stroke
Substance Abuse and Mental Health Services Administration
(SAMHSA), 703
Successful aging, and health status, 629
Sudden cardiac death
conclusions on, 10
current, former, and never smokers, 427
described, 415f
smokefree laws, 437
smokefree laws, studies on, S292–293t
Sudden infant death syndrome (SIDS)
active smoking, and evolution of conclusions regarding, 86t
advances in understanding of, 469
nicotine, 118–119
secondhand smoke, 5f
secondhand smoke, and evolution of conclusions regarding, 69, 98t
smoking-attributable mortality (2010–2014), 659, 660f
Sufficient evidence
all-cause mortality risk increased by smoking, 641, 642
asthma exacerbation in adults and smoking, 376, 392
causal inferences, strength hierarchy for, 3f, 53
COPD, smoking as dominant cause of, 371, 391
health status and smoking, 632, 642
Mycobacterium tuberculosis disease and smoking, 385, 392
relative risk of dying from cigarette smoking, increase in, 641, 642
smokefree laws and reduction in coronary events, 442, 444
stroke and secondhand smoke, 434, 444
tuberculosis mortality and smoking, 385, 392
Suggestive but not sufficient evidence
asthma and smoking in adults, 374, 392
asthma and smoking in children and adolescents, 373, 391, 392
breast cancer and tobacco smoke, 283
causal inferences, strength hierarchy for, 3f, 53
idiopathic pulmonary fibrosis and smoking, 388, 392
recurrent tuberculosis disease and smoking, 385, 392
smokefree laws and reduction in cerebrovascular events, 442, 444
smokefree laws and reduction in other heart disease outcomes, 442, 444
Suggestive of no causal relationship, described, 3f, 53
Sulfotransferase 1A1 (SULT1A1), 252, 274
Superoxide dismutase (SOD2), 252–253
Surfactant protein D, 367
Tar
constituents in, 154–155, 156f
low-tar cigarettes, 157–158
Targacept, 124
Tamoxifen, 145f, 212
Taxes
federal excise, increases in, 869, 874
legislative willingness to increase, 852
state cigarette excise taxes, 790f
supporting tobacco control programs, 805
tobacco control policies, as, 788–792
tobacco price index and per capita cigarette consumption, 789/
Tax stamps, 791
TB. See Tuberculosis (TB)
TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin), 420
T cells
    immune function, 557–558
    T-helper cell 2 (Th2), 371–372
Teeth. See under Dental
Temporal relationship of association
    breast cancer, 282
    cancer patient adverse outcomes, 289
    causation, criterion for, in 1964 report, 21
Terry, Luther L.
    1964 Surgeon General’s Report, 45, 46/
    1964 Surgeon General’s Report, phases of, 23
    1964 Surgeon General’s Report, purpose of, 22
    1964 Surgeon General’s Report, release of, 3
Thrombin, 422
Thrombosis, defined, 415/
Thrombogenesis, 443
Thrombopoietin, 422
Thrombosis, defined, 415/
Thromboxane A2, 421
Thumbs Up Thumbs Down! project, 775
“Tips from Former Smokers” (TIPS) campaign, 813, 874
Tissue plasminogen activator (tPA), 421, 422
TNF-α proinflammatory cytokine, 368
Tobacco. See also Smokeless tobacco; Smoking; specific topics
    addiction to, 784
    changing public image of, 773–787
        advocacy efforts, 778–779
        military, smoking in, 778
        smokefree policies, 777–778
        tobacco impressions delivered by top-grossing U.S.
            movies, 776/
        tobacco incidents in top-grossing U.S. movies, 776/
        growing and curing, 153–154
        production and consumption in the Americas, 50/
        tuberculosis, 379–384
Tobacco amblyopia, 88/
Tobacco Centers of Regulatory Science, 787
Tobacco cessation, clinical and educational approaches, 803–817. See also Smoking cessation
    cessation interventions, 814, 816–817
    conclusions on, 827
generally, 50/
    health care policies, 804
    health communication interventions, 812–814
as part of comprehensive tobacco control strategy, 848
smoking behavior, studies on effects of mass media
    campaigns on, 815–816/
state and community interventions, 811–812
state program components, 807–808/
state tobacco control programs, total funding, 806/
state tobacco-related revenues, 809–810/
statewide tobacco control programs, 804–817
Tobacco control. See also Smokefree legislation and policies;
Tobacco epidemic
cardiovascular diseases
    angina and sudden cardiac death, 437, 441/
    biologic basis, 435–436
    cerebrovascular events, 437, 440/
    coronary events, 437, 438/
    meta-analyses, 436–437
recent studies, 439–441, 442/
changing landscape of, 845–859
cigarette price increases as tobacco control, 869
current status and future directions, 13
smokefree laws
    cardiovascular disease, 445
    cerebrovascular accidents, studies on, S281–286/
    coronary events, studies on, S255–280/
other heart disease, studies on, S287–293/
prenatal smoking, 464
Tobacco control, current status of, 771–842
conclusions on, 12, 827
international tobacco control, 818–826
FCTC role in trade and investment, 825–826
global tobacco control MPOWER key findings, 821t, 824t
international trade and, 823, 825
WHO key indicators, 822/
World Conferences on Smoking and Health, 819t
overview, 773
summary, 826
Tobacco, changing public image of, 773–787
advocacy efforts, 778–779
military, smoking in, 778
smokefree policies, 777–778
Tobacco control policies, 788–802
advertising and promotion, bans and restrictions on, 796–798
smokefree and tobacco-free legislation, 792–795
taxes, 788–791
Tobacco product litigation, 798–803
Tobacco product litigation, punitive damages, 799/
state tobacco control programs, 804–817
tobacco product litigation, *United States v Philip Morris, Inc.*, 800–803
youth access, regulations on, 796
tobacco industry, changes in, 779–780
tobacco products, changes in, 780–783
menthol, 782–783
modified traditional and novel tobacco products, 781

tobacco regulations, changes in, 783–787
FDA actions, 785–787
*Tobacco Control Act*, 783–785, 787
*Tobacco Control Act of 2009 (Family Smoking Prevention and Tobacco Control Act)*
challenges to full implementation of, 787
changes in, 783–785, 787
cigarette per capita consumption, 18
effects of, 851
FDA regulation of tobacco products, 33, 34, 869
flavoring ban, 783
implementation of, 787
inclusion of Judge Kessler’s findings, 871
overview, 783–785
passage of, 3
public health standard, 873
tobacco epidemic end game, possible impact on, 854
*Tobacco control policies*, 788–802
advertising and promotion, bans and restrictions on, 796–798
comprehensive, models of effects of, 847–848
prenatal smoking, impact on, 464
smokefree and tobacco-free legislation, 792–795
taxes, 788–791
tobacco product litigation, 798–803
tobacco product litigation, punitive damages, 799
*tobacco product litigation, state attorney general cases*, 798–800
*tobacco product litigation, United States v Philip Morris, Inc.*, 800–803
youth access, regulations on, 796
*Tobacco epidemic*. See also *Tobacco use, patterns of conclusions*, 858
continuing, evidence of, 867, 869
drug game strategies, 852–857, 858, 872
future of, 851–852
history of, 845–846
implications for ending, 859
models of accelerating end of, 847–851
summary, 857–858
*tobacco control, contemporary era of*, 846
tobacco control, future of, 846–847
vision for ending, 867–875
health consequences, 870
historical perspective, 867–870
methods for ending, 870–874
reducing tobacco use, accelerating national movement for, 874–875
*Tobacco Epidemic: A Tobacco Control Strategic Plan* (U.S. Department of Health and Human Services), 13

*Tobacco industry*
campaign to counteract changing public beliefs and behaviors, 34, 779
changes in, 779–780
cigarette filters and mutagenicity of tar, 184
as driver of cigarette smoking, 846
epidemiological evidence, dismissal of, 22
*Federal Cigarette Labeling and Advertising Act of 1965*, influence on, 24
history of, 17
litigation against, 32, 798–803
mergers and acquisitions in, 780
nicotine addiction, evidence for, attempts to discredit, 31
nicotine and cognitive function, 124–125
print media, revenue source for, 26
public, misleading, 7
research funding, 32–33
as root cause of smoking epidemic, 871
sales, sustaining of, 867
scientific evidence, countering, 20
secondhand smoke and disease, countering evidence of, 29

*Tobacco Industry Research Committee*, 20

*Tobacco Institute*
Advisory Committee to 1964 Surgeon General’s report, selection of members for, 22
Master Settlement Agreement (1988), 54

*Tobacco product litigation*
*Cipollone v. Liggett Group, Inc.*, 32
punitive damages, 799
*R.J. Reynolds Tobacco Co. v. U.S. Food and Drug Administration*, 785
State Attorney General cases, 798–800
*United States v Philip Morris, Inc.*, 32, 800–803

*Tobacco products*
changes in, 780–783
geographic variations in prevalence rates, 846
harmful and potentially harmful constituents, 786
menthol in, 782–783
modified risk tobacco products, 784, 786
modified traditional and novel tobacco products, 780, 781
noncombustible, prevalence of use, 846
novel and modified traditional, 780, 781
other than cigarettes
consumption of, 705–707, 706
new and emerging products use among adults, 743–750, 750
among youth, 742, 746–747, 748–749
patterns of, 742–750
patterns of use, 730–750
regulations on marketing of, 784
standards for, 783–784, 785
taxes on, 788–792

*Tobacco Products Agency (hypothetical construct)*, 855

*Tobacco smoke*
asthma, 545, 547
classification as human carcinogen, Group A, by EPA, 29
health risks from inhaling, 871
infectious diseases, 545, 546
Tobacco use, patterns of, 701–770
  cigarette smoking, 708–729
  conclusions on, 12, 761
  current use, defined, 742
  data sources, 704
  denormalization of, 31–33
  dynamic model of forces affecting, 850
  historical trends, 705–707
  key epidemiologic measures, 704
  measures of, 763–766
  per capita consumption, 705, 705f
  products other than cigarettes, 705–707, 706
  Tonsillectomy, 94
  Tourette syndrome
    conclusions on, 484, 499
    epidemiologic evidence, 482
    prenatal smoking and, studies on, S332–333
  Toxic Substances Control Act of 1976, amendments to, 29
  TP53 gene
    lung cancer, 150
    methylation of genes, 151
  TPA (tissue plasminogen activator), 421, 422
  Tracheal cancer, 4f
  Track and trace systems, 791, 872
  Trade, international, 823, 825
  Treating Tobacco Use and Dependence guidelines (Fiore), 464
  Triple negative phenotype, 246, 247
  Triple-risk model for SIDS, 469, 470f
  TRPA1s (transient receptor potential cation channel, subfamily A, member 1), 372
  Truth® campaign, 777, 799
  Tuberculosis (TB)
    active smoking, 80f
    biologic mechanisms, 376–377
    conclusions on, 9, 385–386, 392
    immune function, 566
    natural history of, 377, 378f
    recurrent TB disease, 381–382, 385
    recurrent tuberculosis and tobacco use, studies on, S241–243t
    relative risks, adults, 657, 658f
    risk factors, 377, 379
    secondhand smoke, and evolution of conclusions regarding, 97f
    smoking, linked to, 4f
    smoking-attributable mortality for adults (2005–2009), 659–662, 661f, 663f
    smoking-attributable mortality for adults (2010–2014), 659, 660f
    TB mortality, 383, 384f, 385
  U
  Ulcerative colitis
    conclusions on, 584
    current smoking, studies on, S417–426t
    current smoking and, 579, 580–581f
    epidemiology of, 579–581
    former smoking, studies on, S429–433t
    former smoking and, 581, 582f
    incidence of, 576
    protective factors for, 576
    smoking and
      biologic basis, 576–577
      dose-response, 582–583
      evidence synthesis, 583
    implications, 583
  unfolded protein responses (UPRs), 562
  United Kingdom General Practice Database, 530
  United States v. Philip Morris, 32, 800–803
  UPRs (unfolded protein responses), 562
  Ureteral cancer, 4f
  U.S. Congress, 55
  U.S. Food and Drug Administration, R.J. Reynolds Tobacco Co. v., 785, 787
  U.S. National Health Interview Survey, 637, 641f
  U.S. Radiologic Technologist Cohort, 218–219
  U.S. Smokeless Tobacco Company, 706
  U.S. Standard Certificate of Live Birth, 461, 462, 463
  Uterine cancer, 66, 66f
  V
  Varenicline, 117
  Vascular disease
    relative risks, adults, 657, 658f
    smoking-attributable mortality for adults (2005–2009), 659–662, 661f, 663f
    smoking-attributable mortality for adults (2010–2014), 659, 660f
Veterans Administration (VA) health care services, 628–629, 630

Vietnam Experience Study, 495, 496, 497

Viral infections associated with smoking, 562–563, 564–565

Vitamin D levels, 197

Vitamin E levels, 205

Von Willebrand factor, 421, 422

Warning labels, requirements for, 785–786, 787, 855

West (U.S. region)

cigarette smoking among adults
- attempts to quit in the past year or interest in quitting, 716, 717
- current, 709, 712
- intermittent and daily, 710–716, 714f, 715f
- quit ratio, 716, 718

cigarette smoking among young people
- current, 709, 711f
- intermittent and daily, 710, 713f

cigar use
- current, among adults, 736, 738f
- current, among young people, 737f

polytobacco use
- current, among adults, 745f
- current, among young people, 744f

smokeless tobacco use
- current, among adults, 730, 732f
- current, among young people, 730, 731f

WHO. See World Health Organization (WHO)

WHO Framework Convention on Tobacco Control (FCTC), 785, 818–819, 825–826

Withdrawal symptoms (physical abstinent syndrome)
- addiction, feature of, 30
- nicotine addiction, 113

Women. See Females

Women and Smoking (2001 report)
- all-cause mortality, 103t
- bone density, low, 89t
- breast cancer, 70t, 90t
- breast cancer and active cigarette smoking, 217
- cervical cancer, 70t
- colorectal cancer, 71t, 198
- congenital malformations, 83t
- COPD, 78t
- coronary heart disease, 91t, 424–425
- diabetes mellitus, 87t
- endometrial cancer, 71t
- eye diseases, 88t
- fertility, 83t
- fetal death, stillbirths, and infant mortality, 84t, 98t, 467
- hip fractures, 88t
- infant birth weight, 84t, 99t
- leukemia (acute), 72t
- liver cancer, 72t, 187
- lung cancer, 73t, 90t
- ovarian cancer, 74t
- pregnancy complications, 85t
- respiratory effects in infants and children, 86t
- secondhand smoke, 69
- stomach cancer, 75t
- subject and highlights, 50t
- sudden infant death syndrome, 86t

Women’s Health Initiative (WHI)

adult RR estimates, 655, 656
- breast cancer and secondhand smoke, 259, 260
- colorectal cancer, 202
- duration of cigarette smoking, 235
- health status and smoking, 629
- hormone receptors and breast cancer, 247
- sudden cardiac death, 427

Women’s Health Initiative Observational Study, 220

Women’s Health Study, 428

Workplace absenteeism
- morbidity and smoking, 631
- relative risk of, and smoking, studies on, S455–456t
- smoking, studies on, S454t

Workplace health
- 1985 Surgeon General’s Report, 49t

Occupational Safety and Health Administration, 29

World Conferences on Smoking and Health (World Conference on Tobacco or Health), 818, 819f

World Health Organization (WHO)

Confronting the Tobacco Epidemic in a New Era of Trade and Investment Liberalization, 826

estimates of smoking-attributable mortality, 690
Framework Convention on Tobacco Control (FCTC), 785, 818–819
health status and smoking, 628
passive smoking, effects of, 28
physical abstinence syndrome, lack of, with cigarette smoking, 30
smoking prevalence by country, 217, 218f
tobacco control policies, key indicators for, 822f
World Trade Organization (WTO), 825–826

X

Xeroderma pigmentosum, 149
XRCC5 gene, 364

Y

Young adults. See also Adolescents; Adults
cigarette access, 796
cigarette smoking
current, 709, 711f, 764, 765
daily, trends over time, 720–724, 726f
daily versus intermittent, 710, 713f

cigar use, current, 735, 737f
mentholated cigarettes, 783
movie viewing and smoking initiation, 775, 777
need for prevention aimed at, 846
new and emerging products use, 742
polytobacco use, current, 741, 744f
Preventing Tobacco Use Among Youth and Young Adults (2012 report), 51f
secondhand smoke exposure, 793
smokeless tobacco use, current, 730, 731f
tobacco promotion, exposure to, 813
tobacco use, patterns of, 701–770
Youth or young people. See Adolescents; Young adults
Youth Risk Behavior Surveillance System (YRBS)
overview and methods, 703, 762–763
current smokeless tobacco use, defined, 765
current smoking, defined, 709, 765
definition of current cigar use, 766
YRBS. See National Youth Risk Behavior Survey (YRBS)
YRBSS. See Youth Risk Behavior Surveillance System (YRBSS)